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Metabolomics measures all the small, biologically relevant molecules 
present within a system. An effective way to achieve high-throughput sample 
analysis and diverse pathway coverage in metabolomics is to use ultra 
performance liquid chromatography (UPLC) coupled to high-resolution mass 
spectrometry (HRMS). Depending on the compounds of interest, untargeted or 
targeted methods can be implemented. Efforts have been focused on analyzing 
how different forms of stress alter an organism’s metabolite profile.  
Genetic mutations can inhibit essential metabolic pathways of an organism, 
but there are often redundant or alternative routes available for continued growth. 
By systematically deleting single genes in Escherichia coli responsible for the 
production of individual enzymes in the tricarboxylic acid cycle, it was possible to 
measure alterations in metabolites and correlate them to specific mutations.  With 
the use of untargeted UPLC-HRMS, 146 known metabolites and over 1,800 
significant unknown spectral features were identified. Comparative and 
multivariate analysis show intense changes were observed in strains lacking 
Aconitase B and unique global metabolic profiles were enzymatically linked and 
not strictly based on pathway disruption.  
Enterococcus faecalis has been shown to develop antibiotic tolerance to 
daptomycin by incorporation of host-produced fats. The exact biological 
mechanism by which  this bacterium incorporates host lipids into their membranes 
is currently unknown. The use of a hybrid quadrupole Orbitrap mass spectrometer 
allowed for the development of a novel method to simultaneously quantify two-
tailed phospholipids and four-tailed cardiolipins which pose analytical challenges 
due to low biological abundances and poor ionization efficiencies. By leveraging 
HILIC separation and parallel reaction monitoring (PRM), additional information 
with respect to identities about which specific fatty acids composition was 
simultaneously measured. 
vii 
 A sub-population of Spodoptera frugiperda has been identified as resistant 
to genetically modified corn and has been causing rampant pest related crop loss. 
Previous research has shown a link between resistance and a mutation to the ATP 
binding cassette subfamily C2 gene. Untargeted metabolomic analyses were 
applied to profile the gut tissue of the larvae and found potential metabolites related 
to this mutation. From the 126 metabolites, six were found in significantly higher 
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 Metabolomics is the most recent addition and arguably the most important  
level of the omics cascade with respect to biological phenotype. Unlike other, more 
mature and standardized omic analyses such as genomics, transcriptomics, or 
proteomics, metabolomics does not possess a standard approach to identification, 
validation, and publication of data. This presents an analytical challenge for 
scientists to compare and optimize experiments; however, this leaves ample 
opportunity to develop new approaches in attempts to find suitable metrics across 
the diverse metabolomics community. The field is still in its infancy, leading to a 
variety of constraints including lack of metabolite knowledge, instrumentation 
limitations, and management of immense data sets  
The single, most challenging factor in metabolite detection is the sheer 
number of different molecule types that are included in the umbrella term  
“metabolomics”. In genomics, methods are optimized to detect the arrangements 
of four or five different nucleotides. Since these compounds are conserved across 
many different organisms, genomic techniques are simply transferred between 
unlike systems with minimal modification. A similar situation is seen in the 
proteomics field, but instead of detecting the nucleotides, there are a handful of 
amino acids that are necessary to measure. The amino acids have similar 
chemical properties and are common among different organisms, resulting in  a 
small number of methods being needed. Again, this leads to measurement 
techniques and the data generated to be easily understood by all individuals in the 
field. In addition to just measuring specific amino acids, proteomics involves the 
probing of secondary and tertiary structures of the whole protein as well as 
accounting for various post translational modifications. This was the first time that 
the scientific community was faced with the phenomena of “big data”, where 
experiments were creating information faster than results and conclusions could 
be interpreted. This has led to large, publicly available repositories of protein data 
which has encouraged collaborative data analyses across the world.  
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Within the realm of metabolomics, the goal is to measure all metabolites 
present in a system. This poses a challenge unlike any other omics technique due 
to the large number of possible molecules that are measurable in the system of 
interest.  Additionally, the set of metabolites present in an organism is not 
consistent; therefore, transferring methods across sample types can be 
challenging. For example, if one metabolomics experiment is optimized for plant 
metabolites, it is most likely not ideal for mammalian metabolite analysis. The 
issues are not solely based on the vast number of compounds, but the fact that the 
compounds have diverse structures. Metabolites typically have mass to charge 
ratios (m/z)’s up to 2,000 Da and contain a variety of functional groups. Depending 
on the metabolite class and its intrinsic properties, the methods required to 
measure these varying classes of metabolites are often very different. This further 
exemplifies the need to apply multiple analytical methods to measure groups of 
metabolites that have different structures within the same organism. The final 
challenge in metabolomics is being able to quickly and reproducibly halt 
metabolism in order to measure the metabolites present. The metabolites can be 
very labile, unlike proteins or DNA, therefore great care is necessary to prevent or 
limit the degradation throughout the sample collection, metabolite extraction, and 
analysis process.  
 
Analytical Technique for Metabolite Analysis 
 
At the onset of metabolomics, mass spectrometry was the key for detecting  
many compounds simultaneously. Prior to any type of mass analysis, a 
chromatography step is introduced to allow for the separation of compounds based 
on an interaction with a stationary phase. Initially, gas chromatography (GC) was 
chosen due to its simplicity and ability to interface with a mass spectrometer. The 
knowledge of GC separation was well known and produced reliable data with 
detectors such as flame ionization detection (FID) or thermal conductivity detection 
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(TCD). With the uses of a hard ionization source like electron ionization (EI) or 
chemical ionization (CI), it was possible to obtain mass to charge (m/z), and 
fragmentation data for compounds separated via GC. The typical mass 
spectrometer is coupled to a GC and uses a quadrupole or an ion trap as the mass 
analyzer. GC-MS provides excellent information for a variety of experiments 
including structure elucidation based on fragmentation, but it is limited by its low 
mass accuracy. GC is inherently selective for compounds that are nonpolar, have 
small m/z’s, and are easily volatilized (short chain fatty acids, alkanes, alcohols, 
and aromatic compounds). When combining these concerns, GC-MS metabolite 
analyses can only cover a small portion of an organism’s metabolome, especially 
if the organism contains a large water-soluble fraction.  
In order to investigate water-soluble metabolites, liquid chromatography-
mass spectrometry (LC-MS) is used. Unlike GC-MS, this technique allows for 
separation and detection of polar and amphiphilic molecules. Depending on the 
specific LC column chosen, it is possible to separate a wide variety of metabolite 
classes. Ionization of the LC eluent is typically achieved by electrospray ionization 
(ESI) or atmospheric pressure chemical ionization (APCI), creating [M-H]- or 
[M+H]+ species. Initially, triple quadrupole mass spectrometers were the most 
popular choice for metabolite analysis. The detection of a metabolite is achieved 
by the initial selection of a parent ion, followed by a fragmentation step, then the 
selection of a specific fragment. This approach is ideal when looking for a limited 
number of specific compounds because the triple quadrupole is only capable to 
detecting a single  m/z at a time. If multiple m/z’s are scanned during the same 
time window, the instrument must cycle through scan events causing a reduction 
in sensitivity. The mass resolution of a tripled quadrupole instrument is low, 
causing problems when attempting to distinguish between two m/z’s that differ by 
a small amount, As the metabolomics field matures, the need to profile many 
compounds simultaneously, as well as perform experiments in an untargeted 
fashion has become apparent. 
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The use of high-resolution mass spectrometers (HRMS), such as Orbitraps, 
have attempted to resolve the limitations of the triple quadrupole. The Orbitrap 
uses a football shaped electrode as the mass analyzer to measure the frequency 
of image currents. Fast Fourier transform deconvolutes the frequencies into mass 
to charge ratios. This allows for the detection of all m/z’s concurrently without the 
need for specific user input values. Another benefit of using HRMS, is high mass 
accuracy, which is five parts per million or less, providing the ability to distinguish 
small metabolites with very similar exact masses.  
This technology advances metabolomics by providing analytical 
instrumentation to identify changes in biological systems based on metabolites that 
are both known and unknown. These “unknowns” have metabolite features in the 
chromatographic and mass domains but do not correspond to a known metabolite. 
The newest class of high-resolution mass spectrometers consists of hybrid 
Orbitraps, which combine the benefits of an Orbitrap with the ability to target ions 
using a quadrupole mass filter. This technology provides instrumentation needed 
to begin identifying unknown spectral features  and determine what role they play 
in metabolism. 
 
Types of Metabolomics Analyses 
 
Metabolomic analyses can be divided into two broad classifications: 
untargeted and targeted. Each specific type of analysis has attributes that are 
optimized for the goals of the experiment. An untargeted experiment is used in an 
exploratory approach where the goal is to measure as many compounds as 
possible and investigate changes in metabolite trends compared to a control. Data 
is collected across a wide m/z range and metabolites are identified in a post-
acquisition manner, using multiple verification factors such as retention time, exact 
mass, and isotopic abundance patterns. As aforementioned, this method is also 
able to measure changes in spectral features that are not identifiable as specific 
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metabolites. Data collected from this analysis tends to be in the form of relative 
abundances and not absolute concentrations. Metabolite comparisons are made 
for the same metabolite across the different sample treatments not between 
different metabolites within the same sample treatment. 
In a targeted approach, specific compounds of interest are identified prior 
to analysis, allowing for the chromatographic and mass spectrometric conditions 
to be optimized. The only data collected are for the transitions designated by the 
acquisition method. These transitions are linked to the m/z of the parent ion and a 
known m/z fragment. Since the method is only analyzing a limited number of m/z’s, 
and not scanning across a wide range, there is an increase in instrument 
sensitivity. This fact, combined with an external calibration curve or internal 
standards, allows for collection of absolute quantitative data with low detection 
limits. The downside to using a targeted approach is the loss of ability to search  
collected data for metabolites that were not originally included in the analysis. A 
hybrid Orbitrap, such as the Q-Exactive Orbitrap, has a quadrupole mass filter prior 
to the mass analyzer allowing for selection of a parent ion and a full scan of 
fragments, instead of being limited to a single fragment per scan event. When 
operating in this mode, it is possible to obtain high-resolution, quantitative data 
using known transitions while also gathering information about many other 
fragments from the same parent ion. This proves beneficial not only for quantitation 
from multiple fragments, but also serves as a possible way to isolate an ion which 
does not have a known structure. The fragmentation can then be used to attempt 
to identify the molecule.  
 
Data Analysis for Metabolomics 
 
Data analysis for metabolomics is not currently standardized which leads to 
processing specifics to vary based on the type of analysis, the goals of the 
experiment, specific metabolites detected, and the lab doing the analysis. Due to 
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the highly dynamic nature of metabolites, it is very important to include specific 
controls, blanks, and an appropriate number of replicate samples. This ensures 
any changes in the data are a result of the independent variable and not due to 
random or systematic errors propagated through the extraction and analysis steps. 
Chromatographic features can be classified into two classes: annotated or 
identified. In this dissertation, annotated features refer to features that have an 
exact m/z and retention time but cannot be correlated to a metabolite in the 
database. Identified refers to matching exact m/z and retention time to a metabolite 
in a database. Annotation can be performed by many freely available software 
packages as well as subscription-based services. Peak identification can be 
performed by the mass spectrometer’s software, or by third party software such as 
XCMS. After all the peaks in the chromatogram have been annotated with m/z’s 
and retention times, molecular formulas can be generated for all features that did 
not match to a compound in the database. This assigned formula can be used to 
determine potential metabolite structure and correlate molecules to compound 
classes or even used to discover a potential biomarker 
 
The Future of Metabolomics 
 
From its humble onset of detecting tens of common metabolites using a 
triple quadrupole, the field of metabolomics is growing at an exponential rate. As 
more and more sample types are being analyzed using metabolomics, there is 
always a need to refine metabolite protocols and extract more meaningful 
conclusions from the data. Currently, metabolomics is faced with challenges of 
complex sample matrices, such as rhizospheres. In this example, the analytical 
challenge comes from having many different bacterial species in a common soil, 
along with roots from plants. It is difficult to isolate, extract, and correlate the origin 
of the metabolites. To overcome this, a combination of isotopic labeling and 
independent extractions can be useful. Information about how different species are 
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symbiotically produce and consume metabolites can show how species share and 
utilize nutrients in a common environment. Again, this could lead to the discovery 
of new molecules that are responsible for metabolite transfer between organisms 
or to the expansion of current metabolic pathways. Additionally, in order to 
enhance coverage of the metabolome or analyze more complex samples, there 
must be continued advancement of instrumental technologies. The newest line of 
high-resolution mass spectrometers utilizes three different mass analyzers to 
achieve complex metabolite measurements simultaneously.   
 
Outline of Dissertation  
 
Herein, the versatility of metabolomics of and its applications within three 
unique environments will be discussed. The first chapter uses multiple untargeted 
approaches to profile hydrophilic and phospholipid compounds on a global level 
for seven different genetic variants of E. coli. In addition to relative concentrations 
of metabolites, a relative flux analysis was performed using the same untargeted 
approach, but cells were grown in the presence of an isotopically labeled substrate 
to measure relative rates of metabolites. The second chapter focuses on the 
development of a targeted method to quantitate phospholipids, currently thought 
to be related to antibiotic tolerance in E. faecalis. The same samples were used to 
analyze global phospholipids and free fats in the membrane of the wild type and 
genetically modified versions of the bacteria. The third chapter shows how 
metabolomics was used to probe a complex higher order organism and understand 
the relationship between resistance and abundant small molecules. Gut samples 
from toxin resistant and susceptible Spodoptera frugiperda larvae were analyzed 







CHAPTER 1 GENETIC MUTATIONS TO THE TRICARBOXYLIC 







Multiple metabolomic analyses were applied to an organism which lacked 
enzymes in a very important metabolic pathway in order to understand how it 
continued to grow. This not only helped quantify the changes of metabolites in this 
specific pathway, but also provided data to generate new hypotheses about how 
the distant metabolic pathways were interrelated as well as how unknown spectral 
features (unidentified metabolites) were changing. 
Escherichia coli was genetically modified to not produce different enzymes 
that were critical to the tricarboxylic acid cycle (TCA). Seven different strains were 
made, each containing a single gene mutation, accounting for the majority of the 
enzymes in the cycle. It was not possible to make a viable mutant strain that lacked 
citrate synthase, the first enzyme in the TCA cycle, as the cells required heavy 
nutrient supplementation. All of the other strains were able to grow in minimal 
media with a single carbon source. An untargeted hydrophilic metabolite analysis 
was initially performed, and over 10,0000 total spectral features were detected. In 
addition, 146 metabolites were identified across all the strains including 8 of the 9 
metabolites directly involved in the cycle. The standard metabolomics analysis 
provides a static view of the metabolite populations, but it was unable to show how 
those metabolite pools were changing over time. To achieve temporal resolution 
of these metabolite, an isotopically labeled flux analysis was conducted. This 
involved switching the bacteria’s only carbon source from unlabeled glucose to one 
that was fully labeled with carbon-13 atoms, and sampling at different time points. 
The same untargeted metabolite analysis was conducted but it was now possible 
to identify how many carbons in the metabolite contained a heavy atom. Based on 
how quickly isotopologues were detected, turnover rates of the metabolite pool 
could be inferred, as well as if that metabolite was produced from solely glucose 
or from some other recycling pathway.  
Knowing the metabolome consists of much more than just polar molecules, 
an untargeted lipidomics analysis was also performed. This technique targeted 
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phospholipids in five different head group classes. It was possible to detect multiple 
phospholipids species within a class, and distinct changes were seen among the 
different mutants. This showed that phospholipid levels were directly related to lack 
of a specific enzyme in central carbon metabolism. 
This data will be part of an initial publication, which is the first to collect a 
global metabolite profile for these specific mutants. Future publications are 
planned with the intent to further investigate the unidentified features using 
bioinformatics tools to identify new classes of or individual molecules changing due 
to these mutations. 
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1.1 Abstract  
 
The most important process for an aerobic organism is the ability to 
metabolize sugars into usable energy through a series of oxidative processes. At 
the heart of carbon metabolism is the tricarboxylic acid cycle (TCA) which is 
imperative for its survival. Even in the event of a genetic mutation, a critical enzyme 
in this cycle could be missing but the cell does not perish. The full understanding 
of how an organism compensates for these enzyme deficiencies is not fully 
established.  By measuring metabolites and how they change between mutant 
strains and the parental strain (or wild type strain) provides a snapshot into how 
the organism is compensating for this stress. Using the bacterium Escherichia coli 
as a model system, genes encoding for seven major enzymes in the TCA cycle 
were systematically deleted. This is the first time a comprehensive metabolic 
profile has been collected for these E. coli variants. Herein, metabolomics, 
lipidomics, and relative flux analyses were employed to determine how the 
organism adjusted its metabolite concentrations to compensate for the loss of 
specific enzymes. Ultra performance liquid chromatography - high resolution mass 
spectrometry measured 146 unique known metabolites, 28 different phospholipids, 
and thousands of unknown metabolite-like features. Additionally, flux analysis was 
used to monitor the relative rates of metabolite production and consumption over 
time. If the mutation exists early in the TCA cycle, the bacteria exhibits more 
perturbations to its metabolite pools. A strain deleted for the gene acnB (Aconitase 
B) proved to cause the most alterations in the global metabolome when compare 
to the other mutants.  These broad analyses show that cells possess machinery to 
combat mutations to an essential pathway, the TCA cycle, and the effects can be 






Aerobic organisms utilize the tricarboxylic acid (TCA) cycle to convert a 
carbon source such as glucose into metabolites necessary to sustain life and 
replicate. The TCA cycle uses acetyl-CoA generated from the processing of 
pyruvate from glycolysis to produce energy carrying cofactors (NADH, and FADH2) 
which are recycled in the electron transport chain to produce a large amount of 
ATP 1.  This recycling process is achieved with the aid of specific enzymes working 
in a cyclic fashion to generate small organic molecules necessary for the 
proceeding reactions. These intermediates not only provide for the continuation of 
the cycle but also allow for the biosynthesis of several amino acids2. If a single 
enzyme in this cycle is not functioning correctly, the cell could encounter growth 
inhibition, oxidative stress, and even death. To protect from these situations, cells 
have adopted many strategies to circumvent immediate death. It has been shown 
that even if a cell is missing an essential enzyme, it is still able to survive3. It is not 
fully known how such a mutant cell continues its metabolic processes and what 
effect it has on auxiliary pathways and those metabolite pools.  
In order to understand how bacterial cells grow, three complementary 
metabolomic techniques will be used to correlate genetic mutations with altered 
metabolism. Employing an untargeted metabolomics approach captures a global 
snapshot of what small molecules are present. By using ultra performance liquid 
chromatography (UPLC) paired with high resolution mass spectrometry (HRMS), 
metabolites with varying size and polarity can be analyzed in a single run. This is 
an ideal analysis approach because it is possible to gather relative concentrations 
of hundreds of compounds with known m/z’s and retention times in addition to 
thousands of spectral features with unidentified biochemical functions. This 
technique has been applied to biological systems ranging from simple cultured 
bacteria4 to the complex interactions of fungi and endobacteria5 and shows how a 
unique metabolic profile is related to distinct phenotypic changes. By adjusting the 
extraction, and chromatographic conditions, it is possible to measure both small 
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(<1000 m/z), hydrophilic compounds and phospholipid species in under one hour. 
Using the same mass spectrometric technologies but substituting the carbon 
source with a fully isotopically labeled materials allows for temporal information 
regarding relative rates of metabolite flux to be collected6. This shows how quickly 
a metabolite’s pool is being turned over and can elicit pathways that undergo 
drastic changes. 
Escherichia coli (E. coli) was chosen for the study because it is easy to 
culture in a lab, most lab strains are nonhazardous, and the genome is fully 
sequenced7. It is considered a model organism, so the metabolomics conclusions 
generated from this study can be applied to more complex systems. E.coli does 
not require complex media additives to survive, making it an ideal starting place to 
analyze global metabolome changes as a result of non-lethal genetic mutations to 
the TCA cycle. Seven different enzymes in the TCA cycle of E. coli were 
systematically removed via genetic modification, and their metabolomes 
measured.  Previously, producing these genetic mutations within this organism has 
been proven to be successful and selective8. Even though many have investigated 
the cellular effects of genetic mutations of E.coli9-12, a large profiling of metabolites 
and their relative net fluxes for these specific mutants has yet to be completed. An 
understanding of what the cells are doing at the metabolite level in order to 
continue growing in the presence of genetic stress is still not known.   
This work shows that it is possible to acquire and differentiate global 
metabolomics data for cells with a deletion of genes encoding for a single 
metabolic enzyme. Moreover, these data show that a single genetic mutation that 
affects production of a single protein will have considerable repercussions on many 
other pathways. Discernible effects with respect to relative amounts of  specific 
polar molecules, and phospholipids can also be seen using this approach. Taking 
this into account, researchers will be keeping abreast of novel drug targets, have 
a clearer understanding of the linkage between cellular processes, and discover 
new avenues of research with respect to how an organism’s global metabolite 




1.3.1 Strain generation 
The strains used in this study are listed in Table 1.1; all oligonucleotide 
sequences used in strain generation are listed in Appendix Table1.7 Specific 
gene deletion strains generated were acnA (aconitase hydratase A), acnB 
(aconitase hydratase B)  sucAB (alpha-ketoglutarate dehydrogenases), sucCD 
(Succinyl CoA synthase alpha and betta subunits), shdAD (succinate 
dehydrogenase subunits A,B,C, and D), fumA (fumarase A), and mdh (malate 
dehydrogenase). All deletion strains were generated using mini- λ Red 
recombination13-16.  Primers were used to amplify the kanamycin cassette of 
pKD413, and contained approximately 40 nucleotides of homology to the 
chromosomal region.   
1.3.2 Bacterial growth conditions 
Cells were grown on M9 minimal media (42.2 mM Na2HPO4;  22.0 mML 
KH2PO4; 18.6 mM NH4Cl; 0.9 mM NaCl) supplemented with micronutrients at final 
concentrations of 1mM MgSO4, 0.1mM CaCl2, 1 µg/mL thiamine, and 0.4% 
glucose for all experimental analysis. Agar media was prepared by adding 15 g/L 
agar to the previously mentioned M9 media. Strains were grown from a frozen 
stock and single colonies were isolated from an overnight plate before being 
transferred to liquid culture. Cells were kept at a constant 37°C and continuously 
shaken at 200 rpm. Cells were grown overnight in minimal media and diluted to an 
OD600 of 0.01 to determine generation time for biological triplicates for all strains.  
For metabolomic analysis, overnight cultures were diluted 1:100 and grown 
to an  OD600 of approximately 0.40.  Then, 5mL of culture was filtered via vacuum 
onto a 0.40 µm polycarbonate filter (Whatman). Metabolism was quenched by 
placing the filter in cold extraction solvent (4:4:2 methanol: acetonitrile: water with 
0.1% formic acid) immediately following filtration. Cells for lipidomics were grown 
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Name  Relevant genotype or description Source 
Escherichia coli MG1655 Wildtype E. coli Lab stock, Fozo 
acnA::kan MG1655 ΔacnA::kan This study 
acnB::kan MG1655 ΔacnB::kan This study 
sucCD::kan MG1655 ΔsucCD::kan This study 
sdhCADB::kan MG1655 ΔsdhCADB::kan This study 
mdh::kan MG1655 Δmdh::kan This study 
sucAB::kan MG1655 ΔsucAB::kan This study 
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similarly but were harvested via centrifugation at 16,600 x g at 4°C for 10 minutes 
to form a pellet. 
For flux analysis, cells were initially grown in liquid media to an OD600 of 
0.10, then 5 mL of cells were filtered and allowed to grow on the filters placed atop 
agar media plates (unlabeled glucose) until an OD600 of 0.40 (Figure 1.1)17.To 
ascertain approximate optical densities of the cells on the filters, optical densities 
of an extra biological replicate were measured by washing the cells off with 5 mL 
of  media. Media plates that contained 13C glucose were prepared in the same 
fashion as the unlabeled plates except for the carbon source was switched to 13C-
6 glucose (Cambridge Isotope Laboratory, 98% purity). After the flux experiment 
was complete, cells were then quenched by placing filters in cold extraction 
solvent.  
1.3.3 Microscopy 
Cells were collected at an OD600 of ~0.40. 1 mL of cells were diluted in 4 
mL of PBS and centrifuged to form a pellet. The supernatant was decanted, and 
20 mL of fresh PBS was added to the tube and mixed thoroughly. An agarose mat 
was used to immobilize the cells prior to imaging. 20 L of cellular solution was 
dropped on the mat. A bright field microscope with a 100x oil immersion lens was 
used to investigate any possible changes in size, shape, or growth patterns among 
mutants.  
1.3.4 Metabolomics  
The extraction protocol is adapted from a previously described method18. 
Briefly, samples were extracted using an acidic acetonitrile solution (40:40:20 
ACN:MeOH:H2O with formic acid at a final concentration of 0.1 M) . After cell 
collection on the filter, filters were left in extraction solvent, cell side down, for 20 
minutes at -20°C. The extraction solution was then transferred to conical vials and 
the filter washed to ensure a complete transfer of material. The vials were then 
centrifuged, and supernatant moved to a clean vial. The remaining cell pellet was 
washed with solvent and allowed to extract for another 20 minutes, followed by
20 
 
Figure 1.1 Workflow for how cells were grown on isotopically labeled media. 
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centrifugation and transfer of supernatant to the previous aliquot. A stream of 
nitrogen was used to evaporate the solvent, then 300µL of Millipore water was 
used to re-suspend the samples.  
A Dionex UltiMate 3000 Ultra Performance Liquid Chromatography (UPLC)( 
Thermo Scientific, Waltham, MA) system coupled to an Exactive Plus Orbitrap 
Mass Spectrometer (Thermo Scientific, Waltham, MA) was used to separate and 
detect the metabolites found in the extracted cell cultures. The method utilized a 
reverse phase chromatography system with detection in the negative mode of the 
mass spectrometer19. A Synergi Hydro-RP column (100 mm x 2 mm 2.5 µm) 
(Phenomenex Torrance, CA, USA) was used to separate a 10 µL aliquot of sample 
and was maintained at 25° C.  Mobile A was 15mM acetic acid, 11mM tributylamine 
in 97:3 (v/v) water: methanol and mobile phase B was 100% methanol. The solvent 
gradient was: t= 0 min 100% solvent A 0% solvent B; t=5 min 80% solvent A 20% 
solvent B; t=13 min 45% solvent A 55% solvent B; t=15.5 min 5% solvent A 95% 
solvent B; t= 19 min 100% solvent A 0% solvent B; t=25 min 100% solvent A 0% 
solvent B. The flow rate was kept at 0.200µL/min. An electrospray ionization 
source (ESI) had a sheath gas of 25, aux gas of 8, and sweep gas of 3 at a constant 
voltage of 3.00 kV. The capillary temperature was 300° C. The mass spectrometer 
collected negative ions at resolution of 140,000, with an AGC of 3x 106 ions over 
the range of 72 m/z to 1000 m/z. Detection of known metabolites was based upon 
the exact mass of the negative ion (m/z), and a known retention time (RT) then 
compared to an in-house curated database. These two pieces of information 
allowed for the annotation of several hundred unique metabolites within each 
sample. 
1.3.5 Lipidomics 
The extraction of lipids from the cells used a well-established method that 
has been previously reported20. After the cell pellet was suspended in 9:1 
methanol: chloroform, 10 µL of sample was injected onto the UPLC instrument with 
a Kinetex HILIC column (150 mm x 2.1 mm, 2.6 µm) (Phenomenex, Torrance, CA, 
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USA). The mobile phases consisted of 10mM ammonium formate in water, mobile 
phase A and 10mM ammonium formate in 93% acetonitrile and 7% water for 
mobile phase B, both solvents were adjusted to a pH of 3.0. The flow rate was held 
constant at 0.200µL per minute and the column oven was set to 25°C for the 35-
minute duration. Gradient: t= 0 min 0% solvent A, 100% solvent B; t =1 min 0% 
solvent A 100% solvent B; t =15 min 19% solvent A 81% solvent B; t =15.1 min 
52% solvent A 48% solvent B; t =25 min 52% solvent A 48% solvent B; t =25.1 min 
0% solvent A 100% solvent B; t =35 min 0% solvent A 100% solvent B.21  
 An Exactive Plus Orbitrap mass spectrometer and  Dionex UltiMate 3000 
UPLC with an electrospray ionization source was used to analyze the eluent.  Mass 
spectrometer parameters were set as follows; spray voltage set to 4 kV, heated 
capillary 350 °C, sheath and aux gas to 25 and 10 units respectively. Lipid analysis 
was performed in both positive and negative mode to detect as many 
phospholipids as possible. Full scan and all ion fragmentation data was gathered 
at maximum resolution with a mass range of 100-1,500 m/z and 30 ev normalized 
collision energy. Annotation of compounds was achieved by exact mass, retention 
time and head group fragmentation.  
1.3.6 Flux analysis 
After the filtered cells reached an OD600 of 0.40 while growing on minimal 
medial plates that were supplemented with unlabeled glucose, the entire filter was 
transferred cell side up to 13C glucose supplemented minimal media plate. Cellular 
growth was quenched by chilled extraction solvent at 1, 2, 5, 10, 15, 30, and 60 
minutes in biological triplicate for all time points17.  Plots showing percentage 
incorporation over time was calculated and plotted using the FluxR package in R 
(publication pending). The software package averages the replicates and fits the 
data to a decay function y=Ae-kt,+C allowing for the turnover rate, k, to be 
calculated or each metabolite across all strains. To calculate relative pool size 
(Rp), or relative turnover rates (Rk), a simple ratio is taken compared to the value 
of the wild type and the error is calculated. Relative flux (Rf) is calculated by taking 
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the product of the relative pool size (Rp) and the relative turnover rate (Rk) 
(Equations 1 and 2). 
Equation 1: 
𝑅𝑓𝑥 =  𝑅𝑝𝑥 ∗  𝑅𝑘𝑥  
Equation 2: 







Rfx= relative flux of metabolite x 
Rpx= relative pool size of metabolite x 
Rkx= relative turnover rate of metabolite x 
δRfx= error of relative flux of metabolite x 
δRkx= standard deviation of turnover rate of metabolite x 
δRpx= standard deviation of pool size for metabolite x 
1.3.7 Data processing 
Data files were converted to mzML using MsConvert22 a tool within 
Proteowizard23 and processed using MAVEN software24. Annotation parameters 
consisted of exact masses within a ±5 ppm window and known retention times of 
standards.  All integrated areas were normalized to optical density. Heatmaps were 
generated using an in-house created R Script with all fold changes being log2 
transformed prior to plotting. Significance was determined by a Student’s T-test. 
Comparisons were made with respect to the wild type strain and fold changes are 
based on a log2 scale. The DiscriMiner package in R was utilized for multivariate 
analysis such as partial least squares discriminate analysis (PLSDA)25 with a leave 
one out cross validation. Data were log transformed, three components were used, 
and leave one out cross validation was applied. The calculation of relative flux for 
each metabolite is the product of the relative metabolite pool and the relative 
turnover rate.  
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1.3.8 Unidentified spectral features 
XCMS, an open source script developed to analyze chromatographic peaks 
generated by high resolution mass spectrometry data26 was used to annotate m/z-
retention time pairs. CAMERA27 was then used to identify m/z-RT pairs as possible 
adducts and/or isotopes. These features were removed prior to any further 
processing to avoid potential metabolite bias from these features. To further 
reduce the quantity of features and reduce the noise, the signal intensity had to be 
3 times the signal intensity of the extraction and media controls. Values were 
normalized to OD600 measurements, prior to any analysis. Multivariate analysis 
was performed on the data set to determine features with significant change. 
Theoretical molecular formulas were generated by using Seven Golden Rules28, 
with a 5 ppm error window, and restrictions to the following elements: C, N,H, O, 
P, and S. 
1.4 Results and Discussion  
1.4.1 Growth changes 
Though the cells were all grown in the same media with glucose as the only 
source of carbon, distinct changes in their generation time was observed (Figure 
1.2). The WT (MG1655) strain reached stationary phase the fastest with a doubling 
time of 1.68 hours, which is consistent with literature values29, 30. All seven mutant 
strains had a significantly longer doubling time than the wild type, most likely 
because the pathway for energy production, the tricarboxylic acid cycle, lacked 
critical enzymes. Doubling times ranged from over 2.75 hours for ΔacnB strain to 
1.90 hours for ΔfumA strain (Table 1.2). The ΔacnB, ΔsucAB and, ΔsucCD strains 
all had doubling times that were significantly different from the other 4 mutant 
stains, but not significantly different from one another.  The ΔacnA, ΔsdhAD, 
ΔfumA, and Δmdh mutant strains also had doubling times that were similar to one 
another but significantly different from the previously mentioned mutant strains. 
The difference in doubling times demonstrates that if a gene is deleted that codes
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Figure 1.2 Growth of E. coli over time 
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Table 1.2 Growth times of 8 different E. coli strains 
Error is calculated by standard deviation of the replicates, and significance is calculated by an unpaired Student’s T-test. Values 
in bold represent comparisons of doubling time that is <0.05. 
Strain Td (hr) 
p-values 
ΔacnB ΔsucAB ΔsucCD Δmdh ΔsdhAD ΔacnA ΔfumA WT 
ΔacnB 2.79±0.29 1 0.163 0.099 0.035 0.029 0.032 0.031 0.022 
ΔsucAB 2.44±0.12 0.163 1 0.216 0.011 0.009 0.008 0.008 0.007 
ΔsucCD 2.31±0.07 0.099 0.216 1 0.014 0.015 0.003 0.002 0.002 
Δmdh 2.01±0.09 0.035 0.011 0.014 1 0.657 0.315 0.148 0.020 
ΔsdhAD 1.98±.010 0.029 0.009 0.015 0.657 1 0.633 0.336 0.036 
ΔacnA 1.94±0.06 0.032 0.008 0.003 0.315 0.633 1 0.464 0.014 
ΔfumA 1.90±0.05 0.031 0.008 0.002 0.148 0.336 0.464 1 0.012 




for an enzyme in the beginning of the TCA cycle, their growth will be similar to the 
other mutant strains which lack enzymes in this half of the cycle. The opposite is 
also true for mutant stains lacking enzymes in the second half of TCA cycle. The 
only exception to this trend appears to be the ΔacnA strain. Although not 
possessing an enzyme that is located at the beginning of the cycle, its growth 
pattern resembles mutant strains with enzyme deficiencies later in the cycle. Upon 
optical inspection of the wildtype and mutant stains, all cells appeared to be rod-
shaped with no observable anomalies and relatively consistent sizes (Appendix 
Figure 1.11). 
1.4.2 Global metabolites  
Using an in-house curated list of standards, 146 metabolites were identified 
based on exact mass (± 5 ppm) and retention time. The heat map shows all 
identified metabolites in which each strain is compared to the WT (Figure 1.3, 
Appendix Table 1.8). Metabolites that had significant changes are noted with the 
following: p-value <0.01-***, <0.05-**,<0.1-*. The color of the box indicates the 
direction of the change, orange representing the metabolite was detected in higher 
amounts in the mutant strains when compared to the wild type strain. The first 
column, representing ΔacnA strain, shows that 50% of the metabolites measured, 
had fold changes greater than 2, and only 1 metabolite had a fold change less than 
0.5. The opposite trend can be seen the ΔacnB  strain where 42.5% of the 
metabolites showed a fold change of less than 0.5, as represented by the blue 
color in the heatmap. The Δmdh strain had the fewest number (8%) of fold changes 
greater than 2 and less than 0.5. This is visually interpreted by the muted colored 
cells in the last column of the Figure 1.3. This is not overly surprising because 
malate dehydrogenase is the final enzyme in the TCA cycle so many of the critical 
intermediate metabolites necessary for biosynthesis have already been produced 
earlier in the cycle. 
A similar trend in fold changes is seen when comparing ΔacnB and ΔsucCD 
strains. In addition to observing large wholistic fold changes, some of the smaller
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Figure 1.3 Heat map for known metabolites. 
Each column represents a log2 fold change of the average intensity for each metabolite 
compared to the average intensity of the WT. p-values are represented by asterisks 
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fold changes are still significant  can aid in explaining how the mutation is affecting 
metabolism. Again, we see ΔacnB mutants have the greatest number of significant 
fold changes (p-value <0.1) with 39 metabolites (Table 1.3). While ΔacnA had the 
least number of significant fold changes, and the intensity of these fold changes 
were very large, suggesting large variation within this mutant strain.  
1.4.3 Tricarboxylic acid cycle metabolites 
Changes in the relative amounts of TCA metabolites were anticipated to be 
observed and this analysis was able to detect 6 of 9 of those metabolites.  The 
TCA pathway with overlaid heat map slices was created to allow for the direct 
comparisons to be made (Figure 1.4). Once again, deletion of ΔacnB perturbed 
many metabolites throughout the pathway. Pyruvate was 2.4 times lower in the 
ΔacnB strain indicating that the amount of substrate entering the cycle is lower 
compared to the wild type strain. Next, the levels of citrate and aconitate were over 
ten times higher in this strain, presumably due to the lack of biosynthesis of 
isocitrate. It is important to note that citrate and isocitrate were detected as the 
same feature because they have identical m/z and are not separable in the 
chromatographic space used. All metabolites in the TCA cycle after the aconitase 
B deleted enzyme (2-oxoglutraric acid, succinate, fumarate, and malate) showed 
significant decreases, leading to the assumption that there is slow down of cycle. 
This was confirmed by the above-mentioned increase in doubling time. These 
changes are not mirrored by the homologous enzyme AcnA, but this is consistent 
with previous data suggesting these enzymes operate under unique conditions31 
We see a significant accumulation of succinate and decrease in fumarate in the 
ΔshdAD strain, confirming that the dehydrogenation reaction is reduced.  
1.4.4 Arginine biosynthesis  
In addition to being able to look at molecules directly related to the cycle 
where the mutation has occurred, an untargeted metabolomics approach can 
produce information about a wide variety of other pathways. The arginine 
biosynthesis pathway had near complete coverage with the detection of 12 
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Table 1.3 Number of significant metabolites for each strain.  





a fold change >2 
Metabolites with 
a fold change 
<0.5 
ΔacnA 10 73 1 
ΔacnB 39 9 62 
ΔsucAB 34 64 2 
ΔsucCD 25 8 61 
ΔsdhAD 27 55 4 
ΔfumA 14 49 2 




Figure 1.4 Heatmap overlaid on pathway map of TCA cycle 
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metabolites. Arginine is an essential amino acid for the continuation of cell growth, 
and accounts for 5% of all amino acids in the proteins within in E.coli32. Since these 
cells were grown in minimal media, they must produce these compounds de novo 
which starts with the conversion of glutamate, followed by a variety of 
intermediates which serve as branching off points for other metabolic pathways, 
before finally producing arginine33. With the ability to measure many of the 
intermediates, it is possible to explain how the cells’ metabolite pools are changing 
(Figure 1.5). A decrease in all identified metabolites, except for aginosuccinate 
are observed for the ΔacnB strain. The overall decrease can be traced back to the 
low levels for 2-oxoglutaric acid, a precursor to glutamate, which was produced as 
a direct effect of the genetic mutation. None of the other strains demonstrate this 
total decrease in metabolite levels throughout arginine synthesis, presumably 
because there is an adequate supply of glutamate being produced 
1.4.5 Chemometric analysis 
Multivariate tools like PLSDA were used to separate mutants based on 
which metabolites showed the greatest change34, 35 among groups.  These plots 
attempt to calculate how much of the explained variance is being contributed from 
each variable, or metabolite36.  The PLSDA (Figure 1.6) shows the separation of 
all seven mutant strains and the wild type using the 146 identified metabolites. The 
distance between the ellipses denotes the degree of uniqueness of the mutation’s 
metabolite profile. Using this analysis ΔacnB strain is completely isolated in 
component space, indictive of its metabolome being vastly different from the WT 
strain  and the other strains. The other mutant strains have metabolite profiles  
similar to the WT strain when compared to the ΔacnB strain. To determine which 
specific metabolites were driving the separations, variable importance in projection 
values (VIP) were extracted and analyzed. These values represent which 
metabolites contribute most to the separation seen within the PLSDA plot. A score 
greater than 1 was used as the minimum to be considered a significant metabolite 
in the separation36-38. A total of 43 metabolites were reported as having a
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Figure 1.6 Partial least squares discriminate analysis using known metabolites for all mutant 
strains and wild type 
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significant weight for driving the separation, and almost all of them were directly 
related to the production of amino acids or nucleotide base synthesis (data not 
shown). This further solidifies the argument that deletion of this single gene has 
detrimental effects on the cell’s ability for cellular reproduction and protein 
substrate formation. Pairwise PLSDA comparisons (Appendix Figures 1.12-1.18) 
and VIP scores (Appendix Table 1.9)  between each mutant and wild type strain 
show each group is separable by multivariate analysis; however the metabolites 
that drive the separation are different. Mutations ΔacnB and ΔsucCD had the most 
metabolites with VIP scores greater than 1, while ΔacnA had the fewest (Table 
1.4). Only one metabolite, glucosamine, was identified as contributing to 
separation between each mutant and the wild type strains.  
1.4.6 Unidentified spectral features 
One benefit of using a high-resolution mass spectrometer in full scan modes 
is the collection of chromatographic peaks across a large m/z range. This means 
it is possible to identify a m/z-retention time  peak as a “known” metabolite it if 
matches a previously analyzed standard. In addition to the metabolites that have 
been identified, there were thousands of other m/z-RT pairs (spectral features) that 
did not match any compound in the selected database. After postprocessing the 
unknown spectral features generated by XCMS and CAMERA, 1869 features 
remained. These features exhibited metabolite like characteristics, but the exact 
structures are not known. After meticulous data reduction,  it is possible to use this 
data gathered for multivariate analyses to determine what unknown features were 
changing across the strains. The PLSDA for the unknowns (Figure 1.7) look very 
similar to the PLSDA of the known metabolites (Figure 1.6).  This plot shows the 
profiles of unknown metabolites are unique for the ΔacnB strain when compared 
to the WT and the other genetically modified strains. Again, pairwise PLSDA was 
performed (Appendix Figures 1.19-1.25) showing each individual strain has an 
unknown metabolite profile that separable in multivariate space compared to the 
wild type. When VIP scores were calculated of this set of unknows, 822 features
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Table 1.4 Summary of the number of knowns metabolites identified as significant in pairwise 
PLSDA. 











Figure 1.7 Partial Least Squares Discriminate Analysis using unknown features for all 
mutant strains and wild type 
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had values ≥1. Eleven of these significant VIPs features corresponded the exact 
m/z for different dipeptides.  
Aside from looking at the unknown features collectively, it is also possible 
to further probe the data for individual compounds that may not have any direct 
relation to the pathways of interests or have a specific function. Within these data, 
22 features were tentatively annotated as dipeptides, based on an exact mass with 
an error less than 5 ppm (Table 1.5), and a molecular formula match using the 
Seven Golden Rules. Since the UPLC-HRMS method did not perform any 
fragmentation scans, and standards for each dipeptide were not in the reference 
library used,  it was not possible to confirm the exact identity of any isomeric amino 
acid residues. The heat map (Figure 1.8, Appendix Table 1.10 ) shows how these 
dipeptides are changing in relative abundance when compared to the wild type. 
There were relatively few significant changes, but the bulk of the changes are seen 
in the ΔacnB and ΔsucAB strains with 6 and 7 significant changes respectively. 
This corresponds with the earlier known metabolomics data that shows these two 
strains result in the most varied metabolome. With the ΔacnB strain, the majority 
of the dipeptides are in lower abundance, and most notability are Gly-Asp, Met-
Glu, Met-Asp, and Glu-Pro. The individual free amino acids, glutamate, 
methionine, and aspartic acid are all lower in abundance as well (Figure 1.8). 
Conversely, the ΔsucAB strain have the majority of the dipeptides in greater 
abundance than the wild type, as seen by glycine-cystine, and glutamine-alanine. 
The detection of these short peptides has only been reported in a handful of 
bacterial samples, notability when the organism is facing some sort of stress 
1.4.7 Lipid analysis  
Previous literature reports phosphatidylethanolamine (PE), 
phosphatidylglycerol (PG), and cardiolipin (CL) are the major lipid species present 
in E.coli, membranes39 while others show that PA and PS make up much smaller 
percentages.40-42 Although many studies have focused on investigating how lipid 
composition changes during different growth phases in response to temperature
39 












159.0774 159.0775 Ala-Ala 0.629 1.18 
173.0930 173.0931 Val-Gly 0.578 1.69 
177.0339 177.0338 Gly-Cys 0.565 1.47 
189.0517 189.0516 Gly-Asp 0.529 8.23 
191.0672 191.0673 Ser-Ser 0.523 1.16 
201.0881 201.0880 Ser-Pro 0.497 8.33 
202.0833 202.0832 Asn-Ala 0.495 6.71 
215.1035 215.1036 Thr-Pro 0.465 1.24 
216.0991 216.0989 Gln-Ala 0.926 7.37 
217.0828 217.0830 Glu-Ala 0.921 4.51 
233.0778 233.0779 Glu-Ser 0.429 6.43 
243.0986 243.0986 Glu-Pro 0.000 4.88 
251.0515 251.0528 Cys-Met 5.178 11.18 
259.1299 259.1299 Leu-Glu 0.000 8.89 
260.0888 260.0888 Asn-Glu 0.000 4.98 
261.0730 261.0728 Asp-Glu 0.766 11.25 
263.0707 263.0706 Met-Asp 0.380 8.65 
275.0889 275.0885 Glu-Glu 1.454 11.17 
277.0864 277.0863 Met-Glu 0.361 7.40 
279.0834 279.0841 Met-Met 2.508 4.63 
309.1096 309.1092 Glu-Tyr 1.294 9.96 




Figure 1.8 Heat map of unknown features annotated as dipeptides  
Ratios are mutant compared to the wild type. Significance is dented by the asterisks 
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or by the elimination of a protein responsible for lipid synthesis39, lipidomic analysis 
is able to capture lipid changes based on genetic mutations in a cycle not directly 
related to the biosynthesis of phospholipids. Primary acyl chain lengths in E.coli 
are hexadecanoic acid (C16:0), tetradecanoic (C14:0), cis-9-hexadecanoic 
(C16:1), and cis-11-octadecenoic (C18:1).43 The untargeted lipid analysis detected 
five different phospholipid classes; phosphatidylethanolamine (PE), 
phosphatidylglycerol (PG), phosphatidic acid (PA), phosphatidylserine (PS), and 
cardiolipin (CL). Unique compounds were identified by exact mass (±5 ppm) and 
known head group retention time. Since this analysis is not capable of determining 
the exact fatty acid tails attached to the glycerol backbone, unique species are 
listed  by head group abbreviation, the sum of carbons, and double bonds in all 
fatty acid tails. Four CL, five PA, nine, PE, six PG, and four PS compounds were 
identified across all samples. A heat map shows all detected phospholipids 
compared to the wild type (Figure 1.9, Appendix Table 1.11). The continued trend 
that a deletion of the ΔacnB gene causes large changes is also reflected in the 
lipidomics data. All the significant lipids show a decrease for the ΔacnB mutant, 
whereas many of the other mutants have very small and nonsignificant fold 
changes. When investigating the nine PE compounds detected, eight of the lipids 
were significantly decreased in the ΔacnB strain. Although E.coli possesses a 
mechanism to maintain the ratio of PE to PG/CL44,drastic changes can be seen for 
PE(30:2) and PE(28:1) in ΔacnA and ΔfumA mutants.  It is known that PE makes 
up 70% of the cell’s membrane, and the inability to produce such compounds can 
lead to complications within cellular division45, 46. It is surprising to see such 
negligible changes in all mutants other than ΔacnB. These data support the idea 
that the phospholipid composition is highly dependent on the site of mutation.  
1.4.8 Flux analysis 
The flux analysis was able to measure isotopic labeling of carbons in 87 of 
the 146 metabolites detected, including six metabolites used as substrates in the 
TCA cycle. Not all metabolites measured showed appreciable labeling due to slow
42 
 
Figure 1.9 Heat map for lipids detected for each strain compared to WT. 
Significance depicted by asterisks 
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de novo biosynthesis. Six metabolites that had different rates of incorporation for 
specific mutants are shown (Figure 1.10). 2-oxoglutrate shows very rapid labeling 
in the WT and all mutant strains except for ΔacnA and ΔsucAB. These mutants 
showed a slight decrease in how quickly these metabolites were labeled with 13C.  
Succinate showed quick labeling in the wild type strain which indicates that the first 
half of the TCA cycle was working rapidly, but the ΔsdhAD strain, which is 
responsible for the dehydrogenation of succinate to form fumarate, only became 
partially labeled after 60 minutes. This suggests that only half of the succinate 
molecule is being produced from the labeled glucose and taken through the TCA 
cycle. Strangely, all other deletion strains show no labeling suggesting that 
succinate in not being produced from glucose, but from some salvage pathway. 
Once again, ΔacnB mutants show unique behavior for fumarate, malate, and 
glutamate with decreased labeling. Phenylalanine has an opposite trend where the 
WT, ΔacnA, and ΔacnB strains show no labeling but the remaining mutant strains 
show a similar trend of rapid incorporation. 
It is also possible to compare the relative flux of the metabolite pools, which 
considers the metabolite concentration and the turnover rate of the metabolite47. 
The relative flux calculation is based on the ratio of mutant flux compared to wild 
type for both the metabolite pool and the turnover rate. The metabolite pool is 
collected from the untargeted metabolomics data, and the turnover rate is collected 
from the isotope flux data. If the flux is large, it could be a result of a very large fold 
change in a metabolite, a very quick turnover, or some combination of both.  
Relative flux was only calculated for eighty-one metabolites, (Appendix Tables 
1.12-1.14) since a metabolite must be detected in both the untargeted 
metabolomics data and the flux experiment. A subset of relative flux data shows 
drastic changes across the different strains (Table 1.6). This phenomenon is best 
observed when comparing glutamate, glutamine, 2-oxoglutaric acid glutathione, 
and glutathione disulfide.  
As noted in the arginine section above, ΔacnB strains show a significant 
decrease in pool size of these intermediate metabolites, which include glutamine, 
44 
 
Figure 1.10 Flux plots showing a reduction of unlabeled material over time 
45 
Table 1.6 Relative pool size, relative turnover, and relative flux for five metabolites.  
All comparisons are made with reference to the wild type strain. 
Metabolite 
Relative Pool Size 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
Glutathione 1.03±0.18 1.06±0.14 1.05±0.16 1.00±0.34 0.78±0.1 1.16±0.18 0.91±0.15 
Glutathione 
disulfide 
7.41±10.39 1.41±1.53 4.54±5.37 7.58±12.57 6.98±9.17 2.24±1.57 4.02±4.3 
2-oxoglutaric 
acid 
1.01±0.24 0.19±0.04 1.09±0.13 1.07±0.48 0.52±0.29 0.56±0.06 0.70±0.14 
glutamate 1.17±0.27 0.58±0.07 1.1±0.17 1.05±0.13 0.89±0.21 0.91±0.09 0.87±0.12 




ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
Glutathione 1.07±0.02 1.12±0.03 0.88±0.04 1.11±0.05 1.00±0.04 1.03±0.02 0.93±0.02 
Glutathione 
disulfide 
1.54±0.17 1.39±0.17 0.99±0.12 1.51±0.18 1.21±0.15 1.15±0.13 0.73±0.14 
2-oxoglutaric 
acid 
2.4±0.31 0.45±0.05 0.46±0.05 1.46±0.17 1.23±0.19 0.94±0.14 1.83±0.25 
glutamate 1.84±0.16 0.42±0.03 0.32±0.02 1.13±0.09 1.15±0.09 0.91±0.08 1.36±0.13 
glutamine 1.87±0.25 0.47±0.05 0.29±0.03 1.14±0.14 1.17±0.15 0.93±0.13 1.39±0.19 
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Table 1.6 continued 
Metabolite 
Relative Flux 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
Glutathione 1.07±0.02 1.12±0.03 0.88±0.04 1.11±0.05 1.00±0.04 1.03±0.02 0.93±0.02 
Glutathione 
disulfide 
11.46±16.07 1.96±2.13 4.5±5.34 11.51±19.11 8.46±11.13 2.58±1.81 2.94±3.19 
2-oxoglutaric 
acid 
2.42±0.61 0.08±0.02 0.5±0.06 1.57±0.71 0.64±0.37 0.53±0.08 1.28±0.29 
glutamate 2.16±0.51 0.24±0.03 0.35±0.05 1.19±0.16 1.03±0.25 0.83±0.1 1.18±0.19 
glutamine 3.56±1.81 0.21±0.04 0.36±0.17 0.83±0.31 1.48±0.5 0.97±0.39 1.57±0.47 
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glutamate, and 2-oxoglutaric acid. This information combined with the lower 
relative turnover rates (~0.43) resulted in drastically diminished flux of material 
through this cycle. Flux rates were 8% of the wild type for 2-oxoglutaric acid, and 
21% and 22% of the wild type for glutamate and glutamine. This further shows that 
the arginine cycle is not only subjected to low amounts of material entering the 
cycle, but also slowed conversion of metabolites within this cycle. Interestingly, the 
opposite trend was seen with the ΔacnA strain in which metabolite concentrations 
were not significantly different than the wild type. However, flux rates were 
between 200%-350% of the wild type. This shows that even though these two 
strains act on the same substrate in the TCA cycle they have drastically distinct 
effects on the arginine biosynthetic pathway.  
The ΔsucAB strain does not produce the oxoglutarate dehydrogenase 
complex, limiting the conversion of 2-oxoglutate to succinyl-CoA through the TCA 
cycle, but this mutation would not directly interfere with the conversion of 2-
oxoglutarate into glutamate which happens at the beginning of the arginine 
biosynthetic pathway. Measuring the pool size or turnover rate independently 
would not provide enough information to understand if the alterations observed 
were related to amount of metabolite available (pool size) or if the metabolite’s 
conversion rate (turnover) was slowed. No change was seen in the pool size of 2-
oxglutarate or glutamate, but there was a steep decrease in the relative flux of 
these metabolites due to the low turnover rates (Table 1.6). These data further 
suggest that the inability to produce a single enzyme effects metabolism is 
adjacent pathways, leading to unique metabolite profiles. 
In an ancillary pathway centered around glutathione metabolism, changes 
to glutathione (GSH) and glutathione disulfide (GSSH) levels are indicative of the 
oxidative stress of the cell. Investigating the flux of these two metabolites reveled 
a stark discrepancy between strains, with flux ratios hovering around 1 for 
glutathione and values ranging from 2 to over 11 for glutathione across all mutants. 
These values are a result of differences in total metabolite pool size and not the 
turnover rate of the metabolites (Table 1.6). Since the metabolomics experiment 
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does not provide absolute quantities and ionization efficiencies of each metabolite 
are varied, it is not possible to generate meaningful ratios between these two 
metabolites. Presence of large amounts of the oxidized glutathione has been 
shown to directly relate to stress conditions in cells due to interactions with reactive 
oxygen species 48, 49. Generalities relating to increased oxidative stress can be 




Using an untargeted UPLC-HRMS approach on a systematic set of central 
carbon metabolism mutants in Escherichia coli allowed for the identification of 146 
metabolites to be profiled and their relative changes applied to specific pathways. 
Effects were not only seen on the direct metabolites of the TCA cycle, but also 
measured on auxiliary pathways like arginine biosynthesis. The Aconitase B 
deletion strain was the only strain that had a depressed growth rate as well as  a 
unique metabolite profile as determined by PLSDA. Over 1,700 unidentified 
features were detected and by applying  multivariate analyses as well as Van 
Krevelen diagrams, information about how the small molecules were changing 
collectively were elucidated. Twenty-two unknowns were putatively assigned as 
dipeptides, which have cellular functions yet to be determined. Lipid analysis 
showed ΔacnB strain had reduced levels of several phosphatidylethanolamine and 
cardiolipin species, where as other strains had few significant changes. The flux 
analysis probed the conversion specific metabolites within the TCA and arginine 
pathways showing changes in a metabolite can be due to total metabolite levels 
or due to changes in metabolite turnover. It been shown by combining three 
different metabolomic analyses a clearer understanding of how small molecules 




Table 1.7 Oligonucleotides used in this study 
Name 
5'-3' Sequence (Nucleotides that correspond to E. coli MG1655 genome in italics;  
capital letters for pKD4 template) 
Use 
EF1352 caccctgaagagaatcagggcttcgcaaccctgtcattaagGTGTAGGCTGGAGCTGCTTC deletion of 
acnA 
EF1353 ccgtcgcgccgggttgtaggttttgcagatcgccaatatcCATGGGAATTAGCCATGGTCC deletion of 
acnA 
EF1356 gcgtgaagagaatcgcctgccgcactatgacaatgagagcgaggGTGTAGGCTGGAGCTGCTTC deletion of 
acnB 










Table 1.7 continued 
Name 
5'-3' Sequence (Nucleotides that correspond to E. coli MG1655 genome in italics; 






EF1365 gtagagggaagcggcgagggctatttcttattacagatatttaTCAGAAGAACTCGTCAAGAAGGCGA deletion 
of sucCD 
EF1368 ctccaggtaacagaaagttaacctctgtgcccgtagtccccagGTGTAGGCTGGAGCTGCTTC deletion  
of sdhCADB 
EF1369 ggtttacgcattacgttgcaacaacatcgacttgatatggccCATGGGAATTAGCCATGGTCC deletion  
of sdhCADB 
EF1376 cagcggagcaacatatcttagtttatcaatataataaggagGTGTAGGCTGGAGCTGCTTC deletion  
of mdh 
EF1377 cgtatccagcataccttccagcgcgttctgttcaaatgcgctcagCATGGGAATTAGCCATGGTCC deletion  
of mdh 
EF1394 caacggaacacccgcccagagcataaccaaaccaggcagtaagGTGTAGGCTGGAGCTGCTTC deletion  
of fumA 

















Figure 1.11 Optical microscopy images of seven mutant and one wild type strain of E.coli. 
A) ΔacnA cells; B) ΔacnB cells; C) ΔsucAB cells; D) ΔsucCD cells; E) ΔshdAD cells; F) 








Figure 1.11 continued 
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Table 1.8 Ratios and p-values used for heat map of knowns 
Compound 
Ratio compared to WT 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Pyruvate 0.817559 0.408834 1.192752 0.662213 1.356302 1.079559 0.979796 
Alanine/Sarcosine 2.599924 0.543318 1.99279 0.462391 2.122322 1.558015 1.050535 
Lactate 1.383265 1.260585 4.586125 0.94888 4.182785 1.715196 1.243399 
4-Aminobutyrate (GABA) 2.443333 1.154082 1.397196 0.852195 1.538444 1.276367 1.129969 
Serine 2.81257 0.379781 2.160891 0.288083 2.008892 2.312769 1.136157 
Glycerate 7.538137 0.333212 3.208331 0.201578 2.018131 2.447011 0.747273 
Uracil 9.563469 0.232203 5.87937 0.110987 3.557714 4.333116 1.348408 
Creatinine 0.899143 0.20559 9.469383 0.061896 1.503947 5.378761 0.940182 
Proline 5.591032 0.061975 2.430255 0.107863 0.708409 1.555911 0.387508 
Fumarate 1.779682 0.412344 1.459412 0.802468 1.08632 1.528558 1.828354 
Valine 3.648324 0.499727 2.031192 0.480008 1.231319 1.729553 0.880606 
Succinate/Methylmalonate 1.795821 0.445029 1.328169 0.566887 2.138568 1.375372 0.861365 
3-Hydroxyisovaleric acid 1.142933 1.410548 1.729162 0.926189 1.379613 1.130431 1.130838 




Table 1.8  continued 
Compound 
Ratio compared to WT 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Cysteine 3.871757 0.781341 2.018452 0.46256 0.647504 2.212705 0.942082 
Nicotinate 6.63197 0.153298 2.575137 0.08917 1.427931 3.320796 0.923592 
Taurine 0.402968 0.100164 1.566734 0.026815 5.330869 0.733307 0.234901 
Thymine 1.753228 0.36707 0.972456 0.461619 0.892933 0.897483 0.866856 
Pyroglutamic acid 5.11582 0.305763 3.956248 0.261902 1.751922 3.206496 0.983102 
Citraconate 1.788604 3.052834 1.367968 0.871908 8.895901 1.352892 6.498326 
N-Acetylputrescine 0.997376 0.15651 0.845436 0.620806 0.741228 1.00056 1.568425 
N-Acetyl-beta-alanine 3.486717 0.765327 2.145103 0.642692 4.356841 1.881201 0.901909 
Hydroxyproline 2.502303 0.583862 3.369341 0.198118 3.7062 3.261463 2.159947 
Creatine 0.688364 0.450644 7.580578 0.054622 2.683826 2.691387 1.148442 
Leucine/Isoleucine 5.73384 0.269982 3.049796 0.194697 1.986458 2.552818 0.906318 
Asparagine 3.244821 0.564972 1.594903 0.460796 1.436331 1.558249 0.84441 
Hydroxyisocaproic acid 1.864028 0.626585 5.739818 0.440571 1.228531 1.097088 0.692171 
Ornithine 2.430611 0.774572 2.491186 0.861141 1.742193 1.997608 1.564771 
Aspartate 1.836341 0.481845 1.24309 0.761951 1.374369 1.140794 0.492444 
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Table 1.8 continued 
Compound 
Ratio compared to WT 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Homocysteine 0.631608 0.377504 0.541333 0.870647 1.008292 0.815081 0.743085 
Adenine 2.001719 0.749836 2.244176 0.45282 2.176883 1.499465 1.357539 
Hypoxanthine 1.143556 0.371931 9.294552 0.092317 3.534935 5.348831 1.037236 
Hydroxybenzoate 9.359499 0.301932 4.539554 0.28089 0.506388 5.631176 0.489996 
Acetylphosphate 0.85148 0.723526 1.023923 0.668612 0.936944 0.624193 0.79658 
Carbamoyl phosphate 4.254655 0.567499 2.35573 0.873407 6.645534 2.762511 2.080337 
Histidinol 0.640886 0.136758 1.199794 0.123238 0.558329 1.614433 1.067868 
2-Oxoglutaric acid 1.011598 0.195506 1.097869 1.070703 0.522836 0.701251 0.56353 
Glutamine 1.904689 0.447973 1.22787 0.730874 1.271724 1.131239 1.043497 
Lysine 3.204039 0.601794 2.548965 2.4315 1.871548 1.905474 0.868669 
Glutamate 1.171228 0.58048 1.109454 1.054979 0.897603 0.870723 0.914434 
2-Hydroxy-2-methylsuccinate 3.015156 0.5383 3.697426 0.568479 1.50545 1.676633 1.292648 
L-Methionine 7.332898 0.234882 1.374438 0.571223 0.448249 2.722408 0.518033 
Guanine 1.394658 0.460679 7.995589 0.148 1.840911 3.648315 1.227919 
Hydroxyphenylacetate 9.251212 0.160269 2.075246 0.123668 0.2548 4.786232 0.247012 
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Table 1.8 continued 
Compound 
Ratio compared to WT 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Xylitol 2.256215 0.172082 1.121968 0.090117 4.102346 1.023754 1.128361 
2-3-Dihydroxybenzoate 1.38224 0.771676 0.95845 0.550185 0.767852 0.964008 1.005449 
Histidine 11.40544 0.302309 2.955617 0.211636 1.539817 3.854994 0.312439 
Orotate 1.096382 1.356069 1.00348 0.949207 0.881372 0.910768 1.414926 
Dihydroorotate 1.420312 2.361942 1.362844 1.400315 1.075346 1.326142 2.403442 
Allantoin 4.716015 0.261038 3.487318 0.01386 6.342719 2.759211 1.108042 
2-Aminoadipate 9.371814 0.683427 3.922114 0.372044 3.72092 3.215391 1.988742 
Phenylpyruvate 0.96189 0.756318 1.046036 0.847224 0.919344 0.874964 1.011164 
Phenylalanine 4.048332 0.421759 3.452762 0.23434 2.816218 2.491669 1.019163 
Phenyllactic acid 1.372359 0.881605 2.778919 0.57037 2.141397 1.798984 0.925527 
Phosphoenolpyruvate 3.923624 1.21529 1.924871 0.740034 1.500343 2.07519 1.002911 
Uric acid 2.204427 0.19315 2.56087 0.023116 2.096855 7.433322 1.051663 
3-4-Dihydroxyphenylacetate 
(DOPAC) 
2.361691 0.951139 1.406228 0.601898 2.813496 1.649975 1.861731 
Cysteate 11.5133 0.151236 2.133426 0.055773 11.72645 3.422364 3.155136 
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Table 1.8 continued  
Compound 
Ratio compared to WT 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Sulfolactate 3.167741 0.908813 2.075801 0.912203 3.017429 3.064962 1.44379 
D-Glyceraldehdye 3-
phosphate 
0.852538 0.773496 1.246961 0.726963 1.245555 1.00339 1.262345 
sn-Glycerol 3-phosphate 6.218536 0.327668 3.34111 0.182198 4.96311 3.980677 1.66124 
Aconitate 2.930559 10.15992 1.734409 0.689959 13.29157 1.848187 9.178361 
Shikimate 1.231818 1.460672 1.194573 0.852308 1.414955 1.536265 1.492225 
N-Acetylornithine 1.352175 0.397064 1.474562 0.698786 1.252374 1.243904 1.296039 
Arginine 7.102184 0.11298 3.218138 0.095762 2.650289 2.688913 0.953388 
Citrulline 1.719241 1.038782 2.388313 1.062527 1.586526 1.589883 1.710965 
N-Carbamoyl-L-aspartate 1.354358 1.638516 0.810493 0.812686 0.946863 0.812921 1.788641 
Allantoate 9.854608 0.004105 2.243668 0.002558 7.487993 3.62477 1.961358 
2-Isopropylmalate 1.441357 3.555884 1.435344 2.199517 1.777269 1.494843 1.448003 
Glucosamine 2.221652 0.606628 2.381403 0.346521 2.167028 3.350744 1.364071 
Tyrosine 5.268642 0.187487 2.511975 0.126022 2.740414 1.803791 1.197748 
Homovanillic acid (HVA) 1.298503 0.432882 1.198988 0.279216 3.173546 1.044708 0.420466 
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Table 1.8 continued 
Compound 
Ratio compared to WT 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Homocysteic acid 1.400728 0.095233 1.23194 0.016431 9.650709 1.681537 0.304546 
4-Pyridoxate 1.613595 1.473651 1.695174 0.850279 2.773981 1.761852 1.27167 
3-Phosphoserine 1.605564 1.640136 1.495041 1.192422 1.132869 1.296696 0.763316 
3-Phosphoglycerate 2.715271 1.229201 1.918035 0.956163 1.575748 2.099121 1.062949 
N-Acetylglutamine 1.485194 1.089171 1.488591 1.234549 1.53487 1.422357 0.987455 
Acetyllysine 1.250287 0.665801 1.609792 2.723738 1.866086 1.011614 0.786242 
N-Acetylglutamate 1.650854 0.370694 1.394935 2.666892 0.968358 1.567312 2.271437 
Citrate/isocitrate 2.493952 17.25215 1.756963 0.660992 1.668573 2.432668 0.790152 
2-Dehydro-D-gluconate 3.980524 0.522708 1.938809 0.066004 10.82273 2.732236 0.363228 
D-Gluconate 7.945641 0.65773 6.578516 0.357373 9.982397 8.042475 1.236061 
Tryptophan 3.734099 0.393015 2.909213 0.311004 4.986518 2.24324 0.889259 
Xanthurenic acid 11.90371 0.006628 3.014224 0.005151 0.543634 4.114538 0.329907 
D-Glucarate 33.00513 0.220341 7.789856 0.039015 13.77967 19.56253 2.773641 
Deoxyribose phosphate 1.396047 1.136123 1.130736 0.529849 1.098417 0.798009 1.160815 
Pantothenate 2.543105 0.671166 1.558541 0.53127 1.50719 1.810509 1.104043 
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Table 1.8 continued 
Compound 
Ratio compared to WT 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
N-Acetylglucosamine 7.539576 0.151323 3.506879 0.041498 6.023714 2.290944 1.726523 
Cystathionine 5.020598 0.149044 2.544757 0.271944 0.780783 2.747714 0.552731 
Ribose phosphate 1.082406 1.539087 1.095683 1.220328 0.950142 1.066856 1.00538 
Thymidine 6.288857 1.802158 11.66445 0.889888 71.52812 5.401197 1.310555 
Cytidine 5.334848 0.058048 2.198278 0.007294 5.226988 1.962057 1.623158 
Uridine 4.917963 0.385754 3.08733 0.293487 5.337861 2.399608 0.776382 
Shikimate-3-phosphate 1.382471 1.000213 1.444664 1.020679 0.947174 1.240452 1.470273 
Deoxyinosine 14.26959 0.047914 2.873008 0.010961 13.20736 5.294777 0.399697 
Glucosamine phosphate 0.759313 1.288793 0.767206 0.958057 0.757546 0.6792 0.904602 
Glucose 6-phosphate 1.22936 1.305655 1.182584 1.239902 1.115238 1.17743 1.263294 
S-Ribosyl-L-homocysteine 0.937026 0.294905 0.663814 2.499252 0.688943 0.843503 0.679761 
Adenosine 11.29933 0.470685 4.001915 0.051083 19.91322 1.393327 1.499717 
Inosine 12.45544 0.097312 3.319042 0.011562 7.486919 1.776252 1.149079 
6-Phospho-D-gluconate 1.28075 2.566063 1.25326 1.090835 1.390978 1.450253 0.746247 





Table 1.8 continued 
Compound 
Ratio compared to WT 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Guanosine 11.78554 0.034277 3.635347 0.021395 2.706876 3.097138 0.895944 
Xanthosine 1.566921 0.607456 7.219069 0.137127 17.6873 1.002636 0.645449 
Glycinamide ribotide (GAR) 1.165352 0.615558 0.871689 1.825291 0.744214 0.918876 0.926487 
Ophthalmate 1.074735 1.398286 1.304632 1.167689 1.10377 0.997524 1.004373 
Sedoheptulose 1/7-phosphate 2.368293 1.745418 1.489786 1.039251 1.801168 1.55371 0.939441 
L-Argininosuccinate 1.033199 1.399447 1.2863 1.163563 1.08611 0.934547 0.998164 
Aminoimidazole ribotide (AIR) 0.872952 0.713945 0.668699 0.865067 0.651038 0.678655 0.941627 
N-Acetylglucosamine1/6-
phosphate 
5.685138 0.542695 2.061399 0.469715 2.591054 2.458341 1.433114 
dCMP 2.633051 0.64221 1.37099 0.591884 2.246449 1.331868 0.864121 
Glutathione 1.038381 1.066427 1.051167 1.003517 0.781016 0.914961 1.164645 
dUMP 1.360428 0.205407 1.034724 0.33133 1.137782 0.539705 0.843618 
Octulose 8/1P 1.482358 1.631491 1.400373 0.581056 1.445783 1.075167 1.146374 
dTMP 1.815937 0.609651 1.221246 0.66859 1.263741 0.943098 0.980325 




Table 1.8 continued 
Compound 
Ratio compared to WT 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
UMP 8.016368 0.089128 3.107172 0.182362 3.457899 3.475042 1.351323 
cAMP 1.472813 0.522246 1.234339 0.882613 1.390511 1.137886 0.688245 
dAMP 7.644848 0.219817 1.769097 0.528377 1.462176 2.866802 0.780611 
AICAR 1.076166 0.439659 0.662515 0.789972 0.527173 0.772698 0.585088 
Fructose 1-6-bisphosphate 1.510135 0.752697 1.848661 1.845592 1.442023 1.813032 1.793679 
Trehalose/Sucrose/Cellobiose 2.816096 2.086252 1.307267 0.489209 3.225713 1.5062 0.723092 
AMP/dGMP 7.718746 0.106969 3.121977 0.097167 3.800375 3.467976 1.516861 
IMP 2.702533 2.355208 3.584845 1.595023 2.887482 1.429597 2.422436 
GMP 6.196369 0.346137 3.221855 0.238211 3.286996 3.679078 1.081144 
Xanthosine 5--phosphate 1.240618 1.562197 1.301846 1.57425 0.920716 1.130003 1.258852 
Sedoheptoluse bisphosphate 1.790522 1.623576 2.158161 1.622842 1.488936 1.771769 1.196282 
Octulose bisphosphate 2.128861 1.639425 2.582704 1.876357 2.217216 1.836527 1.427445 
Sucralose 0.811571 0.128594 0.399461 0.348711 0.128819 0.110828 0.272512 
dTDP 1.095808 0.394028 0.250553 0.193797 0.142857 0.106998 0.56189 
UDP 1.091648 0.606564 1.942985 0.774482 0.937755 1.410943 0.799198 
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Table 1.8 continued 
Compound 
Ratio compared to WT 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Trehalose 6-phosphate 1.594984 1.383391 1.312339 3.514777 1.237247 1.353936 0.959988 
ADP 2.417404 0.830957 2.147184 0.584052 1.730543 2.55483 0.970592 
GDP 1.691171 2.311809 2.790494 1.364149 1.235829 2.348203 0.938009 
FMN 0.938344 0.693389 0.93031 0.506128 0.715199 0.738716 0.901063 
UDP-glucose 1.131803 0.797451 1.144863 1.131207 0.618039 0.965063 1.421822 
UDP-glucuronate 0.974791 0.797922 1.290523 1.293456 1.272567 0.899373 1.419145 
ADP-glucose 0.905388 0.67405 0.862655 0.967736 0.603296 0.758243 0.98903 
UDP-N-acetylglucosamine 3.869191 0.500877 1.449668 0.577016 1.215771 1.732194 1.169687 
Glutathione disulfide 7.417341 1.410187 4.544838 7.581481 6.982106 4.028293 2.249509 
NAD+ 1.156482 0.978494 1.073981 0.875703 0.942093 1.011531 1.019715 
NADH 2.065357 0.679624 2.831388 2.093241 1.821029 1.639478 1.453124 
NADP+ 1.213001 0.968979 1.148822 0.646595 0.964138 1.141682 0.949886 
FAD 1.070981 0.688994 0.976141 0.683638 0.665256 0.80389 1.123639 
Acetyl-CoA 1.321138 1.056979 1.814033 1.234619 1.006229 1.507803 1.502358 
Malate 2.110262 0.335274 1.454708 0.720285 1.693052 1.730418 2.150864 
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Table 1.8 continued 
Compound 
p-value 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Pyruvate 0.051 0.001 0.261 0.044 0.010 0.399 0.876 
Alanine/Sarcosine 0.285 0.044 0.051 0.026 0.180 0.190 0.867 
Lactate 0.568 0.690 0.077 0.934 0.163 0.323 0.692 
4-Aminobutyrate (GABA) 0.259 0.269 0.393 0.324 0.044 0.331 0.597 
Serine 0.326 0.315 0.211 0.266 0.151 0.366 0.894 
Glycerate 0.368 0.362 0.384 0.296 0.276 0.361 0.752 
Uracil 0.354 0.243 0.107 0.199 0.102 0.251 0.742 
Creatinine 0.828 0.156 0.227 0.126 0.713 0.353 0.932 
Proline 0.354 0.291 0.561 0.309 0.702 0.676 0.460 
Fumarate 0.207 0.024 0.229 0.361 0.780 0.021 0.005 
Valine 0.384 0.177 0.262 0.167 0.493 0.388 0.753 
Succinate/Methylmalonate 0.334 0.072 0.190 0.134 0.007 0.146 0.749 
3-Hydroxyisovaleric acid 0.421 0.126 0.284 0.710 0.110 0.557 0.475 
Homoserine/Threonine 0.336 0.224 0.279 0.882 0.470 0.511 0.716 
Cysteine 0.362 0.628 0.041 0.182 0.035 0.433 0.852 
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Table 1.8 continued  
Compound 
p-value 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Nicotinate 0.320 0.240 0.421 0.217 0.514 0.293 0.932 
Taurine 0.426 0.267 0.564 0.241 0.415 0.735 0.324 
Thymine 0.435 0.030 0.953 0.040 0.499 0.723 0.686 
Pyroglutamic acid 0.228 0.271 0.053 0.250 0.249 0.277 0.978 
Citraconate 0.148 0.044 0.232 0.456 0.031 0.091 0.421 
N-Acetylputrescine 0.996 0.110 0.729 0.352 0.555 0.999 0.235 
N-Acetyl-beta-alanine 0.322 0.453 0.134 0.294 0.300 0.165 0.773 
Hydroxyproline 0.159 0.295 0.039 0.075 0.002 0.325 0.158 
Creatine 0.550 0.349 0.197 0.161 0.214 0.409 0.809 
Leucine/Isoleucine 0.388 0.256 0.122 0.224 0.324 0.328 0.903 
Asparagine 0.303 0.163 0.375 0.105 0.151 0.369 0.771 
Hydroxyisocaproic acid 0.531 0.509 0.437 0.354 0.676 0.872 0.579 
Ornithine 0.226 0.268 0.064 0.493 0.029 0.187 0.062 
Aspartate 0.334 0.043 0.326 0.211 0.609 0.533 0.046 
Homocysteine 0.006 0.001 0.092 0.453 0.969 0.299 0.034 
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Table 1.8 continued 
Compound 
p-value 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Adenine 0.233 0.197 0.000 0.017 0.283 0.407 0.116 
Hypoxanthine 0.794 0.270 0.133 0.153 0.504 0.338 0.960 
Hydroxybenzoate 0.395 0.293 0.417 0.283 0.423 0.234 0.413 
Acetylphosphate 0.559 0.262 0.917 0.113 0.448 0.010 0.238 
Carbamoyl phosphate 0.203 0.479 0.100 0.844 0.295 0.101 0.347 
Histidinol 0.547 0.180 0.780 0.175 0.412 0.541 0.943 
2-Oxoglutaric acid 0.940 0.001 0.248 0.823 0.098 0.037 0.004 
Glutamine 0.218 0.036 0.552 0.208 0.318 0.515 0.868 
Lysine 0.317 0.168 0.161 0.005 0.069 0.311 0.760 
Glutamate 0.371 0.002 0.338 0.525 0.487 0.180 0.228 
2-Hydroxy-2-methylsuccinate 0.354 0.281 0.408 0.330 0.247 0.242 0.546 
L-Methionine 0.422 0.122 0.680 0.282 0.199 0.495 0.240 
Guanine 0.545 0.416 0.164 0.215 0.631 0.333 0.808 
Hydroxyphenylacetate 0.440 0.202 0.585 0.190 0.236 0.325 0.232 
Xylitol 0.170 0.050 0.705 0.045 0.298 0.967 0.906 
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Table 1.8 continued 
Compound 
p-value 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
2-3-Dihydroxybenzoate 0.452 0.203 0.848 0.066 0.200 0.841 0.980 
Histidine 0.421 0.256 0.410 0.215 0.604 0.336 0.260 
Orotate 0.225 0.006 0.984 0.797 0.154 0.503 0.038 
Dihydroorotate 0.106 0.003 0.438 0.247 0.806 0.498 0.022 
Allantoin 0.177 0.196 0.035 0.131 0.053 0.338 0.933 
2-Aminoadipate 0.351 0.620 0.367 0.367 0.303 0.330 0.634 
Phenylpyruvate 0.744 0.058 0.759 0.398 0.489 0.317 0.938 
Phenylalanine 0.358 0.107 0.114 0.065 0.222 0.357 0.972 
Phenyllactic acid 0.393 0.629 0.247 0.168 0.386 0.265 0.759 
Phosphoenolpyruvate 0.309 0.482 0.382 0.418 0.104 0.264 0.993 
Uric acid 0.553 0.271 0.153 0.212 0.457 0.438 0.966 
3-4-Dihydroxyphenylacetate 
(DOPAC) 
0.183 0.780 0.256 0.099 0.056 0.376 0.405 





Table 1.8 continued 
Compound 
p-value 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Sulfolactate 0.232 0.652 0.081 0.744 0.293 0.193 0.203 
D-Glyceraldehdye 3-
phosphate 
0.619 0.285 0.128 0.406 0.133 0.984 0.060 
sn-Glycerol 3-phosphate 0.323 0.213 0.343 0.161 0.249 0.240 0.678 
Aconitate 0.308 0.066 0.334 0.397 0.037 0.083 0.456 
Shikimate 0.458 0.210 0.488 0.661 0.280 0.244 0.141 
N-Acetylornithine 0.395 0.050 0.279 0.177 0.215 0.224 0.267 
Arginine 0.268 0.203 0.292 0.197 0.053 0.331 0.965 
Citrulline 0.065 0.804 0.063 0.765 0.167 0.124 0.065 
N-Carbamoyl-L-aspartate 0.051 0.040 0.092 0.314 0.676 0.072 0.006 
Allantoate 0.217 0.131 0.504 0.130 0.001 0.341 0.675 
2-Isopropylmalate 0.036 0.078 0.059 0.257 0.061 0.206 0.106 
Glucosamine 0.137 0.166 0.013 0.053 0.120 0.345 0.306 
Tyrosine 0.363 0.303 0.247 0.277 0.143 0.478 0.875 
Homovanillic acid (HVA) 0.547 0.283 0.685 0.206 0.436 0.939 0.274 
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Table 1.8 continued 
Compound 
p-value 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Homocysteic acid 0.551 0.210 0.737 0.188 0.373 0.608 0.312 
4-Pyridoxate 0.275 0.143 0.007 0.324 0.168 0.122 0.184 
3-Phosphoserine 0.003 0.204 0.004 0.724 0.491 0.348 0.185 
3-Phosphoglycerate 0.354 0.459 0.109 0.912 0.144 0.082 0.673 
N-Acetylglutamine 0.221 0.649 0.071 0.334 0.078 0.230 0.945 
Acetyllysine 0.331 0.099 0.034 0.029 0.272 0.955 0.366 
N-Acetylglutamate 0.124 0.140 0.366 0.140 0.935 0.169 0.114 
Citrate/isocitrate 0.408 0.041 0.296 0.369 0.205 0.058 0.521 
2-Dehydro-D-gluconate 0.412 0.428 0.155 0.167 0.400 0.336 0.317 
D-Gluconate 0.385 0.540 0.196 0.252 0.346 0.280 0.841 
Tryptophan 0.423 0.256 0.095 0.217 0.326 0.345 0.860 
Xanthurenic acid 0.437 0.387 0.546 0.387 0.666 0.322 0.544 
D-Glucarate 0.387 0.177 0.432 0.135 0.328 0.315 0.572 
Deoxyribose phosphate 0.049 0.425 0.289 0.034 0.536 0.266 0.189 
Pantothenate 0.339 0.051 0.443 0.012 0.197 0.248 0.588 
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Table 1.8 continued 
Compound 
p-value 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
N-Acetylglucosamine 0.214 0.279 0.387 0.240 0.365 0.384 0.712 
Cystathionine 0.414 0.143 0.566 0.181 0.632 0.490 0.360 
Ribose phosphate 0.738 0.031 0.517 0.379 0.676 0.767 0.973 
Thymidine 0.200 0.634 0.307 0.886 0.376 0.280 0.806 
Cytidine 0.249 0.197 0.460 0.183 0.004 0.538 0.742 
Uridine 0.366 0.208 0.017 0.171 0.290 0.322 0.651 
Shikimate-3-phosphate 0.394 0.999 0.018 0.952 0.777 0.361 0.135 
Deoxyinosine 0.359 0.286 0.423 0.272 0.429 0.333 0.488 
Glucosamine phosphate 0.298 0.150 0.073 0.681 0.124 0.049 0.461 
Glucose 6-phosphate 0.380 0.107 0.246 0.159 0.644 0.254 0.262 
S-Ribosyl-L-homocysteine 0.744 0.022 0.083 0.052 0.098 0.394 0.092 
Adenosine 0.210 0.630 0.228 0.391 0.313 0.795 0.788 
Inosine 0.357 0.173 0.276 0.153 0.372 0.579 0.911 
6-Phospho-D-gluconate 0.139 0.170 0.163 0.864 0.278 0.133 0.246 
1-Methyladenosine 0.361 0.305 0.282 0.287 0.338 0.505 0.751 
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Table 1.8 continued 
Compound 
p-value 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Guanosine 0.372 0.235 0.182 0.231 0.150 0.367 0.924 
Xanthosine 0.690 0.621 0.002 0.237 0.368 0.997 0.663 
Glycinamide ribotide (GAR) 0.574 0.098 0.191 0.065 0.343 0.608 0.769 
Ophthalmate 0.504 0.014 0.030 0.344 0.254 0.984 0.970 
Sedoheptulose 1/7-phosphate 0.209 0.066 0.358 0.886 0.327 0.256 0.823 
L-Argininosuccinate 0.680 0.033 0.158 0.474 0.209 0.542 0.985 
Aminoimidazole ribotide (AIR) 0.376 0.164 0.085 0.355 0.078 0.086 0.791 
N-Acetylglucosamine 1/6-
phosphate 
0.301 0.220 0.436 0.176 0.130 0.268 0.626 
dCMP 0.203 0.033 0.028 0.041 0.376 0.342 0.270 
Glutathione 0.739 0.465 0.605 0.987 0.077 0.410 0.163 
dUMP 0.168 0.042 0.867 0.059 0.520 0.105 0.504 
Octulose 8/1P 0.053 0.043 0.040 0.030 0.115 0.719 0.500 
dTMP 0.027 0.067 0.211 0.097 0.518 0.699 0.888 
CMP 0.286 0.087 0.418 0.050 0.035 0.300 0.765 
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Table 1.8 continued 
Compound 
p-value 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
UMP 0.347 0.189 0.456 0.219 0.173 0.289 0.804 
cAMP 0.311 0.094 0.466 0.640 0.574 0.630 0.373 
dAMP 0.238 0.100 0.537 0.222 0.406 0.347 0.662 
AICAR 0.654 0.001 0.034 0.342 0.009 0.048 0.033 
Fructose 1-6-bisphosphate 0.069 0.298 0.083 0.410 0.122 0.129 0.076 
Trehalose/Sucrose/Cellobiose 0.414 0.527 0.483 0.222 0.336 0.476 0.477 
AMP/dGMP 0.311 0.233 0.473 0.230 0.059 0.276 0.755 
IMP 0.237 0.051 0.279 0.138 0.261 0.391 0.026 
GMP 0.364 0.273 0.416 0.222 0.229 0.279 0.933 
Xanthosine 5--phosphate 0.250 0.269 0.131 0.349 0.629 0.522 0.160 
Sedoheptoluse bisphosphate 0.169 0.207 0.146 0.548 0.102 0.108 0.528 
Octulose bisphosphate 0.132 0.291 0.034 0.481 0.042 0.171 0.312 
Sucralose 0.420 0.009 0.019 0.001 0.000 0.001 0.000 
dTDP 0.832 0.176 0.020 0.006 0.014 0.005 0.039 
UDP 0.802 0.107 0.123 0.623 0.880 0.263 0.314 
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Table 1.8 continued 
Compound 
p-value 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Trehalose 6-phosphate 0.566 0.353 0.560 0.009 0.635 0.505 0.924 
ADP 0.374 0.723 0.214 0.353 0.256 0.147 0.927 
GDP 0.370 0.396 0.061 0.671 0.579 0.258 0.860 
FMN 0.723 0.187 0.681 0.056 0.177 0.210 0.573 
UDP-glucose 0.524 0.294 0.502 0.596 0.105 0.860 0.097 
UDP-glucuronate 0.913 0.410 0.439 0.634 0.662 0.744 0.272 
ADP-glucose 0.664 0.105 0.394 0.880 0.067 0.184 0.950 
UDP-N-acetylglucosamine 0.362 0.121 0.566 0.151 0.389 0.310 0.745 
Glutathione disulfide 0.374 0.667 0.339 0.445 0.350 0.308 0.197 
NAD+ 0.257 0.810 0.523 0.237 0.684 0.906 0.828 
NADH 0.103 0.572 0.263 0.232 0.376 0.214 0.393 
NADP+ 0.427 0.896 0.510 0.304 0.922 0.571 0.771 
FAD 0.765 0.136 0.905 0.213 0.116 0.280 0.528 
Acetyl-CoA 0.286 0.904 0.143 0.749 0.981 0.244 0.180 














Figure 1.14 Known metabolite pairwise PLSDA for ΔsucAB 
 
 





Figure 1.16 Known metabolite pairwise PLSDA for ΔfumA 
 





Figure 1.18 Known metabolite pairwise PLSDA for Δmdh 
 
77 
Table 1.9 VIP scores for pairwise PLSDA 
Metabolite 
VIP scores for pairwise comparisons 
ΔacnB ΔacnA ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Glucosamine 1.019 1.032 1.311 1.145 1.055 1.098 1.080 
Allantoate 1.333 1.076 0.708 1.392 1.298 1.012 1.212 
X2.Isopropylmalate 1.252 1.400 1.134 0.928 1.206 1.213 1.560 
IMP 1.247 1.024 1.136 1.142 1.048 0.871 1.886 
UDP 1.004 1.281 1.077 0.655 1.006 1.050 1.079 
X2.Oxoglutaric.acid 1.346 1.362 0.862 0.438 1.431 1.754 1.959 
Homocysteine 1.316 1.879 1.203 0.709 0.189 1.156 1.891 
Citraconate 1.282 1.001 0.908 0.601 1.430 1.413 1.012 
N.Carbamoyl.L.aspartate 1.250 1.555 1.280 0.826 0.609 1.677 1.938 
Octulose.8.1P 1.196 1.232 1.208 1.249 1.069 0.539 0.714 
N.Acetylglutamate 1.184 1.232 0.697 1.145 0.811 1.178 1.528 
dCMP 1.155 1.014 1.258 1.180 0.839 0.912 1.120 
ADP.glucose 1.064 1.547 1.204 0.463 1.237 1.346 0.318 




Table 1.9 continued 
Metabolite 
VIP scores for pairwise comparisons 
ΔacnB ΔacnA ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Pyruvate 1.327 1.800 0.955 1.179 1.354 0.904 0.417 
dUMP 1.307 1.279 0.243 1.368 0.784 1.388 0.694 
Orotate 1.296 1.093 0.166 0.479 1.121 0.808 1.821 
L.Argininosuccinate 1.239 1.133 1.088 0.618 1.027 0.655 0.433 
Arginine 1.237 1.082 0.915 1.301 1.103 0.764 0.869 
AMP.dGMP 1.198 1.010 0.710 1.264 1.133 0.782 0.626 
Glycinamide.ribotide..GAR. 1.037 1.522 1.012 1.289 0.810 0.789 0.512 
Pyroglutamic.acid 1.013 1.055 1.172 1.093 0.911 0.860 0.346 
Dihydroorotate 1.287 1.140 0.779 0.894 0.276 0.907 1.833 
Ophthalmate 1.224 1.090 1.328 0.759 0.870 0.291 0.420 
dTMP 1.131 1.345 0.951 1.110 0.700 0.520 0.273 
N.Acetylglucosamine 1.010 1.038 0.914 1.307 0.989 0.807 0.680 
dAMP 1.236 1.027 0.705 0.995 0.844 0.772 0.799 
dTDP 0.762 1.085 1.177 1.367 1.419 1.460 1.808 
S.Ribosyl.L.homocysteine 1.343 0.864 1.201 1.315 1.091 0.858 1.635 
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Table 1.9 continued 
Metabolite 
VIP scores for pairwise comparisons 
ΔacnB ΔacnA ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
AICAR 1.324 0.846 1.361 0.835 1.387 1.621 1.740 
Alanine.Sarcosine 1.201 0.947 1.246 1.225 1.094 1.146 0.337 
X4.Pyridoxate 1.045 0.884 1.308 0.776 1.164 1.426 1.286 
Ornithine 0.906 1.019 1.329 0.653 1.242 1.211 1.606 
Sulfolactate 0.497 1.016 1.188 0.554 1.005 1.345 1.289 
Citrulline 0.469 1.158 1.354 0.532 1.133 1.281 1.636 
Pantothenate 1.248 0.898 0.774 1.281 1.003 1.092 0.686 
Succinate.Methylmalonate 1.213 0.883 1.008 0.938 1.249 1.224 0.691 
Phenylalanine 1.168 0.911 1.261 1.326 1.014 0.759 0.426 
Inosine 1.154 0.997 0.983 1.280 0.969 1.010 1.019 
Uracil 1.109 0.978 1.237 1.286 1.125 0.787 0.423 
Lysine 1.097 0.935 1.024 1.388 1.132 0.869 0.692 
Acetyllysine 1.079 0.732 1.174 1.381 0.959 0.787 1.002 
Glucose.6.phosphate 1.063 0.799 0.969 1.181 0.808 1.113 1.102 
Uridine 1.039 0.923 1.231 1.190 1.071 0.833 0.599 
Aminoimidazole.ribotide..AIR. 1.036 0.649 1.170 0.935 1.081 1.462 0.356 
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Table 1.9 continued 
Metabolite 
VIP scores for pairwise comparisons 
ΔacnB ΔacnA ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
X6.Phospho.D.gluconate 1.015 0.931 1.021 0.473 0.878 1.233 1.114 
FMN 0.852 1.027 0.978 1.130 1.021 1.387 0.628 
Shikimate 0.824 1.418 0.940 0.450 1.144 1.235 1.337 
Octulose.bisphosphate 0.739 1.056 1.307 0.570 1.196 1.227 0.961 
Fructose.1_6.bisphosphate 0.695 1.065 1.156 0.473 0.957 1.421 1.564 
Thymidine 0.424 1.268 1.133 0.648 1.007 1.026 0.427 
Citrate.isocitrate 1.349 0.902 0.941 0.723 1.013 1.586 0.887 
Glutamate 1.334 0.778 0.822 0.558 0.706 1.312 1.185 
Fumarate 1.323 0.976 0.973 0.735 0.822 1.610 1.885 
Thymine 1.314 0.932 0.870 1.342 0.965 1.026 0.741 
Aconitate 1.310 0.804 0.850 0.687 1.401 1.313 0.452 
N.Acetylornithine 1.293 0.763 0.922 0.926 0.838 1.136 1.092 
Xylitol 1.279 0.999 0.910 1.391 1.024 0.964 0.779 
Guanosine 1.260 0.946 0.986 1.266 1.013 0.832 0.923 





Table 1.9 continued 
Metabolite 
VIP scores for pairwise comparisons 
ΔacnB ΔacnA ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
L.Methionine 1.251 0.814 0.664 0.925 1.399 0.630 1.375 
CMP 1.212 0.980 0.792 1.322 1.208 0.903 0.413 
Cytidine 1.099 0.792 0.883 1.327 1.109 0.879 0.906 
Leucine.Isoleucine 1.095 0.899 1.094 1.220 0.931 0.794 0.517 
X1.Methyladenosine 1.085 0.928 1.031 1.280 0.961 0.860 0.943 
sn.Glycerol.3.phosphate 1.085 0.983 0.886 1.286 1.090 0.896 0.445 
FAD 1.069 0.899 0.499 0.844 1.219 1.041 0.699 
Histidine 1.058 0.884 0.849 1.177 0.884 0.814 1.493 
Hydroxyphenylacetate 1.018 0.777 0.638 1.137 0.965 0.712 1.272 
N.Acetylglucosamine.1.6.phosphate 0.997 1.003 0.780 1.123 1.124 0.915 0.539 
D.Glucarate 0.987 1.009 0.776 1.103 1.120 0.772 0.526 
X3.Phosphoserine 0.963 1.449 1.386 0.392 0.587 0.904 1.257 
Uric.acid 0.865 1.067 1.056 1.241 0.879 0.707 0.669 
Deoxyribose.phosphate 0.607 1.806 0.918 1.146 0.512 0.951 1.302 





Table 1.9 continued 
Metabolite 
VIP scores for pairwise comparisons 
ΔacnB ΔacnA ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Shikimate.3.phosphate 0.410 1.541 1.527 0.424 0.445 0.884 1.590 
N.Acetylputrescine 1.244 0.090 0.437 0.643 0.486 0.365 1.137 
Aspartate 1.230 0.835 0.709 0.975 0.679 0.592 1.810 
Ribose.phosphate 1.222 0.788 0.789 0.832 1.100 0.575 0.349 
Cystathionine 1.219 0.740 0.639 1.139 0.482 0.636 0.998 
Proline 1.178 0.868 0.679 1.136 0.491 0.808 0.964 
Sedoheptulose.1.7.phosphate 1.175 0.993 0.845 0.691 0.916 1.076 0.235 
UDP.N.acetylglucosamine 1.161 0.906 0.727 1.017 0.824 0.906 0.427 
Nicotinate 1.153 0.990 0.797 1.288 0.848 0.762 0.580 
Xanthurenic.acid 1.123 0.916 0.769 1.192 0.794 0.869 0.886 
Asparagine 1.109 0.951 0.856 1.201 0.952 0.878 0.768 
Valine 1.104 0.879 0.977 1.170 0.842 0.845 0.545 
Tyrosine 1.060 0.909 0.978 1.193 1.000 0.816 0.500 
X3.Hydroxyisovaleric.acid 1.021 0.709 0.960 0.603 1.082 0.810 0.837 





Table 1.9 continued 
Metabolite 
VIP scores for pairwise comparisons 
ΔacnB ΔacnA ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Trehalose.6.phosphate 0.974 1.041 0.766 1.373 0.668 0.873 0.252 
UDP.glucuronate 0.574 1.005 0.624 0.423 0.756 0.571 1.087 
Xanthosine 0.543 1.103 1.142 0.842 0.913 0.823 0.501 
Glutamine 1.294 0.967 0.712 0.873 0.794 0.848 0.328 
cAMP 1.121 0.929 0.729 0.650 0.871 0.837 0.935 
Phenylpyruvate 1.105 0.793 0.550 0.695 0.846 0.889 0.277 
Homoserine.Threonine 1.045 0.911 0.939 0.458 0.741 0.841 0.545 
Hydroxyisocaproic.acid 0.639 1.010 0.782 0.891 0.779 0.888 0.423 
Sucralose 0.939 0.752 1.381 1.428 1.530 1.475 1.986 
Allantoin 0.894 0.938 1.130 1.333 1.197 0.854 1.022 
Hydroxyproline 0.790 0.978 1.298 1.303 1.306 0.767 1.403 
Glutathione.disulfide 0.346 0.883 1.013 0.467 1.001 1.148 1.304 
Tryptophan 0.999 0.929 1.129 1.147 1.020 0.814 0.469 
Sedoheptoluse.bisphosphate 0.885 0.980 1.147 0.427 1.018 1.375 0.643 





Table 1.9 continued 
Metabolite 
VIP scores for pairwise comparisons 
ΔacnB ΔacnA ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Acetylphosphate 0.851 0.641 0.359 1.015 0.531 1.711 1.254 
Homocysteic.acid 0.811 0.744 1.034 1.075 0.897 0.769 1.024 
D.Glyceraldehdye.3.phosphate 0.806 0.862 1.138 0.735 1.005 0.556 1.643 
Lactate 0.777 0.727 1.178 0.789 1.075 1.101 0.868 
N.Acetyl.beta.alanine 0.710 0.941 1.068 0.775 1.030 1.187 0.334 
N.Acetylglutamine 0.685 0.921 1.107 0.839 1.068 1.081 0.272 
X2.Dehydro.D.gluconate 0.587 0.892 1.031 1.120 0.920 0.773 1.102 
D.Gluconate 0.584 0.923 1.156 0.982 1.054 1.026 0.531 
Phenyllactic.acid 0.542 0.935 1.027 1.047 0.891 1.006 0.253 
X3.Phosphoglycerate 0.539 0.895 1.177 0.511 1.050 1.475 0.591 
X3_4.Dihydroxyphenylacetate..DOPAC. 0.528 0.917 0.942 1.110 1.253 0.887 1.039 
Carbamoyl.phosphate 0.427 0.932 1.029 0.506 1.019 1.150 0.989 
Acetyl.CoA 0.290 0.791 1.030 0.635 0.511 1.084 1.237 
Creatinine 0.998 0.813 1.291 1.317 0.841 0.701 0.742 





Table 1.9 continued 
Metabolite 
VIP scores for pairwise comparisons 
ΔacnB ΔacnA ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Glucosamine.phosphate 0.993 0.832 1.159 0.529 0.983 1.445 0.934 
X2_3.Dihydroxybenzoate 0.991 0.976 0.765 1.068 1.428 0.785 0.230 
GMP 0.974 0.916 0.816 1.130 1.035 0.821 0.546 
Hypoxanthine 0.845 0.818 1.308 1.164 0.783 0.749 0.418 
Guanine 0.762 0.599 1.321 1.162 0.679 0.717 0.508 
Xanthosine.5..phosphate 0.757 0.785 1.013 0.724 0.748 0.660 1.342 
Adenosine 0.748 0.994 1.039 0.923 1.104 0.900 0.654 
UDP.glucose 0.736 0.718 0.560 0.536 1.295 0.384 1.467 
Creatine 0.722 0.741 1.206 1.020 0.951 0.674 0.512 
Cysteine 0.581 0.879 1.327 0.756 1.518 0.755 0.470 
NADH 0.529 0.961 0.732 1.027 0.708 1.179 0.933 
ADP 0.488 0.886 1.014 0.733 0.972 1.304 0.300 
GDP 0.391 0.861 1.135 0.466 0.830 1.103 0.290 
Hydroxybenzoate 0.972 0.819 0.717 1.035 0.969 0.889 0.924 





Table 1.9 continued 
Metabolite 
VIP scores for pairwise comparisons 
ΔacnB ΔacnA ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
Glycerate 0.868 0.892 0.885 1.106 0.927 0.848 0.594 
X4.Aminobutyrate..GABA. 0.805 0.987 0.830 0.802 1.239 0.965 0.666 
X2.Hydroxy.2.methylsuccinate 0.784 0.920 0.811 0.793 0.873 1.058 0.768 
Taurine 0.764 0.753 0.955 1.052 0.846 0.830 0.607 
Homovanillic.acid..HVA. 0.705 0.657 0.997 0.990 0.841 0.725 1.001 
Phosphoenolpyruvate 0.540 0.975 0.827 0.703 1.070 0.995 0.421 
Trehalose.Sucrose.Cellobiose 0.355 0.875 0.957 1.016 0.784 0.829 0.696 
X2.Aminoadipate 0.498 0.953 0.876 0.870 0.977 0.862 0.436 
NADP. 0.259 0.834 0.706 0.759 0.947 0.569 0.365 




Figure 1.19 Unknown feature pairwise PLSDA for ΔacnA 
 
 




Figure 1.21 Unknown feature pairwise PLSDA for ΔsucAB 
 
 




Figure 1.23 Unknown feature pairwise PLSDA for ΔsdhAD 
 
 




Figure 1.25 Unknown feature pairwise PLSDA for Δmdh 
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Table 1.10 Ratios and p-values used for heat map of dipeptides 
 
compound 
Ratio compared to WT 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
Ala-Ala 0.75 0.93 0.78 1.11 0.67 0.85 0.88 
Val-Gly 1.57 0.1 6.76 0 1.41 0.17 0.94 
Gly-Cys 1.63 0.54 1.66 0.88 1.15 0.94 1.08 
Gly-Asp 1.17 1.58 0.44 0.02 1.31 1.63 0.76 
Ser-Ser 2.1 0.24 2.19 0 14.22 0.46 2.57 
Ser-Pro 1.96 1.09 1.16 1.87 3.18 0.54 2.09 
Asn-Ala 4.63 0.23 6.7 0 9.86 0.86 2.37 
Thr-Pro 2.21 0.44 1.54 0.41 1.53 0.54 1.08 
Gln-Ala 0.83 0.86 2.72 0.11 4.74 0.3 1.81 
Glu-Ala 1.91 1.47 1.64 0.87 2.57 1.2 1.81 
Glu-Ser 1.95 0.54 1.91 0.34 13.49 0.56 2.52 
Glu-Pro 2.14 0.51 0.97 0.99 0.82 0.58 1.18 
Cys-Met 0 2.13 1.2 0.26 0.56 0.84 1.32 




Table 1.10 continued 
compound 
Ratio compared to WT 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
Asn-Glu 4.02 0.69 1.32 0.81 1.51 0.76 1.3 
Asp-Glu 0.57 0.29 4.62 0.33 12.62 0.13 5.59 
Met-Asp 1.16 0.65 1 0.64 1.43 0.79 0.91 
Glu-Glu 5.92 0.41 2.46 0.88 8.23 1.4 2.15 
Met-Glu 1.1 0.51 0.57 1.75 1.25 0.45 0.88 
Met-Met 0.85 0.16 1.81 1.52 0.75 0.34 1.13 
Glu-Tyr 13.62 0 2.53 0.04 6.24 2.24 2.53 








ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
Ala-Ala 0.28 0.66 0.26 0.61 0.13 0.46 0.54 
Val-Gly 0.73 0.35 0.41 0.31 0.7 0.38 0.95 
Gly-Cys 0.04 0.28 0.04 0.87 0.7 0.89 0.84 
Gly-Asp 0.48 0.05 0.11 0.01 0.19 0.02 0.2 
Ser-Ser 0.45 0.28 0.41 0.2 0.41 0.49 0.49 
Ser-Pro 0.23 0.88 0.85 0.23 0.41 0.49 0.17 
Asn-Ala 0.26 0.28 0.11 0.2 0.05 0.89 0.39 
Thr-Pro 0.47 0.08 0.24 0.06 0.59 0.11 0.84 
Gln-Ala 0.86 0.8 0.02 0.1 0.2 0.15 0.34 
Glu-Ala 0.09 0.27 0.18 0.74 0.48 0.59 0.12 
Glu-Ser 0.46 0.36 0.35 0.21 0.4 0.4 0.17 
Glu-Pro 0.48 0 0.83 0.96 0.67 0.01 0.29 
Cys-Met 0.1 0.45 0.8 0.16 0.42 0.69 0.71 
Leu-Glu 0.32 0.24 0.24 0.87 0.49 0.87 0.29 
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Table 1.10 continued 
compound 
p-value 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
Asn-Glu 0.39 0.19 0.19 0.38 0.39 0.29 0.53 
Asp-Glu 0.58 0.25 0.09 0.26 0.4 0.17 0.34 
Met-Asp 0.26 0.03 0.98 0.17 0.06 0.19 0.69 
Glu-Glu 0.24 0.13 0.09 0.73 0.3 0.69 0.3 
Met-Glu 0.6 0.05 0.06 0.04 0.19 0.04 0.56 
Met-Met 0.78 0.08 0.1 0.2 0.7 0.14 0.85 
Glu-Tyr 0.3 0.17 0.43 0.17 0.06 0.64 0.36 
Arg-Tyr 0.15 0.19 0.06 0.53 0.01 0.23 0.6 
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Table 1.11 Ratios and p-values used for heat map of lipids 
 
compound 
Ratio compared to WT 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
CL(62:0) 0.83 0.20 0.79 0.80 0.84 0.88 0.88 
CL(64:2) 0.56 0.32 0.80 0.97 0.69 0.73 0.71 
CL(66:1) 0.77 0.38 0.98 1.33 0.80 0.85 0.90 
CL(68:1) 0.95 1.26 0.75 0.82 1.01 1.03 1.02 
PA(30:1) 0.76 0.81 1.04 0.96 0.77 0.76 0.88 
PA(32:1) 0.78 0.65 0.93 1.10 0.75 0.75 0.93 
PA(32:2) 0.74 0.76 1.36 1.43 0.81 1.09 0.85 
PA(34:1) 0.83 0.83 0.92 1.17 0.72 0.82 0.93 
PA(34:2) 0.83 0.58 1.12 1.20 0.88 0.90 0.95 
PE(26:0) 0.76 0.46 0.66 0.60 0.77 0.62 0.70 
PE(28:0) 0.94 0.71 0.79 0.90 0.96 0.77 1.05 
PE(28:1) 0.72 0.33 0.80 0.76 0.69 0.74 0.85 
PE(30:0) 0.96 0.78 0.93 1.10 1.00 0.91 1.08 
PE(30:1) 0.88 0.42 0.96 1.03 0.92 0.83 1.04 
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Table 1.11 contined 
compound 
Ratio compared to WT 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
PE(30:2) 0.64 0.15 0.88 0.76 0.63 0.61 0.75 
PE(32:1) 0.87 0.44 1.07 1.31 0.86 0.85 1.03 
PE(32:2) 0.76 0.31 1.13 1.17 0.83 0.74 1.04 
PE(36:2) 0.93 0.73 1.07 1.07 0.90 0.91 1.13 
PG(30:1) 0.84 0.73 1.04 0.98 0.98 0.90 0.95 
PG(36:2) 0.87 0.87 1.10 1.16 0.89 0.98 1.06 
PG(28:0) 0.85 0.71 0.82 0.90 0.95 0.87 0.89 
PG(32:1) 0.83 0.75 1.10 1.26 0.89 0.97 0.96 
PG(34:1) 0.88 0.89 0.98 1.16 0.86 1.02 0.99 
PG(34:2) 0.85 0.75 1.24 1.17 0.94 0.94 1.04 
PS(32:1) 0.77 1.17 2.55 1.56 0.88 0.86 0.65 
PS(34:1) 1.02 1.21 2.80 1.44 1.20 1.15 0.93 
PS(34:3) 0.80 0.43 1.16 1.37 0.81 0.84 1.00 




Table 1.11 continued 
compound 
p-value 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
CL(62:0) 0.34 0.00 0.41 0.20 0.37 0.49 0.49 
CL(64:2) 0.18 0.05 0.51 0.93 0.33 0.37 0.33 
CL(66:1) 0.06 0.00 0.89 0.00 0.25 0.18 0.39 
CL(68:1) 0.30 0.08 0.15 0.01 0.87 0.53 0.72 
PA(30:1) 0.24 0.58 0.82 0.90 0.27 0.25 0.52 
PA(32:1) 0.39 0.22 0.80 0.78 0.41 0.37 0.81 
PA(32:2) 0.18 0.34 0.18 0.11 0.60 0.85 0.59 
PA(34:1) 0.50 0.54 0.76 0.70 0.34 0.50 0.83 
PA(34:2) 0.25 0.03 0.59 0.28 0.72 0.75 0.85 
PE(26:0) 0.33 0.03 0.32 0.08 0.28 0.09 0.24 
PE(28:0) 0.67 0.10 0.31 0.48 0.78 0.16 0.78 
PE(28:1) 0.04 0.00 0.38 0.06 0.03 0.05 0.24 
PE(30:0) 0.68 0.04 0.61 0.26 0.98 0.30 0.42 




Table 1.11 continued 
compound 
p-value 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD ΔfumA Δmdh 
PE(30:2) 0.04 0.00 0.66 0.10 0.09 0.02 0.08 
PE(32:1) 0.26 0.00 0.60 0.02 0.42 0.17 0.83 
PE(32:2) 0.18 0.01 0.53 0.34 0.49 0.18 0.85 
PE(36:2) 0.52 0.06 0.75 0.62 0.50 0.40 0.46 
PG(30:1) 0.20 0.01 0.73 0.87 0.88 0.34 0.61 
PG(36:2) 0.35 0.10 0.50 0.33 0.45 0.78 0.61 
PG(28:0) 0.30 0.06 0.36 0.46 0.68 0.32 0.52 
PG(32:1) 0.24 0.02 0.32 0.16 0.44 0.82 0.79 
PG(34:1) 0.29 0.20 0.88 0.35 0.20 0.88 0.89 
PG(34:2) 0.31 0.01 0.11 0.27 0.73 0.64 0.79 
PS(32:1) 0.45 0.64 0.22 0.49 0.71 0.66 0.30 
PS(34:1) 0.91 0.34 0.25 0.47 0.37 0.56 0.63 
PS(34:3) 0.04 0.00 0.11 0.00 0.32 0.22 0.98 






Table 1.12 Relative pool values for each strain compared to WT 
Metabolite 
Relative Pool ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
1-Methyladenosine 6.3±10.72 0.08±0.13 4.39±6.52 0.03±0.03 4.64±7.4 0.68±1.37 1.98±3.04 
2_3-
Dihydroxybenzoate 
1.38±0.76 0.77±0.17 0.95±0.34 0.55±0.25 0.76±0.2 1±0.35 0.96±0.28 
2-Aminoadipate 9.37±14.9
1 
0.68±0.65 3.92±5.72 0.37±0.36 3.72±4.9 1.98±3.54 3.21±4.26 
2-Dehydro-D-
gluconate 
3.98±5.86 0.52±0.65 1.93±1.52 0.06±0.08 10.82±18.03 0.36±0.63 2.73±3.17 
2-Hydroxy-2-
methylsuccinate 
3.01±3.34 0.53±0.41 3.69±4.91 0.56±0.49 1.5±0.86 1.29±0.88 1.67±1.11 
2-Isopropylmalate 1.44±0.27 3.55±1.48 1.43±0.33 2.19±1.38 1.77±0.51 1.44±0.39 1.49±0.54 








Table 1.12 continued 
Metabolite 
Relative Pool ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
3-Hydroxyisovaleric 
acid 
1.14±0.28 1.41±0.44 1.72±0.97 0.92±0.3 1.37±0.34 1.13±0.3 1.13±0.37 
3-Phosphoglycerate 2.71±2.55 1.22±0.49 1.91±0.73 0.95±0.62 1.57±0.56 1.06±0.24 2.09±0.77 
3-Phosphoserine 1.6±0.2 1.64±0.62 1.49±0.18 1.19±0.82 1.13±0.29 0.76±0.22 1.29±0.44 
4-Aminobutyrate 
(GABA) 
2.44±1.62 1.15±0.21 1.39±0.65 0.85±0.21 1.53±0.28 1.12±0.37 1.27±0.39 
4-Pyridoxate 1.61±0.76 1.47±0.44 1.69±0.32 0.85±0.21 2.77±1.52 1.27±0.31 1.76±0.61 
6-Phospho-D-
gluconate 
1.28±0.3 2.56±1.41 1.25±0.28 1.09±0.82 1.39±0.54 0.74±0.28 1.45±0.45 
Acetyl-CoA 1.32±0.53 1.05±0.76 1.81±0.94 1.23±1.17 1±0.41 1.5±0.69 1.5±0.77 
Acetyllysine 1.25±0.41 0.66±0.17 1.6±0.42 2.72±0.85 1.86±1.08 0.78±0.33 1.01±0.33 














Table 1.12 continued  
Metabolite 
Relative Pool ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
Adenosine 11.29±19.7
5 
0.47±1.08 4±6.79 0.05±0.09 19.91±38.89 1.49±3.41 1.39±2.85 
ADP 2.41±2.4 0.83±0.72 2.14±1.46 0.58±0.58 1.73±1.1 0.97±0.5 2.55±1.65 
ADP-glucose 0.9±0.33 0.67±0.17 0.86±0.2 0.96±0.34 0.6±0.19 0.98±0.28 0.75±0.18 
AICAR 1.07±0.25 0.43±0.08 0.66±0.13 0.78±0.29 0.52±0.11 0.58±0.16 0.77±0.11 
Alanine/Sarcosin
e 
2.59±1.98 0.54±0.14 1.99±0.62 0.46±0.19 2.12±1.06 1.05±0.48 1.55±0.6 
Allantoate 9.85±11.01 0±0 2.24±3.06 0±0 7.48±5.26 1.96±3.65 3.62±4.44 
Allantoin 4.71±4.55 0.26±0.37 3.48±2.62 0.01±0.01 6.34±4.98 1.1±2.03 2.75±3.09 
Aminoimidazole 
ribotide (AIR) 
0.87±0.17 0.71±0.25 0.66±0.14 0.86±0.17 0.65±0.2 0.94±0.34 0.67±0.16 
AMP/dGMP 7.71±11.18 0.1±0.1 3.12±5.05 0.09±0.09 3.8±3.77 1.51±2.78 3.46±4.3 
Arginine 7.1±9.1 0.11±0.09 3.21±3.8 0.09±0.08 2.65±2.23 0.95±1.67 2.68±3.18 
Asparagine 3.24±3.05 0.56±0.19 1.59±1.05 0.46±0.19 1.43±0.53 0.84±0.82 1.55±0.99 




Table 1.12 continued 
Metabolite 
Relative Pool ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
cAMP 1.47±0.74 0.52±0.2 1.23±0.54 0.88±0.37 1.39±1.08 0.68±0.48 1.13±0.48 
Carbamoyl 
phosphate 
4.25±4.67 0.56±0.62 2.35±1.95 0.87±0.95 6.64±8.86 2.08±2.26 2.76±2.54 





1.75±1.03 0.66±0.52 1.66±0.76 0.79±0.48 2.43±0.92 
Citrulline 1.71±0.56 1.03±0.24 2.38±0.89 1.06±0.34 1.58±0.62 1.71±0.56 1.58±0.56 
CMP 3.33±2.92 0.55±0.13 1.83±1.49 0.42±0.11 1.95±0.62 1.2±1.05 1.84±1.15 





0.06±0.06 1.5±2.23 0.94±1.11 5.37±7.2 
Cystathionine 5.02±7.5 0.14±0.1 2.54±4.22 0.27±0.19 0.78±0.6 0.55±0.5 2.74±3.98 
Cysteate 11.51±14.9
2 
0.15±0.19 2.13±1.71 0.05±0.04 11.72±10.99 3.15±5.74 3.42±3.62 
Cysteine 3.87±4.28 0.78±0.67 2.01±0.52 0.46±0.48 0.64±0.13 0.94±0.48 2.21±2.18 
Cytidine 5.33±6.56 0.05±0.09 2.19±2.92 0±0 5.22±4.57 1.62±3.12 1.96±2.76 
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Table 1.12 continued 
Metabolite 
Relative Pool ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
dAMP 7.64±7.82 0.21±0.14 1.76±1.97 0.52±0.3 1.46±0.98 0.78±0.74 2.86±2.98 
dCMP 2.63±1.57 0.64±0.15 1.37±0.21 0.59±0.2 2.24±1.94 0.86±0.16 1.33±0.5 
Deoxyinosine 14.26±25.4 0.04±0.06 2.87±4.58 0.01±0.02 13.2±26.26 0.39±0.82 5.29±8.44 
Deoxyribose 
phosphate 
1.39±0.27 1.13±0.27 1.13±0.19 0.52±0.21 1.09±0.25 1.16±0.18 0.79±0.24 
D-Glucarate 33±55.27 0.22±0.36 7.78±13.16 0.03±0.04 13.77±19.65 2.77±4.94 19.56±27.61 




0.85±0.44 0.77±0.28 1.24±0.24 0.72±0.46 1.24±0.24 1.26±0.18 1±0.27 
Dihydroorotate 1.42±0.39 2.36±0.68 1.36±0.73 1.4±0.56 1.07±0.5 2.4±0.82 1.32±0.76 
dTDP 1.09±0.7 0.39±0.53 0.25±0.27 0.19±0.12 0.14±0.04 0.56±0.14 0.1±0.1 
dTMP 1.81±0.5 0.6±0.16 1.22±0.26 0.66±0.19 1.26±0.63 0.98±0.2 0.94±0.21 
dUMP 1.36±0.44 0.2±0.08 1.03±0.33 0.33±0.11 1.13±0.35 0.84±0.32 0.53±0.22 
FAD 1.07±0.39 0.68±0.17 0.97±0.32 0.68±0.32 0.66±0.17 1.12±0.33 0.8±0.21 
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Table 1.12 continued 
Metabolite 
Relative Pool ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
FMN 0.93±0.25 0.69±0.28 0.93±0.24 0.5±0.22 0.71±0.21 0.9±0.24 0.73±0.18 
Fructose 1_6-
bisphosphate 
1.51±0.44 0.75±0.3 1.84±0.72 1.84±1.5 1.44±0.48 1.79±0.68 1.81±0.78 
Fumarate 1.77±0.79 0.41±0.06 1.45±0.53 0.8±0.3 1.08±0.48 1.82±0.35 1.52±0.25 
GDP 1.69±1.32 2.31±2.41 2.79±1.69 1.36±1.4 1.23±0.77 0.93±0.52 2.34±1.91 
Glucosamine 2.22±1.16 0.6±0.2 2.38±0.88 0.34±0.26 2.16±1.08 1.36±0.61 3.35±3.49 
Glucosamine 
phosphate 
0.75±0.3 1.28±0.25 0.76±0.14 0.95±0.15 0.75±0.18 0.9±0.19 0.67±0.16 
Glucose 6-
phosphate 
1.22±0.41 1.3±0.3 1.18±0.25 1.23±0.26 1.11±0.4 1.26±0.37 1.17±0.24 
Glutamate 1.17±0.27 0.58±0.07 1.1±0.17 1.05±0.13 0.89±0.21 0.91±0.09 0.87±0.12 
Glutamine 1.9±0.96 0.44±0.09 1.22±0.59 0.73±0.27 1.27±0.42 1.04±0.42 1.13±0.33 
Glutathione 1.03±0.18 1.06±0.14 1.05±0.16 1±0.34 0.78±0.1 1.16±0.18 0.91±0.15 
Glutathione 
disulfide 
7.41±10.39 1.41±1.53 4.54±5.37 7.58±12.57 6.98±9.17 2.24±1.57 4.02±4.3 
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Table 1.12 continued 
Metabolite 
Relative Pool ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
Glycerate 7.53±12.3 0.33±0.33 3.2±4.68 0.2±0.2 2.01±2.22 0.74±1.11 2.44±3.18 
Glycinamide 
ribotide (GAR) 
1.16±0.44 0.61±0.25 0.87±0.13 1.82±0.45 0.74±0.36 0.92±0.38 0.91±0.24 
GMP 6.19±9.04 0.34±0.28 3.22±4.49 0.23±0.23 3.28±3.43 1.08±1.58 3.67±4.23 
Guanine 1.39±1.3 0.46±0.7 7.99±8.74 0.14±0.21 1.84±2.96 1.22±1.61 3.64±4.73 
Guanosine 11.78±20.14 0.03±0.03 3.63±4.31 0.02±0.03 2.7±2.99 0.89±1.7 3.09±4.39 
Histidine 11.4±19.95 0.3±0.23 2.95±3.98 0.21±0.19 1.53±1.85 0.31±0.26 3.85±4.93 
Histidinol 0.64±0.75 0.13±0.12 1.19±1.25 0.12±0.14 0.55±0.44 1.06±1.53 1.61±1.81 
Homocysteic 
acid 
1.4±1.35 0.09±0.15 1.23±1.27 0.01±0.02 9.65±15.58 0.3±0.58 1.68±2.36 
Homocysteine 0.63±0.08 0.37±0.08 0.54±0.28 0.87±0.25 1±0.33 0.74±0.06 0.81±0.24 
Homoserine/ 
Threonine 





Table 1.12 continued 
Metabolite 
Relative Pool ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
Homovanillic acid 
(HVA) 
1.29±0.94 0.43±0.29 1.19±0.89 0.27±0.18 3.17±4.44 0.42±0.31 1.04±0.97 
Hydroxybenzoate 9.35±15.6
5 
0.3±0.25 4.53±7.17 0.28±0.24 0.5±0.45 0.48±0.49 5.63±6.79 
Hydroxyisocaproic 
acid 





0.16±0.12 2.07±3.27 0.12±0.09 0.25±0.24 0.24±0.24 4.78±6.28 
Hydroxyproline 2.5±1.61 0.58±0.49 3.36±1.72 0.19±0.11 3.7±1.62 2.15±1.31 3.26±3.32 
Hypoxanthine 1.14±0.96 0.37±0.49 9.29±8.81 0.09±0.13 3.53±5.97 1.03±1.22 5.34±7.11 
IMP 2.7±1.86 2.35±0.78 3.58±3.13 1.59±0.56 2.88±2.19 2.42±0.7 1.42±0.74 
Inosine 12.45±19.
2 









Table 1.12 continued 
Metabolite 
Relative Pool ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
L-Argininosuccinate 1.03±0.12 1.39±0.18 1.28±0.24 1.16±0.33 1.08±0.1 0.99±0.15 0.93±0.16 
Leucine/Isoleucine 5.73±8.79 0.26±0.21 3.04±2.85 0.19±0.15 1.98±2.02 0.9±1.2 2.55±2.92 
L-Methionine 7.33±11.5
6 
0.23±0.12 1.37±1.48 0.57±0.29 0.44±0.24 0.51±0.29 2.72±3.85 
Lysine 3.2±3.07 0.6±0.19 2.54±1.51 2.43±0.82 1.87±0.77 0.86±0.66 1.9±1.32 
Malate 2.11±1.17 0.33±0.19 1.45±0.55 0.72±0.41 1.69±0.8 2.15±0.33 1.73±0.46 
N-Acetyl-beta-alanine 3.48±3.63 0.76±0.36 2.14±1.26 0.64±0.35 4.35±4.6 0.9±0.51 1.88±1.09 
N-Acetylglucosamine 7.53±9.87 0.15±0.21 3.5±5.28 0.04±0.04 6.02±9.62 1.72±3.35 2.29±3.01 
N-Acetylglucosamine 
1/6-phosphate 
5.68±6.41 0.54±0.26 2.06±2.11 0.46±0.23 2.59±1.66 1.43±1.43 2.45±2.01 
N-Acetylglutamate 1.65±0.82 0.37±0.17 1.39±0.8 2.66±1.76 0.96±0.62 2.27±1.36 1.56±0.79 
N-Acetylglutamine 1.48±0.62 1.08±0.32 1.48±0.44 1.23±0.41 1.53±0.5 0.98±0.28 1.42±0.57 
N-Acetylornithine 1.35±0.64 0.39±0.09 1.47±0.66 0.69±0.26 1.25±0.34 1.29±0.44 1.24±0.3 
N-Acetylputrescine 0.99±0.87 0.15±0.08 0.84±0.66 0.62±0.42 0.74±0.59 1.56±0.95 1±0.56 
NAD+ 1.15±0.21 0.97±0.13 1.07±0.19 0.87±0.13 0.94±0.22 1.01±0.14 1.01±0.15 
NADH 2.06±1.41 0.67±0.78 2.83±2.71 2.09±1.7 1.82±1.65 1.45±1.04 1.63±1.01 
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Table 1.12 continued 
Metabolite 
Relative Pool ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
NADP+ 1.21±0.45 0.96±0.38 1.14±0.38 0.64±0.46 0.96±0.57 0.94±0.25 1.14±0.42 
N-Carbamoyl-L-
aspartate 
1.35±0.21 1.63±0.3 0.81±0.13 0.81±0.25 0.94±0.19 1.78±0.24 0.81±0.08 
Nicotinate 6.63±9.49 0.15±0.15 2.57±3.52 0.08±0.08 1.42±1.35 0.92±1.4 3.32±4.1 
Octulose 8/1P 1.48±0.34 1.63±0.4 1.4±0.24 0.58±0.14 1.44±0.39 1.14±0.34 1.07±0.33 
Octulose 
bisphosphate 
2.12±1.04 1.63±0.92 2.58±1 1.87±1.84 2.21±0.86 1.42±0.68 1.83±0.9 
Ophthalmate 1.07±0.18 1.39±0.2 1.3±0.18 1.16±0.26 1.1±0.13 1±0.18 0.99±0.2 
Ornithine 2.43±1.57 0.77±0.2 2.49±0.99 0.86±0.28 1.74±0.53 1.56±0.49 1.99±1.03 
Orotate 1.09±0.11 1.35±0.12 1±0.27 0.94±0.3 0.88±0.1 1.41±0.19 0.91±0.19 
Pantothenate 2.54±2.17 0.67±0.09 1.55±1.04 0.53±0.14 1.5±0.51 1.1±0.3 1.81±0.91 
Phenylalanine 4.04±4.69 0.42±0.16 3.45±2.05 0.23±0.09 2.81±2.08 1.01±0.87 2.49±2.35 
Phenyllactic acid 1.37±0.74 0.88±0.32 2.77±2.16 0.57±0.22 2.14±1.95 0.92±0.34 1.79±1.11 
Phenylpyruvate 0.96±0.18 0.75±0.14 1.04±0.24 0.84±0.25 0.91±0.17 1.01±0.23 0.87±0.17 
Phosphoenolpyruvate 3.92±3.85 1.21±0.49 1.92±1.5 0.74±0.45 1.5±0.47 1±0.55 2.07±1.31 
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Table 1.12 continued 
Metabolite 
Relative Pool ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
Proline 5.59±9.21 0.06±0.07 2.43±4.47 0.1±0.12 0.7±0.81 0.38±0.63 1.55±2.51 
Pyroglutamic acid 5.11±5.85 0.3±0.25 3.95±3.49 0.26±0.22 1.75±1.47 0.98±1 3.2±3.65 
Pyruvate 0.81±0.09 0.4±0.06 1.19±0.24 0.66±0.16 1.35±0.12 0.97±0.2 1.07±0.14 
Ribose phosphate 1.08±0.39 1.53±0.34 1.09±0.24 1.22±0.38 0.95±0.17 1±0.25 1.06±0.36 
Sedoheptoluse 
bisphosphate 
1.79±0.86 1.62±0.77 2.15±1.11 1.62±1.57 1.48±0.51 1.19±0.52 1.77±0.74 
Sedoheptulose  
1/7-phosphate 
2.36±1.63 1.74±0.75 1.48±0.91 1.03±0.44 1.8±1.3 0.93±0.39 1.55±0.85 
Serine 2.81±3.32 0.37±0.3 2.16±2.04 0.28±0.24 2±1.65 1.13±1.68 2.31±2.68 
Shikimate 1.23±0.55 1.46±0.66 1.19±0.49 0.85±0.5 1.41±0.68 1.49±0.6 1.53±0.79 
Shikimate-3-
phosphate 
1.38±0.61 1±0.48 1.44±0.11 1.02±0.53 0.94±0.28 1.47±0.33 1.24±0.35 
sn-Glycerol 
 3-phosphate 





Table 1.12 continued 
Metabolite 
Relative Pool ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
S-Ribosyl-L-
homocysteine 
0.93±0.3 0.29±0.07 0.66±0.18 2.49±0.84 0.68±0.17 0.67±0.16 0.84±0.26 
Succinate/ 
Methylmalonate 
1.79±1.2 0.44±0.13 1.32±0.43 0.56±0.32 2.13±0.66 0.86±0.66 1.37±0.39 
Sucralose 0.81±0.32 0.12±0.17 0.39±0.17 0.34±0.02 0.12±0.03 0.27±0.04 0.11±0.09 
Sulfolactate 3.16±2.38 0.9±0.29 2.07±0.84 0.91±0.41 3.01±2.6 1.44±0.56 3.06±2.04 









Thymine 1.75±1.39 0.36±0.07 0.97±0.72 0.46±0.09 0.89±0.22 0.86±0.5 0.89±0.44 
Trehalose 6-phosphate 1.59±1.71 1.38±0.78 1.31±0.96 3.51±2.04 1.23±0.89 0.95±0.66 1.35±0.97 
Trehalose/Sucrose/ 
Cellobiose 
2.81±3.38 2.08±2.67 1.3±0.81 0.48±0.25 3.22±3.48 0.72±0.48 1.5±1.22 
Tryptophan 3.73±5.35 0.39±0.28 2.9±2.29 0.31±0.21 4.98±6.31 0.88±0.96 2.24±2.3 
Tyrosine 5.26±8.31 0.18±0.19 2.51±3.01 0.12±0.13 2.74±3.08 1.19±2.11 1.8±2.33 
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Table 1.12 continued 
Metabolite 
Relative Pool ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
UDP 1.09±0.59 0.6±0.23 1.94±0.84 0.77±0.68 0.93±0.64 0.79±0.21 1.41±0.58 
UDP-glucose 1.13±0.35 0.79±0.23 1.14±0.36 1.13±0.41 0.61±0.16 1.42±0.41 0.96±0.31 
UDP-glucuronate 0.97±0.36 0.79±0.32 1.29±0.63 1.29±0.97 1.27±0.98 1.41±0.64 0.89±0.47 
UDP-N-
acetylglucosamine 
3.86±4.43 0.5±0.18 1.44±1.22 0.57±0.27 1.21±0.43 1.16±0.84 1.73±1.11 
UMP 8.01±11.86 0.08±0.07 3.1±4.68 0.18±0.17 3.45±3.49 1.35±2.33 3.47±4.11 
Uracil 9.56±14.63 0.23±0.2 5.87±5.72 0.11±0.09 3.55±3.34 1.34±1.83 4.33±5.06 
Uric acid 2.2±3.55 0.19±0.32 2.56±2.67 0.02±0.02 2.09±2.8 1.05±1.97 7.43±13.53 
Uridine 4.91±6.51 0.38±0.25 3.08±1.81 0.29±0.18 5.33±6.13 0.77±0.7 2.39±2.33 
Valine 3.64±4.43 0.49±0.22 2.03±1.45 0.48±0.21 1.23±0.61 0.88±0.58 1.72±1.35 
Xanthine 




Xanthosine 1.24±0.34 1.56±0.73 1.3±0.32 1.57±0.88 0.92±0.24 1.25±0.28 1.13±0.34 
Xanthosine  
5--phosphate 
11.9±27.06 0±0.01 3.01±6.7 0±0.01 0.54±0.89 0.32±0.74 4.11±7.66 
Xanthurenic acid 2.25±1.32 0.17±0.08 1.12±0.54 0.09±0.03 4.1±4.11 1.12±1.69 1.02±0.91 
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Table 1.13 Relative turnover values for each strain compared to WT 
Metabolite 
Relative Turnover ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
2_3-
Dihydroxybenzoate 
6.4±2.51 8.07±3 0.13±0.05 4.7±1.74 4.64±1.75 9.23±3.36 5.12±1.97 
2-Hydroxy-2-
methylsuccinate 
2.26±0.36 0.56±0.08 0.41±0.07 1.56±0.22 1.69±0.26 1.34±0.22 1.87±0.3 
2-Isopropylmalate 1.22±0.33 1.07±0.26 0.32±0.08 1.07±0.26 0.97±0.24 1.02±0.28 1.23±0.32 
2-Oxoglutaric acid 2.4±0.31 0.45±0.05 0.46±0.05 1.46±0.17 1.23±0.19 0.94±0.14 1.83±0.25 
2-Oxoisovalerate 1.27±0.4 0.7±0.24 0.11±0.03 0.89±0.29 1.08±0.33 0.49±0.16 1.2±0.39 
6-Phospho-D-
gluconate 
1.26±0.92 0.81±0.42 1.12±0.63 1.22±0.66 0.96±0.5 1.17±0.63 1.08±0.57 
6-Phospho-D-
gluconolactone 
0.96±0.45 0.8±0.34 0.29±0.05 1.18±0.13 1.39±0.15 1.16±0.26 1.19±0.75 





1.79±1.41 1.39±1.06 1.71±1.23 1.51±1.53 
AICAR 1.37±0.22 1.06±0.18 0.79±0.12 0.89±0.13 1.3±0.18 1.11±0.17 1.16±0.19 
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Table 1.13 continued 
Metabolite 
Relative Turnover ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
Alanine/Sarcosine 








1.01±0.07 0.93±0.13 0±0 0.91±0.07 #DIV/0! #DIV/0! 1.56±0.21 
AMP/dGMP 3.72±0.95 2.35±0.59 0.68±0.17 4.03±1.01 3.7±0.99 2.25±0.66 #DIV/0! 
Arginine 6.03±2.34 2.07±0.77 0.74±0.27 4.47±1.65 4.56±1.92 2.37±1.06 4.21±1.61 













cAMP 4.37±2.29 0.22±0.36 1.49±0.67 5.58±2.44 4.83±2.17 3.25±1.45 -0.27±0.42 







2.78±3.93 2.5±3.29 3.27±4.19 3.57±5.22 
Citrulline 2.02±0.28 0.61±0.07 0.37±0.04 1.29±0.2 1.51±0.19 1.34±0.18 1.91±0.29 
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Table 1.13 continued 
Metabolite 
Relative Turnover ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
CMP 1.18±0.1 0.89±0.09 0.35±0.04 1.31±0.14 1.23±0.14 1.04±0.1 1.05±0.09 
Creatine 0.6±0.33 0.01±0 0.01±0 0.16±0.13 0.01±0.01 0.68±0.33 0.42±0.21 
Cystathionine 1.36±0.85 #DIV/0! 0.58±0.38 #DIV/0! #DIV/0! 1.25±0.78 #DIV/0! 
Cysteine 






1.52±0.1 1.28±0.07 1.08±0.14 1.03±0.05 1.05±0.05 1.17±0.07 1.72±0.13 
D-Gluconate 11.61±11.76 8.91±8.9 4.75±5.62 9.14±9.77 2.9±3.7 4.85±5.12 8.83±8.92 
Dihydroorotate 2.08±0.23 1.25±0.12 2.66±0.35 1.4±0.13 1.74±0.17 1.61±0.18 2.21±0.23 
dTMP 4.91±2.81 2.73±1.32 0.45±0.23 8.5±4.3 4.38±2.41 2.68±1.47 1.72±1.4 
Fumarate 1.98±0.68 0.13±0.04 0.14±0.06 1.08±0.37 #DIV/0! 1±0.28 2.51±0.75 
Glucosamine 
phosphate 
1.27±0.28 1.02±0.21 1.12±0.24 1±0.2 1±0.2 1.08±0.24 1.22±0.26 
Glucose  
1-phosphate 
1.14±0.33 0.98±0.28 0.93±0.26 1.07±0.3 1.04±0.29 1.06±0.31 1.17±0.34 
Glutamate 1.84±0.16 0.42±0.03 0.32±0.02 1.13±0.09 1.15±0.09 0.91±0.08 1.36±0.13 
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Table 1.13 continued 
Metabolite 
Relative Turnover ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
Glutamine 1.87±0.25 0.47±0.05 0.29±0.03 1.14±0.14 1.17±0.15 0.93±0.13 1.39±0.19 
Glutathione 1.07±0.02 1.12±0.03 0.88±0.04 1.11±0.05 1±0.04 1.03±0.02 0.93±0.02 
Glutathione 
disulfide 
1.54±0.17 1.39±0.17 0.99±0.12 1.51±0.18 1.21±0.15 1.15±0.13 0.73±0.14 
Glycerate 3.33±1.63 3.02±1.46 1.66±0.96 3.61±1.78 1.88±1.27 1.96±1.11 3.25±1.76 
Glycerone 
phosphate 
1.12±0.08 0.88±0.06 0.65±0.05 0.99±0.07 0.97±0.06 1.02±0.07 1.17±0.09 
Glycinamide 
ribotide (GAR) 
1.28±0.1 #DIV/0! 0.94±0.05 #DIV/0! #DIV/0! 1.18±0.14 0.89±0.09 
Guanidoaceti
c acid 
0.96±0.57 0.62±0.46 0.21±0.29 0.69±0.47 0.71±0.44 0.76±0.45 0.79±0.51 
Guanine 3.68±1.05 2.42±0.76 1.22±0.31 3.62±0.94 4.32±1.26 1.02±0.41 1.13±0.49 
Histidine 1.46±0.77 2.12±1.12 1.61±0.86 1.68±0.95 1.84±1.01 2.13±1.08 2±1.07 
Homocystein
e 




Table 1.13 continued 
Metabolite 
Relative Turnover ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
Homoserine/ 
Threonine 




















6.7±10.22 3.16±5.43 5.78±8.98 3.58±5.73 
Leucine/ 
Isoleucine 









L-Methionine 1.24±0.84 1.13±0.84 0.55±0.38 1.17±0.8 1.18±1 1.39±1.48 1.44±0.98 
Lysine 2.34±0.45 3.48±0.71 2.92±0.54 2.08±0.4 1.6±0.3 1.51±0.31 1.01±0.29 
Malate 2.3±0.66 0.18±0.06 1.65±0.55 1.98±0.59 2.44±0.82 0.82±0.23 2.25±0.64 
N-Acetyl-beta 
alanine 




Table 1.13 continued 
Metabolite 
Relative Turnover ± standard Dev. 




1.44±0.54 12.14±4.2 10.76±4.14 7.25±2.62 4.36±1.45 5.88±2.24 5.78±2.12 
N-Acetylglutamate 1.54±0.22 0.76±0.12 0.46±0.07 1.07±0.15 1.21±0.18 1.2±0.22 1.53±0.22 
N-Acetylglutamine 2.5±0.6 1.94±0.46 1.13±0.29 1.92±0.45 1.96±0.46 1.82±0.43 2.37±0.57 
N-Acetylornithine 1.63±0.39 0.75±0.19 0.65±0.16 1.31±0.3 1.42±0.33 1.33±0.35 1.57±0.4 
NAD+ 1±0.03 0.97±0.03 0.85±0.03 1.06±0.05 1.02±0.04 0.9±0.03 0.9±0.03 
N-Carbamoyl-L-
aspartate 
1.84±0.13 1.1±0.06 2.27±0.19 1.28±0.06 1.63±0.09 1.54±0.09 1.94±0.14 
Nicotinate 0.31±0.23 0.24±0.23 -0.09±0.26 0.28±0.29 0.11±0.22 0.28±0.23 0.36±0.23 
Ophthalmate 1.24±0.05 1.03±0.05 1.05±0.1 1.2±0.07 0.81±0.04 0.95±0.04 1.13±0.05 
Ornithine 1.85±0.17 0.57±0.05 0.33±0.03 1.2±0.12 1.31±0.09 1.11±0.09 1.41±0.14 
Orotate 2.01±0.38 1.39±0.25 2.87±0.88 1.47±0.23 1.85±0.31 1.44±0.31 2.38±0.45 
Phenylalanine 









Phenylpyruvate 1.15±0.33 0±0 0±0 0.91±0.22 0.88±0.22 1.13±0.48 1.14±0.4 
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Table 1.13 continued 
Metabolite 
Relative Turnover ± standard Dev. 

















Proline 2.68±1.15 3.31±1.21 3.49±1.25 3.8±1.6 1.51±0.84 2.24±1.01 1.99±0.95 











Ribose phosphate 1.06±0.09 1.06±0.12 0.9±0.11 0.93±0.11 1.12±0.12 1±0.13 0.94±0.11 
Sedoheptulose  
1/7-phosphate 
0.79±1.04 0.84±1.11 1±1.32 0.92±1.2 0.85±1.12 1.09±1.54 0.95±1.25 
Serine 5.7±5.19 2.48±2.29 1.35±1.27 1.94±1.93 2.68±2.62 2.07±2.17 #DIV/0! 























Table 1.13 continued 
Metabolite 
Relative Turnover ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
S-Ribosyl-L-
homocysteine 
1.51±0.22 0.7±0.14 0.31±0.04 1.04±0.14 0.99±0.14 1.27±0.26 1.17±0.16 
Thymine 2.23±0.59 0.72±0.2 0.45±0.12 #DIV/0! 1.89±0.57 1.16±0.34 1.66±0.45 
Trehalose  
6-phosphate 
1.8±1.95 1.05±0.36 1.03±0.43 #DIV/0! 0.75±0.24 1.11±0.51 1.23±0.49 
Trehalose/Sucrose/ 
Cellobiose 

























UDP 0±0 0±0 0±0 0±0 0±0 0±0 0±0 
UDP-glucose 1.35±0.11 1.14±0.09 0.79±0.07 0.99±0.07 1.17±0.09 1.13±0.1 1.24±0.11 
UDP-glucuronate 0±0 0±0 0±0 0±0 0±0 0±0 0±0 
UDP-N-
acetylglucosamine 
1.83±0.19 1.03±0.1 0.57±0.06 1.28±0.13 1.3±0.13 1.38±0.14 1.85±0.2 
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Table 1.13 continued 
Metabolite 
Relative Turnover ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 






















Uridine 0±0 0±0 0±0 0±0 0±0 0±0 0±0 
Valine 4.32±1.63 3.75±1.49 1.04±0.46 4.62±1.73 4.48±1.88 2.29±1 4.14±1.61 




Table 1.14 Relative flux values for each strain compared to WT 
Metabolite 
Relative Flux ± standard Dev. 






















1.61±0.94 2.09±1.18 1.41±0.47 1.33±1.04 1.34±0.54 0.87±0.37 1.57±0.54 
Acetylphos
phate 























Table 1.14 continued  
Metabolite 
Relative Flux ± standard Dev. 




0.88±0.17 0.66±0.25 0±0 0.79±0.17 #DIV/0! #DIV/0! 1.06±0.28 
AMP/dGMP 28.75±41.73 0.25±0.24 2.14±3.47 0.39±0.38 14.07±14.09 3.41±6.29 #DIV/0! 
Arginine 42.88± 
55.36 
0.23±0.19 2.4±2.84 0.42±0.37 12.09±10.55 2.26±4.03 
11.33± 
13.51 













cAMP 6.44±4.08 0.11±0.18 1.84±0.96 4.93±2.43 6.72±5.53 2.23±1.68 -0.3±0.48 
Citraconate 










1.84±2.12 4.17±3.39 2.58±2.2 8.7±8.65 
Citrulline 3.47±1.17 0.63±0.15 0.88±0.33 1.37±0.47 2.41±0.95 2.3±0.77 3.03±1.13 
CMP 3.94±3.46 0.49±0.12 0.65±0.53 0.55±0.15 2.41±0.79 1.25±1.1 1.94±1.21 
Creatine 0.41±0.39 0±0 0.07±0.1 0±0.01 0.05±0.05 0.78±0.82 1.13±1.56 
Cystathionine 6.83±10.25 #DIV/0! 1.49±2.51 #DIV/0! #DIV/0! 0.69±0.63 #DIV/0! 
Cysteine 3.26±3.63 0.62±0.55 0.08±0.04 0.59±0.63 38.06±6.70 0.66±0.34 2.33±2.32 
Deoxyribose 
phosphate 






3.26±3.39 28.99±48.66 6±9.69 
71.04± 
91.44 
Dihydroorotate 2.96±0.85 2.96±0.86 3.62±1.99 1.96±0.79 1.87±0.88 3.89±1.36 2.94±1.69 
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Table 1.14 continued 
Metabolite 
Relative Flux ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
dTMP 8.91±3.96 1.67±0.54 0.55±0.18 5.68±2.09 5.53±3.27 2.63±0.99 1.62±1.16 
Fumarate 3.53±1.78 0.05±0.01 0.2±0.1 0.86±0.39 #DIV/0! 1.83±0.42 3.84±0.88 
Glucosamine 
phosphate 
0.97±0.41 1.32±0.31 0.86±0.2 0.96±0.2 0.76±0.21 0.98±0.25 0.82±0.23 
Glucose 6-
phosphate 
1.41±0.49 1.28±0.31 1.1±0.24 1.33±0.29 1.16±0.42 1.34±0.42 1.38±0.32 
Glutamate 2.16±0.51 0.24±0.03 0.35±0.05 1.19±0.16 1.03±0.25 0.83±0.1 1.18±0.19 
Glutamine 3.56±1.81 0.21±0.04 0.36±0.17 0.83±0.31 1.48±0.5 0.97±0.39 1.57±0.47 
Glutathione 1.12±0.2 1.2±0.16 0.92±0.15 1.11±0.39 0.78±0.11 1.2±0.18 0.85±0.14 
Glutathione 
disulfide 
11.46±16.07 1.96±2.13 4.5±5.34 
11.51±19.
11 
8.46±11.13 2.58±1.81 2.94±3.19 
Glycerate 25.17±41.28 1±1.02 5.35±8.02 0.72±0.73 3.8±4.59 1.46±2.24 7.95±10.6 
Glycinamide 
ribotide (GAR) 
1.49±0.58 #DIV/0! 0.82±0.12 #DIV/0! #DIV/0! 1.1±0.47 0.82±0.23 
Guanine 5.14±4.92 1.11±1.72 9.8±10.82 0.53±0.76 7.95±12.9 1.26±1.71 4.13±5.6 
Histidine 
16.67±29.59 0.64±0.54 4.78±6.59 0.35±0.34 2.84±3.54 0.66±0.58 
7.72± 
10.15 
Homocysteine 0.85±0.14 0.41±0.09 0.65±0.34 0.44±0.13 1.24±0.41 0.85±0.1 0.73±0.25 
Homoserine/Thre
onine 















IMP 2.27±1.6 2.64±0.9 0.07±0.06 1.49±0.54 2.91±2.23 3.04±0.96 1.35±0.72 
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Table 1.14 continued 
Metabolite 
Relative Flux ± standard Dev. 


















L-Methionine 9.14±14.43 0.26±0.15 0.75±0.83 0.67±0.35 0.52±0.39 0.72±0.72 3.93±5.57 
Lysine 7.52±7.24 2.1±0.73 7.45±4.47 5.06±1.77 3±1.28 1.31±1.01 1.93±1.41 
Malate 4.87±2.8 0.06±0.03 2.41±1.06 1.42±0.86 4.14±2.17 1.77±0.36 3.89±1.18 
N-Acetyl-beta-
alanine 












2.55±1.28 0.28±0.13 0.64±0.37 2.86±1.9 1.18±0.76 2.72±1.67 2.4±1.23 
N-
Acetylglutamine 
3.72±1.59 2.11±0.64 1.69±0.54 2.37±0.81 3.01±1 1.79±0.52 3.38±1.37 
N-
Acetylornithine 
2.21±1.07 0.29±0.08 0.96±0.44 0.92±0.35 1.78±0.49 1.73±0.63 1.95±0.54 
NAD+ 1.15±0.21 0.95±0.13 0.91±0.16 0.93±0.14 0.96±0.23 0.92±0.13 0.91±0.14 
N-Carbamoyl-L-
aspartate 





0.02±0.03 0.16±0.34 0.26±0.45 1.22±1.67 
Ophthalmate 1.34±0.22 1.45±0.21 1.38±0.23 1.41±0.32 0.9±0.11 0.95±0.18 1.13±0.23 
Ornithine 4.49±2.93 0.44±0.11 0.82±0.33 1.03±0.35 2.29±0.7 1.74±0.55 2.82±1.47 
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Table 1.14 continued 
Metabolite 
Relative Flux ± standard Dev. 
ΔacnA ΔacnB ΔsucAB ΔsucCD ΔsdhAD Δmdh ΔfumA 
Orotate 2.21±0.34 1.89±0.25 2.88±1.09 1.4±0.45 1.63±0.22 2.04±0.41 2.17±0.52 

























Proline 15.01±25.02 0.2±0.23 8.5±15.67 0.41±0.48 1.07±1.31 0.87±1.45 3.1±5.12 
Pyroglutamic 
acid 
11.94±13.86 0.74±0.61 10.9±9.74 0.43±0.38 1.48±1.41 2.17±2.28 4.95±5.79 
Ribose 
phosphate 
1.15±0.41 1.63±0.38 0.99±0.23 1.14±0.37 1.06±0.2 1.01±0.27 1±0.35 
Sedoheptulose 
1/7-phosphate 
1.88±1.31 1.47±0.65 1.5±0.94 0.95±0.41 1.54±1.12 1.03±0.68 1.47±0.83 
Serine 16.04±19.86 0.94±0.85 2.93±3.05 0.55±0.55 5.39±5.23 2.35±3.8 #DIV/0! 






















1.41±0.47 0.2±0.06 0.21±0.06 2.6±0.88 0.68±0.17 0.86±0.25 0.98±0.31 
Thymine 3.91±3.11 0.26±0.06 0.44±0.33 #DIV/0! 1.69±0.5 1±0.6 1.49±0.75 
Trehalose 6-
phosphate 
2.88±4.29 1.46±0.85 1.35±1.07 #DIV/0! 0.93±0.67 1.06±0.82 1.66±1.26 
126 
 
Table 1.14 continued 
Metabolite 
Relative Flux ± standard Dev. 
































UDP-glucose 1.53±0.48 0.91±0.27 0.9±0.29 1.12±0.41 0.72±0.19 1.61±0.48 1.2±0.39 
UDP-N-
acetylglucosamine 
7.11±8.16 0.51±0.18 0.83±0.7 0.73±0.34 1.58±0.56 1.62±1.17 3.2±2.05 























Valine 15.77±19.3 1.87±0.91 2.12±1.62 2.22±1.03 5.51±3.02 2.02±1.43 7.16±5.76 
Xanthine 









CHAPTER 2 EXPANDING LIPIDOMICS COVERERAGE: 
EFFECTIVE ULTRA PERFROMANCE LIQUID 
CHROMATOGRAPHY-HIGH RESOLUTION MASS 
SPECTROMETER METHODS FOR THE DETECTION AND 






This chapter includes details regarding the development and 
implementation of a targeted metabolomics method which was initially used as a 
means for quantitation for a defined set of lipids within Enterococcus faecalis (E. 
faecalis). This method can be easily applied to many other systems with minimal 
adjustments to the chromatograph or mass spectrometer and a new set of lipid 
compounds could be quantified. It can be seen in this chapter that metabolomics 
is a powerful tool even when only looking at a relatively small number of 
metabolites. A thirty-minute chromatographic method was able to identify and 
quantitate three different classes of lipids which corresponded to 45 individual 
compounds.   
This project was performed in collaboration with Dr. Elizabeth Fozo and her 
graduate students in the Department of Microbiology at the University of 
Tennessee. The Fozo laboratory is focused on the ability of E. faecalis to become 
tolerant to antibiotics, like daptomycin, when exposed to mammalian fluids like 
serum or bile. This tolerance was thought to be caused by the uptake of 
unsaturated fatty acids from the extracellular matrix, and their incorporation into 
the bacteria’s membrane as modified phospholipids. Historically, this was 
performed by thin layer chromatography (TLC) which is simple to perform but is 
limited by only being able to elucidate bulk changes in compound class with no 
information about specific lipids. Fatty acid methyl esterification (FAME) using gas 
chromatography-mass spectrometry (GC-MS) is another technique employed to 
probe lipid membrane composition but relies on a derivatization step. Since this is 
an indirect method of quantitation, information is lost about which lipid head group 
the esterified fat was attached. Another problem with GC-MS is the esterification 
of membrane harbored free fats that are not attached to a phospholipid. Depending 
on the derivatization method, the products detected will be a summation of the tails 
from phospholipids and any free fats present.  
129 
After several attempts with the above-mentioned techniques by my 
collaborators, I was approached by Dr. Fozo, and offered my expertise. This is 
where a high-resolution mass spectrometric technique can be very useful and 
overcome many of the limitations of TLC and FAME analyses. The Fozo laboratory 
was interested in measuring only specific phospholipids including a low abundant 
four tailed lipid, cardiolipin. To measure these phospholipids, a targeted 
metabolomics approach on a hybrid quadruple Orbitrap instrument was chosen in 
conjunction with a HILIC column. Since cardiolipin is not a “standard” phospholipid 
in many bacterial systems, separation conditions had to be optimized in order to 
reliably detect cardiolipin without losing detection of the more common two tailed 
phospholipids. Over the course of several months, various column conditions were 
tried until a 5.8 pH buffered ammonium acetate mobile phase was chosen.  
When using the mass spectrometer, parallel reaction monitoring (PRM) was 
selected to only focus on the handful of metabolites that were of biological interest 
in the study. This created full scan data of the fragments based on the isolation of 
a parent ion. Post analysis allowed for quantitation from multiple fragments and 
the opportunity to identify what types of specific fatty acids were bound to a specific 
cardiolipin. Finally, an untargeted lipidomics method was also used to collect a 
global lipidome from the same bacteria, and interestingly free fats were detected 
in the membrane (in large amounts) of samples supplemented with the same fatty 
acid. This accumulation was not originally thought to occur.  
This targeted and corresponding untargeted lipidomics analyses are being 
published as a standalone method, which uses a small portion of the biological 
data as a proof of concept. Currently, this method is being used heavily to measure 
phospholipid changes for a multitude of different genetic variants responsible for 
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Lipidomics is capable of revealing global alterations in a broad class of 
molecules whose functions are innately linked to physiology. Monitoring changes 
in the phospholipid composition of biological membranes in response to stressors 
can aid the development of targeted therapies.  However, exact quantitation of 
cardiolipins is not a straightforward task due to low ionization efficiencies and poor 
chromatographic separation. Herein, a method is reported to quantitate 
phospholipids using internal phospholipid standards. An extraction using 
chloroform and methanol  paired with a Q Exactive orbitrap mass spectrometer 
allows for quantifying 23 cardiolipins, 10 phosphatidylglycerols and 10 lysyl-
phosphatidylglycerols with detection limits as low as 50 nM in addition to 
measuring changes in free fatty acids. Biological validation with Enterococcus 
faecalis, a Gram-positive bacterium, demonstrates that this analysis is sensitive 
enough to monitor the incorporation of oleic and linoleic acids into the tails of  
membrane lipids as well as discovering free fats in the membrane. When 
supplemented with oleic acid, the amounts of free oleic acid detected is 100 times 





Lipids play an essential role for multiple cellular functions including energy 
acquisition, maintenance of cellular physiology, cellular mobility, and cellular 
transport50. Biological membranes contain several types of phospholipids, and the 
phospholipid composition can vary drastically depending on genetics or 
environmental factors51. Membrane phospholipids consist of polar head groups 
and multiple non-polar tails which form an amphipathic lipid bilayer, creating a 
barrier between internal cellular components and the extracellular environment. 
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The head groups of membrane phospholipids are highly variable and tend to 
combine with tails of varying length and degrees of unsaturation, creating a large 
number of possible combinations. Although the numbers of possible lipids are vast, 
bacteria have limited their membranes to use only three or four different head 
groups52, 53. Bacterial membranes are primarily composed of various combinations 
of cardiolipin (CL), phosphatidylglycerol (PG), phosphatidylethanolamine (PE), 
phosphatidylinositol (PI), phosphatidic acid (PA), or phosphatidylserine (PS). 
Depending on the bacterium, lipids with lyso or amino acid modifications may also 
be present54. Membrane fluidity can be altered by adjusting the fatty acid tails 
(adding degrees of unsaturation) or changing ratios of lipid classes, providing a 
quick way to respond to external stressors55. The ability to alter membrane 
composition has been used to preserve viability when bacteria are challenged by 
antibiotics56 or extreme temperatures57.  
To date, most research has used glycerol phospholipids, which have two 
positions containing fatty acids varying in lengths from 14-18 carbons with the 
possibility of zero, one, or two degrees of unsaturation. The low number of 
biologically relevant tails, combined with their high abundance in biological 
samples, allows this set of lipids being easily measured53. Over 90% of the 
bacterial membranes studied consist of two-tailed lipids such as PG or PE58, which 
come from PA. Cardiolipins (CL) are essentially two PG molecules connected by 
a shared glycerol molecule resulting in a four tailed lipid59. These four-tailed lipids 
are not as abundant in biological specimens as two-tailed lipids50, 58. Doubling the 
number of tails, doubles the number of possible biologically relevant combinations.  
Thus, combining their low abundance in biological membranes with the high 
number of possible CL tail combinations leads to difficulty in measurement. 
Current lipidomics analysis includes various mass spectrometric techniques 
such as direct injection of extracted lipid sample, separation of lipid sample 
components based on chromatography followed by tandem mass-spectrometry, 
and analysis of lipids and imaging of tissues utilizing MALDI60-62. Separation of 
lipids can be done by using reverse phase chromatography, which differentiates 
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based on the aliphatic tails63, or with hydrophilic interaction liquid chromatography 
(HILIC) which differentiates based on the polar head group64-66. Compounds are 
typically ionized using electrospray ionization in both positive and negative mode, 
and the parent ion or a fragment from a MS/MS experiment is detected. Although 
there are many mass spectrometry experiments that allow the detection of 
common phospholipids,64 there are only a handful of methods that explicitly 
measure cardiolipins67-69. An even smaller number of methods quantify 
cardiolipin70, 71.Specifically, Minkler and coworkers used a reverse phase column 
with triethylamine coupled to triple quadrupole ion trap mass spectrometer to 
measure relative amounts  8 different cardiolipin species67, and Rashid and 
coworkers profiled the lipidome of Enterococcus faecalis by the quantitation of PG 
and LPG using a triple quadruple, thus the latter was not able to fully quantitate 
any cardiolipins68. Six different lipid classes including CL were analyzed in 
mitochondrial membranes using a C18 column and an Orbitrap, but no exact 
quantities for CL were measured69. Cardiolipins were quantified with an internal 
standard using a triple quadrupole, but the method only focused on cardiolipins, 
neglecting the other phospholipids70. A HILIC MS/MS method that was able to 
quantitate CL, PG, PA, BMP, and PG has been reported71. However, this analysis 
used a triple quadrupole not allowing for a high-resolution quantitation of multiple 
fragments. The method reported here eliminates the need for an ion-paring agent, 
allows the detection of lipids in an untargeted fashion based on head group 
similarity, and quantitates of over 30 individual compounds using a high-resolution 
mass analyzer. 
Often there is a tradeoff between coverage and the ability to measure 
specific compounds in UPLC analyses. However, this method demonstrates the 
practicality of using a single extraction method for both targeted and untargeted 
lipid analysis. The untargeted analysis uses an orbitrap mass spectrometer 
operating in full scan mode to provide relative quantitation of the six most common 
phospholipid head groups, the lysyl- derivatives, and four free fatty acids that make 
up the tails of bacterial phospholipids. Each of these compound classes have the 
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potential to detect over 30 unique m/z resulting in hundreds of possible known 
lipids detected along with the opportunity to mine the data for unknown lipid-like 
compounds. The targeted approach uses a hybrid quadrupole mass spectrometer, 
allowing for the quantification of specific cardiolipin, phosphatidylglycerol, and 
lysyl-phosphatidylglycerol compounds within a sample. The method was validated 
by analyzing relative lipidome changes as well as measuring exact quantities of 
three lipid classes in Enterococcus faecalis (E.faecalis) samples that were 
supplemented with two unsaturated exogenous fatty acids.  
 
2.3 Experimental Section 
 
2.3.1 Untargeted standards  
Phospholipid standards were used to verify retention time and head group 
ionization. The standards assessed were as follows: phosphatidylinositol with two 
16:0 tails (PI 32:0), phosphatidic acid with one 18:0 and one 18:1 tail (PA 36:1), 
phosphatidylglycerol with two 18:0 tails (PG 36:0), phosphatidylcholine with two 
18:0 tails (PC 36:0), phosphatidylserine with one 16:0 tail and one 18:2 tail (PS 
34:2), phosphatidylethanolamine with two 16:0 tails (PE 32:0), and lysyl- 
phosphatidylglycerol with two 18:1 tails (LPG 36:2). All standards were purchased 
from Avanti Lipids, Inc. and one representative compound was chosen from each 
head group class. The fatty acid standards:  cis-9-ocatdecanoic acid (oleic acid), 
cis 9,12 octadecadienoic acid (linoleic acid), octadecanoic acid (stearic acid), and 
hexadecenoic acid (palmitic acid) were purchased from Sigma Aldrich.  
 
2.3.2 Targeted standards  
Representative standards from three head group classes; cardiolipin (CL), 
phosphatidylglycerol (PL), and lysyl-phosphatidylglycerol (LPG) were purchased 
from Avanti Polar Lipids Inc. Even though this method was targeted, exact 
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matched compounds were not available for all species of interest, therefore one 
compound from each of the three classes was used to make external calibrations. 
Cardiolipin, (CL 72:4) with four 18:1 tails, phosphatidylglycerol, (PG 36:0) with two 
18:0 tails, and lysyl-phosphatidylglycerol, (LPG 36:2) with two 18:1 tails were 
chosen as external standards. Since HILIC chromatography was used, it was 
hypothesized that there would be minimal retention time variation between 
molecules within the same head group regardless of tail configurations. Internal 
standards were chosen based on lipids that were not present or had very limited 
presence in the biological samples. Cardiolipin with four 14:0 tails (CL 56:0) and 
phosphatidylglycerol with two 18:0 tails (PG 36:0) were chosen as the internal 
standards. It should be noted that based on gas chromatography fatty acid methyl 
ester analyses, a small portion (<5%) of fatty acid tails in E. faecalis membranes 
are tetradecanoic acid (C14:0)72, 73.   There were no non-naturally abundant LPG 
standards available for purchase, therefore external calibration curves were used 
to quantify LPGs. Data for the targeted standards is presented in Table 2.1. 
Calibration and test samples were spiked with an internal standard to account for 
any loss of signal due to ionization efficiency or suppression. 
2.3.3 Biological samples 
Enterococcus faecalis cultures were grown in brain heart infusion (BHI) 
medium at 37C.  Overnight cultures were diluted into fresh BHI to an optical 
density (OD600) of 0.01 and supplemented with either 10g/mL of linoleic acid or 
20g/mL oleic acid and allowed to grow until an OD600 of 0.3. 0.1%. Ethanol was 
used as the solvent control.  
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Table 2.1 Details for lipid standards used for the targeted analysis  






















































 2.3.4 Extraction of lipids from biological samples  
Enterococcus faecalis supplemented with the previously mentioned fatty 
acids were harvested in 15 mL aliquots at mid log phase (OD600 ~ 0.3). The cells 
were washed twice with 1X PBS via centrifugation, resuspended in 1mL of 1X 
PBS, and treated with 100g/mL of lysozyme. After 20 minutes of incubation at 
37C, the lysozyme treated cells were transferred to plastic screw top microfuge 
tubes containing 0.5 g of glass beads (≤106 um). The cells were then homogenized 
using a mini bead-beater (Biospec Products, Bartlesville, OK) for two, 1-minute 
intervals. The homogenized cells were then transferred to a 15 mL polypropylene 
conical vial containing a mixture of chloroform: methanol 2:1 (v/v)74, 75. Samples 
were briefly vortexed and then centrifuged for 5 minutes at 3500 rpm. Layers 
formed containing the glass beads at the bottom and the cell debris in the middle. 
The two phases were carefully transferred to a clean 15mL polypropylene conical 
vial containing 1.5mL of 0.9% NaCl, leaving behind the cell debris and glass beads. 
After briefly vortexing, samples were centrifuged, and the lower lipid containing 
organic phase was transferred to a glass screw top vial.  Lipid extracts were dried 
under nitrogen gas and suspended in 260 µL of 1:1 methanol: chloroform and 40 
µL of internal standard before being transferred to autosampler vials with PTFE 
septa. 
 
2.4 Liquid Chromatography- Mass Spectrometry Parameters 
 
Samples and standards were stored at -20 °C until they could be analyzed 
and kept at 4 °C in the autosampler during the analysis. A Dionex ultra 
performance chromatograph (UPLC)(Sunnyvale, CA) was used in conjunction with 
a Kinetex HILIC column 100 Å 2.6µm 150 mm x 2.1 mm (Phenomenex, Torrance, 
CA) to separate lipid compounds for both the targeted and untargeted analysis. 
138 
2.4.1 Untargeted lipid analysis  
The untargeted method used 10 mM ammonium formate adjusted to a pH 
of 3.0 for mobile phase A, and 97:3 acetonitrile: water adjusted to a pH of 3.0  with 
10 mM  ammonium formate for mobile phase B. Gradient: t=0 min 0% solvent A, 
100% solvent B; t=1 min 0% solvent A, 100% solvent B; t=15 min 19% solvent A, 
81% solvent B; t=15.1 min 52% solvent A, 48% solvent B ; t=25 min 52% solvent 
A, 48% solvent B; t=25.1 min 0% solvent A, 100% solvent B; t=35 0% solvent A, 
100% solvent B. The flow rate was set to 0.200 mL/min. An Exactive Plus Orbitrap 
mass spectrometer (Thermo Scientific, Waltham, MA) was used to detect the 
different phospholipids and fatty acids. Electrospray ionization (ESI) was utilized 
under the following settings: sheath gas-25 (arbitrary units); auxiliary gas-10 
(arbitrary units); spray voltage-4 kV; capillary temperature-350 °C; resolution-
140,000. Ions between 100-1500 m/z were recorded in both positive and negative 
mode in separate scan events. In addition to full scan data, the all ion 
fragmentation (AIF) was collected throughout the run using a normalized collisional 
energy of 30 eV with a stepped energy of 50%. Calibration was performed every 
24 hours in positive and negative mode using calibration solutions from Thermo 
Scientific. 
2.4.2 Targeted phospholipid analysis 
The targeted analysis used 5 mM ammonium acetate adjusted to a pH of 
5.8 for mobile phase A, and 97:3 acetonitrile: water adjusted to a pH of 5.8 with a 
final concentration of 5 mM ammonium acetate. Gradient: t=0 min 3% solvent A, 
97% solvent B; t=1 min 3% solvent A, 97% solvent B; t=1.2 min 5% solvent A, 95% 
solvent B; t=4 min 5% solvent A, 95% solvent B; t=4.2 min 10% solvent A, 90% 
solvent B; t=7.6 min 10% solvent A, 90% solvent B; t=8.1 min 30% solvent A, 70% 
solvent B; t=10.9 min 30% solvent A, 70% solvent B; t=11 min 50% solvent A, 50% 
solvent B; t=18 min 50% solvent A, 50% solvent B. The flow rate for separation 
was 0.200 mL/min. Following the 18 min separation, the gradient was set to 3% 
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solvent A, 97% solvent B at a flow rate of 0.500 mL/min for 12 minutes to re-
equilibrate the column.  
Eluent was ionized using an electrospray ionization (ESI) source operated 
under the following settings: sheath gas 30 (arbitrary units); aux gas 8 (arbitrary 
units); sweep gas 3 (arbitrary units); spray voltage 3kV; capillary temperature 300 
°C. A Q-Exactive Plus Orbitrap mass spectrometer (Thermo Scientific, Waltham, 
MA) was used to collected data for all targeted data. All ions were detected in 
negative mode using parallel reaction monitoring (PRM), which requires a list of 
parent m/z’s to isolate and subsequently collects a full scan of the fragments 
produced. Parameters for the mass spectrometer were as follows: resolution-
140,000; automatic gain control (AGC)-3x106 ions; maximum IT time-100 ms; 
isolation window-0.4 m/z; normalized collision energy 35 eV. Calibration was 
performed on the instrument every 24 hours using a negative mode calibration 
solution from Thermo Scientific. 
2.4.3 Targeted compound list 
Phosphatidylglycerol (PG) and lysyl-phosphatidylglycerol (LPG) 
compounds were detected as the [M-H]- ion and the cardiolipin (CL) compounds 
were detected as [M-2H]2- ions. In total, 23 unique CL, 10 PG, and 10 LPG masses 
were targeted for quantitation. This list only included the most abundant fatty acids 
bound to each head group, C16:0, C16:1, C18:0, C18:1, and C18:2, based on 
bacterial profiles56, 72, 73. A complete list of all the lipids included in the analysis is 
provided in  Appendix Table 2.4. The m/z listed in the table corresponds to the 
parent mass isolated and eventually fragmented. However, quantitation was 
performed by selecting a specific fragment that is common to the head group not 
the specific lipid. A dehydrated glycerol phosphate (GP) fragment with a m/z (-) of 
152.9958 was used for all PG and CL compounds, and a lysine fragment with a 




Figure 2.1 Structure of fragments used to quantitate lipids cardiolipin, phosphatidylglycerol, 
and lysyl phosphatidylglycerol.  
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analysis method has the advantage of determining the relative concentrations of 
specific fatty acid tails attached to the parent ion. 
2.4.4 Calibration curve preparation 
Standards for calibration curves were dissolved in 1:1 methanol: chloroform 
using masses of purchased solid standards. A mixed stock of CL 72:4, PG 36:0, 
and LPG 36:2 was prepared at 75µM and stored at -20 °C. Serial dilutions from 
the stock were made at the following concentrations; 50, 10, 5, 1, 0.5, 0.1, 0.05, 
0.01, 0.005, and 0.001 µM. Internal standards of CL 56:0 and PG 16:0 were made 
by dissolving the solid standard in solvent to make a mixed working stock of 50 µM 
and added to each calibration standard at a final concentration of 8.3 µM.  
 
2.5 Data Analysis 
 
2.5.1 Untargeted 
Data generated from the Xcalibur software was converted from the .raw file 
extension to the .mzML using msconvert, a tool in ProteoWizard76, 77. All peak area 
integration was performed within MAVEN78, using a 5 ppm mass window and exact 
m/z based on chemical formula and preferred ionization mode. Phospholipids with 
the head groups of PA, PE, PI, PS, PG, LPG, and fatty acids were detected a [M-
H]-, and PC were detected as [M+H]+.  
2.5.2 Targeted 
Xcalibur’s Quan Browser (Thermo Scientific, Waltham, MA) was used to 
integrate areas under the curve for fragment masses that corresponded to exact 
m/z of the specific ion of interest and were also matched to retention time range of 
phospholipid classes. Cardiolipin molecules elute at 4.5 minutes, 
phosphatidylglycerol elutes at 2 minutes, and lysyl-phosphatidylglycerol elutes at 
10 minutes.  Calibration plots were made by plotting the log of the ratios of the 
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area of the analyte to the area of the internal standard “log( Aa/Ais)”  vs. the log of 
the ratios of concentration of the analyte to the concentration of the internal 
standard “log([Ca]/[Cis])”. Biological data was analyzed using the same protocol, 
and the exact concentration of the lipid was interpolated using the regression line 
for the corresponding standard. Each calibration level was analyzed in replicates 
of six and standard error was calculated.  
 
2.6 Results and Discussion  
 
2.6.1 Untargeted data 
Operating the instrument in dual polarity full scan mode, along with all ion 
fragmentation (AIF) allowed for the collection of information about the parent ion 
and the fragments produced.  Although the hydrophobic extraction preferentially 
selects for compounds with lipid-like moieties, the mass spectrometer is only 
constrained by its m/z range. This allows for analysis of experiments that are 
exploratory in nature or of unknown sample composition.  The analysis leads to an 
initial understanding of the lipid profiles in samples, which has not been previously 
studied.  Additionally, global lipidome changes can be measured between a 
treatment group and a control. The HILIC chromatography is concentrated on 
hydrophobicity therefore, any phospholipid with the same polar head group (PE, 
PC, PG, etc.) will have the same retention time (RT) without regard to the 
composition of aliphatic tails. A typical experiment requires a standard to be 
analyzed using the exact chromatographic and mass spectrometric conditions for 
each compound that is to be identified, but this is not the case for this untargeted 
method. Identification for  exact lipid species can be made by matching two factors: 
exact mass and retention time of the head group. Each phospholipid head group 
only needs to have one representative standard analyzed, saving instrument time 
and cost. This makes it possible to identify any possible tail combination for all 
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head groups, without having multiple standards. This can be very advantageous if 
the compounds desired are not easily purchased or synthesized. 
As a proof of concept, six phospholipid standards, one from each of the 
most abundant head groups, were analyzed by the untargeted lipidomics methods 
and were detected in either positive or negative mode. There was complete 
temporal resolution between groups except for phosphatidylinositol (5.08 min) and 
phosphatidic acid (4.99 min), but because a high-resolution mass analyzer was 
used, there was a low possibility of lipid misidentification. The lysine conjugated 
PG was also detected at 12.3 minutes. Even though no additional amino acid (AA) 
modified phospholipid standards were analyzed, it is indicative that this HILIC-MS 
method is capable of detecting many other AA modified lipids. It has been shown 
that these compounds serve an important role in creating surface membrane 
charge sites, thus providing some form of antibiotic tolerance79, 80 and reduces 
attraction of host generated antimicrobial peptides81  
Since free fatty acids (FFA) are the building blocks of phospholipids it would 
be beneficial to detect those as well82, 83. These compounds were not retained by 
the column, which was expected, but four biologically relevant FFA were detected. 
A summary of this information is  provided in Table 2.2. 
  This method has shown its ability to discriminate seven different 
phospholipids and four fatty acids; it is reasonable to assume that other lipids that 
do not contain phosphorus or have a sugar moiety as a head group will be detected 
in this approach (unpublished data). Photosynthetic organisms have sulfolipids 
such as sulfoquinovosyl diacylglycerols (SQDG) and can replace phospholipids 
with sulfur containing lipids under phosphorus limited conditions84, 85. 
Monogalactosyldiacylglycerol (MGDG) and digalactosyldiacylglycerol (DGDG) are 
the major lipid classes present in plants and have roles in photosynthesis86, 87.  
Being able to precisely measure a large set of compounds within and across 
a lipid class in a 30-minute analysis is very valuable. However, it is possible to 
accurately
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Exact m/z Detected m/z Error (ppm) 
Phosphatidylinositol PI (32:0) C41H79O13P [M-H]- 5.08 809.5180 809.5209 3.58 
Phosphatidic acid  PA (36:1) C39H75O8P [M-H]- 4.99 701.5121 701.5146 3.56 
Phosphatidylcholine  PC (36:0) C44H88NO8P [M+H]+ 11.91 790.6326 790.6315 1.39 
Phosphatidylserine PS (34:2 ) C40H74NO10P [M-H]- 10.79 758.4972 758.4992 2.64 
Phosphatidylethanolamine PE (32:0) C37H74NO8P [M-H]- 9.17 690.5074 690.5093 2.75 
Phosphatidylglycerol PG (36:0) C42H83O10P [M-H]- 3.43 777.5665 777.5659 0.77 
Lysyl-phosphatidylglycerol LPG (36:2) C48H91N2O11P [M-H]- 12.3 901.6282 901.6307 2.77 
Oleic acid OA C18H34O2 [M-H]- 1.59 281.2481 281.2491 3.56 
Linoleic acid LA C18H32O2 [M-H]- 1.66 279.2324 279.2334 3.58 
Palmitic acid P C16H32O2 [M-H]- 1.74 255.2324 255.2334 3.92 
Stearic acid S C18H36O2 [M-H]- 1.53 283.2637 283.2648 3.88 
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detect thousands of m/z that may not match any known lipid. Matching the m/z’s 
retention time can help identify the head group, and AIF can be used to identify 
fragments that are present, aiding in piecing the molecule back together. An 
example can be seen in Figure 2.2. The standard for PS (34:2) elutes at 10.7 
minutes, and several fragments that match the structure can be identified. Based 
upon theoretical fragmentation data from LipidMaps88, 89, it is possible to identify at 
least 5 fragments of the parent ion, including the 16:0 (255.2333 m/z) and 18:2 
(279.2334 m/z) fatty acid tail fragments. This added feature can be useful for 
structure elucidation in the case of an unidentified ion.  
2.6.2 Targeted data 
In efforts to compliment the untargeted approach, the design and 
optimization of a targeted approach was used to quantify a reduced number of 
lipids. Although this exact method only focuses on three lipid classes (CL, PG, and 
LPG) present in a specific bacterium68, 90, the fundamentals can be applied to any 
set of lipids that desire a more precise measurement.  
Herein, we have created a method to quantify CL without the use ion paring agents, 
while still being able to quantify two other lipid classes, PG and LPG. The above-
mentioned untargeted method uses 10 mM ammonium formate at pH 3, which 
provides excellent detection of all six common phospholipid classes and several 
other lipid species; however, CL do not ionize well with these conditions. It was 
determined that rising the pH to 5.8 and changing the buffer’s concentration to 5 
mM ammonium acetate resulted in reliable detection in cardiolipin standards. This 
is supported by experimentation showing pKa1 and pKa2 have values of 2.15 and 
3.15 respectively91, thus shifting equilibrium towards the doubly deprotonated form 
at a pH of 5.8. Again, due to the HILIC nature of the chromatography, separation 
can be achieved based on headgroup regardless of tail composition. There are 
discrete regions in the chromatogram where PG, CL and LPG’s elute (Appendix 
Figure 2.4). In contrast to the AIF that is used in the untargeted method, parallel
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Figure 2.2 All ion fragmentation of PS (34:2) standard.  
A: [M-H]-, B: loss of serine, C: loss of serine and C18:2 fatty acid as ketene D: loss of serine and C18:2 fatty acid as neutral specie, 
E: C18:2 fatty acid, F: C16:0 fatty acid. 
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 reaction monitoring (PRM) is used to isolate and fragment individual lipid m/z. 
High resolution data of the all the fragments originating from the parent mass is 
obtained. This provides an extra level to confirm to the exact structural moieties 
present in a mixed FA lipid while reducing noise thus lowering the detection limit.  
To make the targeted method as quantitative as possible, a calibration 
curve was made by using a single external standard each for lipid class and adding 
an internal standard that is not naturally found in biological samples. Since 
standards for each specific lipid of interest are not available, this methodology for 
quantitation accounts for any changes in ionization efficiency between the chosen 
external standard and the detected lipid. When calibration curves were plotted, a 
high correlation of determination value (R2) was achieved for all lipid classes 
(Appendix Figure 2.5 and Appendix Table 2.5). Less than 2% variation was 
seen in the internal standard across all points in the calibration curve (Table 2.1). 
Cardiolipin and PG were analyzed with a detection limit of 416 nM and 41.6 nM for 
LPG. Linear range for CL and PG spanned three orders of magnitude, and LPG 
was linear over four orders of magnitude. Signal for the standards below these 
concentrations was either not detected or not above the noise.  
2.6.3 Biological validation 
 To show the application of this lipidomics approach, Enterococcus faecalis 
(E. faecalis) cells were supplemented with exogenous fatty acids, and their lipids 
were profiled using both the untargeted and targeted approaches. Treated and 
control samples were grown, and lipids were extracted as mentioned in the earlier 
section. It has been shown that when E.faecalis cells are grown in the presence of 
host unsaturated fatty acids (oleic acid or linoleic acid), Appendix Figure 2.6, a 
tolerance to daptomycin is observed along with alterations in membrane fatty acid 
profiles as measured through GC-FAME56.  Applying our approach on this bacterial 
system shows the advantages of performing both analyses on a single sample. 
Several studies have been published measuring lipid changes in E.faecalis using 
thin layer chromatography (TLC)90, 92, 93, and GC-FAME56, 72, 73. TLC methods 
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suffer from the ability to only identify different classes of lipids and has limited use 
for quantitation. GC-FAME allows for quantitation of individual fatty acids but is 
hindered by the non-specific esterification of phospholipids resulting in loss of 
information about head groups. One group explicitly measured individual 
phospholipids (LPG and PG)  in these bacterium68. Table S3 compares what lipids 
were detected by Rashid and coworkers to what was measured in this study. 
 The untargeted analysis also facilitated the detection of two free fatty acids 
(FFA), 9 lysyl-phosphatidylglycerols (LPG), and 12 phosphatidylglycerols (PG). 
The heat map in Figure 2.3 shows the log2 fold change in the normalized areas for 
each lipid detected (exact ratios shown in Appendix Table 2.6). Each column 
represents the ratio of the samples supplemented with exogenous fatty acids 
compared to the control samples. As expected, a significant difference is seen in 
the relative amounts of FFAs detected in the corresponding supplemented 
samples (e.g. oleic acid is more abundant in the samples when supplemented with 
oleic acid, and likewise for linoleic acid). Smaller, positive, significant fold changes 
are seen in the oleic acid samples for LPG 34:2, LPG 36:2, and LPG 36:4, showing 
that some amount of oleic acid is being incorporated into membrane as LPG. An 
opposite trend is seen when looking at the linoleic acid samples; a decrease is 
seen in monosaturated LPGs such as 36:1, 32:1 34:1. These compounds have 
one degree of unsaturation in either of the two fatty acid tails, but this method is 
lacking the ability to determine exactly which fatty acid tail harbors the double 
bond. Regardless of the fatty acid that is supplemented, there is a global decrease 
in all of the PGs detected when compared to the controls. The one thing this 
analysis cannot provide is the ability to compare the fold change of one lipid to the 
fold change to another lipid (e.g. the fold change for LPG 36:4 vs the fold change 
for PG 36:1). While the untargeted method provides the ability to quickly examine 
how multiple lipids species (within and across head groups) are changing 
compared to others, information about exact concentrations is lacking. This
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Figure 2.3 Heat map of lipid compounds detected using the untargeted analysis.  
All fold changes are compared to control samples and then log2 transformed. An orange 
color represents a fold change >1, and a blue color represents a fold change <1. Asterisks 
depict the level of confidence based on a Student’s T-test.  
150 
 limitation can be overcome by using the targeted method, thus gaining more 
information about lipid species identified as significant from the untargeted method. 
The targeted analysis (n= 6 per group) was able to quantify 9 phosphatidylglycerols 
(PG), 8 cardiolipins (CL)  and 10 lysyl-phosphatidylglycerols (LPG), (Table 2.3 and 
Appendix Table 2.7).  If a value is listed at <LOQ, a peak was identified but its 
concentration was lower than the limit of quantitation, and if a ND is listed, no peak 
was below the limit of detection. This method was capable of quantifying 
cardiolipins which has been difficult to do with previous methods.  When the cells 
were provided linoleic acid, the polyunsaturated CL (72:7 and 72:8) were at 1.46 
and 2.69 µM respectively and were not detected in in the oleic acid and control 
samples. Within the PRM data, it can be verified that the CL72:7 compound’s major 
tail fragment is a C18:2 (m/z 279.2231), and a minor component of C18:1 (m/z 
281.2486).  As expected, the CL72:8 fragmentation data showed only C18:2 tail 
fragments (Appendix Figure 2.7).  It is clear that the quantity of PG lipids with C16 
tails (saturated or unsaturated) was very low when given either of the fats, which 
was also seen in the untargeted data. The targeted approach showed the most 
abundant PG in the control samples is PG 34:1 and has a concentration of 11.21 
µM, which is two times higher than the next most abundant PG. This information 
is not obtainable from the untargeted method alone. This increases the 
understanding of how the membrane composition is changing within a head group, 
but not necessarily across treatments. 
2.7 Conclusion 
 
 The intent of these methods was to highlight the importance of analyzing 
lipids from an untargeted and targeted standpoint. It has shown that using a high-
resolution mass spectrometer in full scan mode allows for the detection of many 
different lipid classes with the ability to discriminate within each class, and a more 
holistic understanding of how lipid profiles change. It was possible to detect 6 major
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Table 2.3 Quantitative lipid data for biological samples.  
The first column represents the lipid species detected, and the second, third, and fourth 
columns represent the three different exogenous fats that were added. The data is an 




























Control Oleic Acid Linoleic Acid 
PG (32:0) 1.79 ±0.23 <LOD <LOD 
PG (32:1) 4.98 ±0.92 <LOD <LOD 
PG (34:0) 1.28 ±0.12 <LOD <LOD 
PG (34:1) 11.21 ±1.76 <LOD <LOD 
PG (34:2) 0.97 ±0.12 <LOD 1.25 ±0.18 
PG (36:1) <LOD 1.21 ±0.25 <LOD 
PG (36:2) 1.87 ±0.44 18.34 ±2.2 <LOD 
PG (36:3) ND <LOD 0.79 ±0.15 
PG (36:4) <LOD <LOD 8.14 ±1.57 
CL (66:0) ND ND 0.75 ±0.14 
CL (70:0) 0.77 ±0.12 ND 1.71 ±0.31 
CL (70:6) ND ND 0.9 ±0.16 
CL (72:0) 3.81 ±0.53 <LOD <LOD 
CL (72:3) <LOD 1.04 ±0.31 ND 
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Control Oleic Acid Linoleic Acid 
CL (72:4) <LOD 2.68 ±0.7 ND 
CL (72:7) ND ND 1.46 ±0.35 
CL (72:8) ND ND 2.69 ±0.68 
LPG (32:0) 0.53 ±0.18 <LOD <LOD 
LPG (32:1) 0.53 ±0.19 0.19 ±0.03 0.04 ±0.03 
LPG (34:0) 0.46 ±0.2 0.05 ±0.01 <LOD 
LPG (34:1) 2.97 ±0.69 0.57 ±0.11 0.08 ±0.12 
LPG (34:2) 0.22 ±0.04 0.38 ±0.04 0.67 ±1.16 
LPG (36:0) <LOD 0.05 ±0.01 ND 
LPG (36:1) 0.17 ±0.02 1.57 ±0.2 <LOD 
LPG (36:2) 0.39 ±0.08 12.8 ±1.46 0.13 ±0.19 
LPG (36:3) <LOD 0.07 ±0.01 0.49 ±0.92 
LPG (36:4) 0.05 ±0.03 <LOD 2.46 ±4.48 
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phospholipids, free fatty acids, and lysine-based lipids, but there is reason to 
believe that many more lipid classes could be detected using this analysis. By 
adjusting the pH of the mobile phase, it was possible to confidently detect 
cardiolipins, which are notoriously difficult to measure. With the implementation of 
representative standards (internal and external) and parallel reaction monitoring, 
it was possible to quantitate cardiolipin, phosphatidylglycerol, and lysyl-
phosphatidylglycerol to the nanomolar range. Biological applications were shown 
by using a single extraction method to measure global lipid changes and quantify 
eight different cardiolipin species in E.faecalis. 
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2.8 Appendix  
 
Table 2.4 Full list of compounds included in PRM.  
Each lipid represents a unique m/z and formula. Only one possible tail combination is listed 




Tail 1 Tail 2 Tail 3 Tail 4 Formula 
CL (64:0) 675.4788 0-8 16,0 16,0 16,0 16,0 C73H142O17P2 
CL (64:1) 674.471 0-8 16,1 16,0 16,0 16,0 C73H140O17P2 
CL (64:2) 673.4632 0-8 16,1 16,1 16,0 16,0 C73H138O17P2 
CL (66:0) 689.4945 0-8 18,0 16,0 16,0 16,0 C75H146O17P2 
CL (66:1) 688.4867 0-8 18,0 16,1 16,0 16,0 C75H144O17P2 
CL (68:0) 703.5101 0-8 18,0 18,0 16,0 16,0 C77H150O17P2 
CL (68:1) 702.5023 0-8 18,0 18,0 16,1 16,0 C77H148O17P2 
CL (70:0) 717.5258 0-8 18,0 18,0 18,0 16,0 C79H154O17P2 
CL (70:1) 716.518 0-8 18,0 18,0 18,0 16,1 C79H152O17P2 
CL (70:3) 714.5023 0-8 18,1 18,1 18,0 16,1 C79H148O17P2 
CL (70:4) 713.4945 0-8 18,1 18,1 18,1 16,1 C79H146O17P2 
CL (70:5) 712.4867 0-8 18,2 18,1 18,1 16,1 C79H144O17P2 
CL (70:6) 711.4788 0-8 18,2 18,2 18,1 16,1 C79H142O17P2 
CL (70:7) 710.471 0-8 18,2 18,2 18,2 16,1 C79H140O17P2 
CL (72:0) 731.5414 0-8 18,0 18,0 18,0 18,0 C81H158O17P2 
CL (72:1) 730.5336 0-8 18,1 18,0 18,0 18,0 C81H156O17P2 
CL (72:2) 729.5258 0-8 18,1 18,1 18,0 18,0 C81H154O17P2 
CL (72:3) 728.518 0-8 18,1 18,1 18,1 18,0 C81H152O17P2 
CL (72:4) 727.5101 0-8 18,1 18,1 18,1 18,1 C81H150O17P2 
CL (72:5) 726.5023 0-8 18,2 18,1 18,1 18,1 C81H148O17P2 
CL (72:6) 725.4945 0-8 18,2 18,2 18,1 18,1 C81H146O17P2 
CL (72:7) 724.4867 0-8 18,2 18,2 18,2 18,1 C81H144O17P2 
CL (72:8) 723.4788 0-8 18,2 18,2 18,2 18,2 C81H142O17P2 
PG (32:0) 721.5025 0-4 16,0 16,0 
  
C38H75O10P 
PG (32:1) 719.4869 0-4 16,1 16,0 
  
C38H73O10P 
PG (34:0) 749.5338 0-4 16,0 18,0 
  
C40H79O10P 
PG (34:1) 747.5182 0-4 16,0 18,1 
  
C40H77O10P 











Tail 1 Tail 2 Tail 3 Tail 4 Formula 
PG (36:0) 777.5651 0-4 18,0 18,0 
  
C42H83O10P 
PG (36:1) 775.5495 0-4 18,1 18,0 
  
C42H81O10P 
PG (36:2) 773.5338 0-4 18,1 18,1 
  
C42H79O10P 
PG (36:3) 771.5182 0-4 18,2 18,1 
  
C42H77O10P 























































Figure 2.4 Extracted ion chromatograms of PRM data for representative compounds in 
targeted analysis. 
A- glycerol phosphate fragment from CL 72:4 standard, B-glycerol phosphate fragment from 




Figure 2.5 Calibration curves for the three standards used in the targeted analysis  
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Table 2.5 Averages for integrated areas used for calibration curves  
log(Con Ratio) * 
for PG and CL 
log (conc) * 
for LPG 

























































4.5363   
-2.00 -1.08 -2.4408 4.5626 -2.7543 
-2.00 -1.08 
 










-1.30 -0.38 -1.3098 5.3839 -2.0076 
-1.30 -0.38 -1.2598 5.4223 -2.1407 
-1.30 -0.38 -1.3764 5.3934 -1.8903 
-1.30 -0.38 -1.7916 5.6217 -1.4476 




-1.00 -0.08 -1.0549 5.6688 -1.6498 
-1.00 -0.08 -1.0103 5.7153 -1.6087 
-1.00 -0.08 -1.2064 5.7102 -1.6136 
-1.00 -0.08 -1.3761 5.8179 -1.1210 
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Table 2.5 continued  
log(Con Ratio) * 
for PG and CL 
log (conc) * 
for LPG 
CL 72:4 LPG 36:2 PG 36:0 
-1.00 -0.08 -1.3489 5.8936 -1.1925 
-1.00 -0.08 -1.5358 5.8941 -1.1548 
-0.30 0.62 -0.1344 6.4722 -0.9013 
-0.30 0.62 -0.1266 6.5331 -0.8143 
-0.30 0.62 -0.0718 6.5720 -0.8535 
-0.30 0.62 -0.3952 6.6557 -0.3178 
-0.30 0.62 -0.3895 6.5777 -0.4373 
-0.30 0.62 -0.3833 6.6061 -0.4362 
0.00 0.92 0.2361 6.8547 -0.4687 
0.00 0.92 0.1882 6.7911 -0.3391 
0.00 0.92 0.1754 6.8171 -0.5109 
0.00 0.92 -0.0491 6.8482 -0.3174 
0.00 0.92 0.0333 6.8958 -0.2783 
0.00 0.92 -0.0038 6.9196 -0.2540 
0.70 1.62 0.8821 7.1921 0.1290 
0.70 1.62 0.8950 7.2271 -0.0776 
0.70 1.62 0.9121 7.1744 0.0460 
0.70 1.62 0.6953 7.3607 0.2809 
0.70 1.62 0.6589 7.3820 0.2845 





Figure 2.6 Structure of exogenous fats added to biological samples  
cis-9-octadecanoic acid (oleic acid), and cis-9,12 octadecadienoic acid (linoleic acid) 
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Table 2.6 Ratios and p-values used to create heat map for untargeted data 
Group 









PG(28:1) 0.03581 0.11944 0.01471 0.01775 
PG(28:0) 0.07747 0.18728 0.02324 0.03091 
PG(30:2) 0.03283 0.14695 0.02264 0.02664 
PG(30:1) 0.08938 0.20557 0.02011 0.02715 
PG(30:0) 0.06653 0.16347 0.02008 0.02570 
PG(32:2) 0.06431 0.23426 0.02700 0.04005 
PG(32:1) 0.09773 0.15317 0.01987 0.02351 
PG(32:0) 0.15862 0.33890 0.01135 0.02538 
PG(34:2) 0.09845 0.32987 0.01951 0.03617 
PG(34:1) 0.09909 0.13150 0.01896 0.02150 
PG(36:2) 0.17041 0.11875 0.01917 0.02003 
PG(36:1) 0.08640 0.10994 0.00499 0.00470 
PG(34:0) 2.11512 6.91868 0.18827 0.00950 
LPG (36:4) 2.18853 5.44162 0.03862 0.00020 
LPG (36:3) 0.90305 81.05640 0.83167 0.00044 
LPG (36:2) 2.65211 0.68710 0.00126 0.06461 
LPG (36:1) 0.88182 0.43156 0.31713 0.00700 
LPG (34:2) 1.50144 1.79755 0.03007 0.01173 
LPG (34:1) 1.19384 0.62900 0.26489 0.06188 
LPG (34:0) 1.76964 1.82762 0.37784 0.03974 
LPG (32:1) 1.32663 0.69432 0.09888 0.05592 
LPG (32:0) 1.40897 1.09997 0.09222 0.18917 
Oleic Acid 113.03278 0.69938 0.01543 0.30020 
Linoleic 
Acid 




Table 2.7 Concentrations for lipids measured in each sample for the targeted method  
Sample 
number 
21 22 23 24 61 62 63 64 65 101 102 103 104 105 




















PG (32:0) 2.480 1.519 1.662 1.510 0.009 0.000 0.009 0.000 0.000 0.018 0.000 0.000 0.000 0.009 
PG (32:1) 7.628 4.914 3.837 3.575 0.147 0.031 0.088 0.071 0.057 0.068 0.088 0.000 0.271 0.060 
PG (34:0) 1.044 1.633 1.203 1.245 0.009 0.000 0.000 0.006 0.000 0.009 0.010 0.000 0.165 0.016 
PG (34:1) 6.660 15.268 11.225 11.689 0.353 0.021 0.236 0.328 0.182 0.167 0.240 0.064 0.000 0.156 
PG (34:2) 0.634 1.237 0.954 1.055 0.135 0.025 0.138 0.126 0.075 1.359 1.545 1.605 0.556 1.187 
PG (36:1) 0.118 0.556 0.501 0.576 1.238 1.079 2.113 1.054 0.583 0.013 0.011 0.000 0.000 0.006 
PG (36:2) 0.870 3.003 1.951 1.658 17.390 24.377 22.451 14.434 13.075 0.064 0.212 0.315 0.000 0.125 
PG (36:3) 0.000 0.000 0.000 0.000 0.086 0.000 0.060 0.062 0.014 0.687 1.026 1.286 0.423 0.539 
PG (36:4) 0.000 0.085 0.025 0.010 0.000 0.000 0.008 0.000 0.000 4.781 8.998 10.733 12.043 4.153 
CL (66:0) 0.000 0.180 0.000 0.164 0.000 0.000 0.000 0.000 0.000 0.332 1.080 0.848 1.001 0.502 
CL (70:0) 0.973 0.895 0.418 0.824 0.262 0.160 0.129 0.298 0.000 1.292 2.914 1.696 1.413 1.244 
CL (70:6) 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.592 1.492 1.025 0.761 0.639 
CL (72:0) 4.838 3.413 4.517 2.506 0.048 0.193 0.191 0.066 0.076 0.077 0.000 0.297 0.185 0.081 
CL (72:3) 0.076 0.000 0.000 0.104 2.004 0.659 1.524 0.773 0.260 0.000 0.000 0.000 0.000 0.000 




Table 2.7 continued 
Sample 
number 
21 22 23 24 61 62 63 64 65 101 102 103 104 105 




















CL (72:7) 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.657 2.721 1.503 1.458 0.969 
CL (72:8) 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 1.345 5.269 2.739 2.383 1.737 
LPG 
(32:0) 
0.217 1.007 0.630 0.274 0.000 0.000 0.000 0.044 0.000 0.009 0.012 0.000 0.000 0.000 
LPG 
(32:1) 
0.269 1.095 0.470 0.304 0.208 0.099 0.173 0.302 0.211 0.040 0.065 0.021 0.000 0.062 
LPG 
(34:0) 
0.243 0.945 0.637 0.044 0.070 0.020 0.044 0.099 0.048 0.000 0.007 0.000 0.000 0.014 
LPG 
(34:1) 
1.791 4.974 2.394 2.746 0.628 0.254 0.548 0.956 0.506 0.114 0.093 0.067 0.007 0.164 
LPG 
(34:2) 
0.222 0.208 0.144 0.343 0.435 0.225 0.367 0.435 0.448 0.909 0.991 0.256 0.058 1.160 
LPG 
(36:0) 
0.018 0.014 0.000 0.000 0.067 0.011 0.048 0.074 0.060 0.000 0.000 0.000 0.000 0.000 
LPG 
(36:1) 
0.191 0.177 0.103 0.213 1.998 0.879 1.383 1.842 1.797 0.000 0.007 0.000 0.000 0.014 
LPG 
(36:2) 
0.471 0.285 0.227 0.587 16.290 7.966 12.288 15.357 12.11
6 
0.211 0.150 0.028 0.000 0.157 
LPG 
(36:3) 
0.000 0.000 0.000 0.012 0.084 0.021 0.060 0.076 0.123 0.579 0.905 0.186 0.054 0.747 
LPG 
(36:4) 
0.000 0.000 0.013 0.090 0.010 0.000 0.000 0.000 0.000 2.996 4.565 0.935 0.178 3.649 
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Figure 2.7 Fragmentation spectra of cardiolipin compounds detected in biological samples 
supplemented with linoleic acid 
 A- CL72:7 B-CL72:8 
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CHAPTER 3 MIDGUT METABOLOMIC PROFILING OF FALL 
ARMYWORM (SPODOPTERA FRUGIPERDA) WITH FIELD-




This chapter focuses on understanding how an insect that was once 
susceptible to a toxin produced by a plant has now become resistant. This works 
builds on established data showing a mutation to a specific gene and subsequently 
altered protein expression. The use of untargeted metabolomics allows for the 
small molecule profiles to be collected and assessed for changes between the two 
groups of insects. Evaluating metabolites which show an increase in abundance 
provides an opportunity to identify small molecule markers present in the resistant 
phenotype. 
The project stems from a collaboration with Dr. Juan Fuentes and Dr. Heba 
Abdelgaffar from the Entomology and Plant Pathology Department. They were 
working with a species of fall armyworm (Spodoptera frugiperda) that typically was 
not able to feed on genetically modified crops like corn. This corn plant has been 
modified to produce a Cry1F protein that was originally discovered in Bacillus 
thuringiensis and is toxic to many insects. This genetically modified crop has been 
commercialized and used extensively by the agricultural industry to combat pests 
and increase crop yield.  
The mode of action for Cry1F toxins are well known and work as an effective 
insecticide but populations of S. frugiperda that showed resistant started showing 
up in Puerto Rico in 2010. Since this mutation provides a competitive advantage, 
crops in the southeast United States soon were threatened by this resistant insect. 
Previous research has shown the mutation was in the ATP binding cassette 
subfamily C2 (SfABCC2) gene and reduces the binding of the Cry1F toxin. The 
family of proteins affected also control the transport of compounds in and out of 
the cell and have been seen in other organisms. Armed with this information, it 
was hypothesized that if the fall armyworm harbored this mutation, it would be 
resistant, as well as produce a buildup of a unique subset of metabolites that could 
be used an indirect indicator of resistance.  
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By analyzing four different genotypes of insects and feeding them two 
different diets, it would be possible to monitor metabolite changes among the 
groups. An untargeted metabolomics analysis was performed using liquid 
chromatography and an Orbitrap mass spectrometer. From the 126 metabolites 
identified, comparative and multivariate analyses showed that metabolite profiles 
were unique among the resistant, susceptible, and the hybrid offspring. The diet of 
the insects also dictated unique metabolite profiles. Investigation of the individual 
metabolites produced a list of six compounds that will be used to further aid the 
classification of the resistant phenotype.  
This research has already been published and is a great example of the 
versatility of the metabolomics platform in guiding researchers to explain the 
complicated process of environmentally evolved resistance. Hopefully, data 
produced from this set of experiments will lead agricultural research to a new route 




A version of this chapter was originally published by in Insect Biochemistry and 
Molecular Biology and was reproduced with permission of the journal containing 
the following citation. 
 
Citation: 
Abdelgaffar, H.; Tague, E. D.; Castro Gonzalez, H. F.; Campagna, S. R.; Jurat-
Fuentes, J. L., Midgut metabolomic profiling of fall armyworm (Spodoptera 
frugiperda) with field-evolved resistance to Cry1F corn. Insect Biochemistry and 
Molecular Biology 2019 
 
Contributions: 
JF, HA, designed the experiment, performed the bioassay and wrote the 
manuscript. HFC and SRC, designed the metabolomics experiments, wrote the 
manuscript. EDT designed the experiment, extracted the samples, performed and 





Populations of the fall armyworm (Spodoptera frugiperda) have developed 
resistance to transgenic corn producing the Cry1F insecticidal protein from the 
bacterium Bacillus thuringiensis (Bt). Resistance in S. frugiperda from Puerto Rico 
is genetically linked to a mutation in an ATP Binding Cassette subfamily C2 gene 
(SfABCC2) that results in a truncated, non-functional Cry1F toxin receptor protein. 
Since ABCC2 proteins are involved in active export of xenobiotics and other 
metabolites from the cell, we hypothesized that Cry1F-resistant fall armyworm with 
a non-functional SfABCC2 protein would display altered gut metabolome 
composition when compared to susceptible insects. Mass spectrometry and 
multivariate statistical analyses identified 126 unique metabolites from larval guts, 
of which 7 were found to display statistically significant altered levels between 
midguts from susceptible and Cry1F-resistant S. frugiperda larvae when feeding 
on meridic diet. Among these 7 differentially present metabolites, 6 were found to 
significantly accumulate (1.3 to 3.5-fold) in midguts from Cry1F-resistant larvae, 
including nucleosides, asparagine, and carbohydrates such as trehalose 6-
phosphate and sedoheptulose 1/7-phosphate. In contrast, metabolomic 
comparisons of larvae fed on non-transgenic corn identified 5 metabolites with 
statistically significant altered levels and only 2 of them, 2-isopropylmalate and 3-
phosphoserine, that significantly accumulated (2.3- and 3.5-fold, respectively) in 
midguts from Cry1F-resistant compared to susceptible larvae. These results 
identify a short list of candidate metabolites that may be transported by SfABCC2 




The fall armyworm (Spodoptera frugiperda) is an important polyphagous 
pest native to tropical regions in the Americas with a long migratory range 94. 
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Larvae of this insect have also been reported as a devastating invasive pest of 
corn in Africa95, 96. Options for effective control of S. frugiperda larvae were greatly 
improved in 2003 by commercialization of transgenic corn producing the Cry1F 
insecticidal protein from the bacterium Bacillus thuringiensis (Bt)97. As other Cry 
toxins, the Cry1F protein recognizes receptors in the midgut of S. frugiperda larvae 
as a critical step to kill enterocytes and ultimately disrupt the midgut epithelium and 
facilitate deadly septicemia98. Field-evolved resistance to Cry1F corn has been 
reported in S. frugiperda populations from Puerto Rico99, Florida and North 
Carolina100, Brazil101, 102, and Argentina103.  
In a strain of S. frugiperda from Puerto Rico, resistance to Cry1F was linked 
to a mutation in an ATP Binding Cassette subfamily C2 (SfABCC2) gene that 
resulted in a truncated protein and reduced Cry1F toxin binding104. This 
observation mirrored similar cases of resistance to Cry toxins linked to mutations 
in ABCC2 genes in Heliothis virescens105, Plutella xylostella106, Helicoverpa 
armigera107, Bombyx mori108 and Spodoptera exigua109. Members of the ABCC2 
protein family play a critical role in detoxification and chemoprotection by 
controlling the efflux of both exogenous and endogenous compounds across the 
cell membrane110. These proteins have broad specificity and act upon many 
different compounds, including representatives of most classes of insecticides111 
However, ABC transporters are not always involved in resistance to insecticides 
112, and functional interactions need to be tested experimentally. Despite diversity 
in susbtrate specificity and binding, ABC proteins commonly perform active export 
of xenobiotics from cells to reduce their intracellular concentration and thus 
reducing noxious effects113. Consequently, we hypothesized that altered ABCC2 
in Cry1-resistant insects would lead to accumulation of certain metabolites in gut 
cells when compared to susceptible larvae. In this work, we test this hypothesis by 
performing the first metabolomic analysis of the midgut epithelium from an insect 
and quantitatively comparing metabolite patterns between susceptible and Cry1F-
resistant S. frugiperda larvae. Identification of metabolome alterations in the 
midgut of resistant larvae suggests candidate metabolites that may be transported 
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by SfABCC2 as potential targets in the development of novel technologies to 
monitor for resistance to Cry toxins and Bt crops linked to alterations in ABCC2 
genes. However, further studies are necessary to demonstrate the link between 
the significantly differentially expressed metabolites and the mutated ABCC2 
gene.  
 
3.3 Materials and Methods 
3.3.1 Insect strains 
Eggs of a Cry1F-susceptible strain of S. frugiperda (Ben) were purchased 
from Benzon Research (Carlisle, PA). The Cry1F-resistant S. frugiperda strain 
456LS3 was originated from field collections in Puerto Rico and its resistance 
phenotype is described elsewhere114. The 465LS3 strain was crossed with Ben 
and re-selected at the F2 generation on corn event TC1507 (producing Cry1F 
toxin) for 7 days, and this process repeated thrice to generate a similar genomic 
background between the strains, except for the resistance allele present in 
456LS3104. For the purpose of this work, heterozygous strains were generated by 
mating 25 female/male moths from the Ben and 456LS3 strains to generate strains 
456F or 456M according to the sex of the resistant adult in the parental cross (F 
for female and M for male). All insect rearing and treatments were performed in 
incubators at 26 ± 2°C, 44% relative humidity, and an 18-h light/6-h dark 
photoperiod. 
3.3.2 Protoxin preparation 
The Cry1F protoxin was produced in a recombinant Bacillus thuringiensis 
(Bt) HD-73 strain generously provided by Dr. Jie Zhang (Institute of Plant 
Protection, Chinese Academy of Agricultural Sciences, Beijing, China) and 
described elsewhere115. The bacteria were grown on 1/3 tryptic soy broth (TSB) 
agar containing erythromycin (5 µg/ml) for three days, and then a single colony 
was suspended in 1 mL of autoclaved water and heated for 45 min at 70°C to kill 
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vegetative cells. An aliquot (500 μL) of the suspension was used to inoculate 500 
mL of 1/3 TSB medium containing erythromycin. The culture was incubated for 4 
days at 28 °C with agitation (160 rpm) until sporulation was confirmed by 
microscopic observation. Cultures were then collected by centrifugation (14,981 g, 
4 °C for 10 min) and pellets washed three times with 1 M NaCl containing 0.1% 
Triton X-100 with brief (5 min) sonication before centrifugation. Washes were 
repeated for another 2 cycles as before using distilled water. The final pellet was 
re-suspended in 50 ml of solubilizing solution (50 mM Na2CO3, 0.1% β-
mercaptoethanol, 0.1 M NaCl, pH 10.5), sonicated as above and then incubated 
overnight at 30°C with agitation (180 rpm). After centrifugation at 27,167 g for 30 
min, the supernatant containing solubilized Cry1F protoxin was purified using 
anion exchange chromatography as described elsewhere116. One major 
absorbance peak containing Cry1F protoxin (based on band size in SDS-
10%PAGE) was detected during the elution, and fractions in that peak were 
pooled, aliquoted and keep at -80ºC until used. 
3.3.3 Bioassays 
Eggs of susceptible, resistant and heterozygous strains were collected, and 
diet contamination bioassays were carried out under standard laboratory-
controlled environmental conditions (26 ± 2°C temperature, 44% RH, 16L: 8D 
photoperiod) using meridic diet (Beet Armyworm diet, product #F9219B, Frontier 
Scientific Services, Newark, DE). Diet was poured on individual wells of 128-cell 
polystyrene bioassay trays (Bio-BA-128) and after setting a solution of Cry1F 
protoxin was applied on the surface. A range of 11 different toxin concentrations 
(0.0035, 0.007, 0.014, 0.028, 0.056, 0.112, 0.224, 0.445, 0.896, 1.792 and 3.585 
µg/cm2) prepared in sterile MilliQ water and a water control were tested with Ben 
and heterozygous neonates. Four different Cry1F protoxin concentrations (4.75, 
14.4, 28.8 and 36.1 µg/cm2) were tested for 456LS3 neonates. Sixteen neonates 
per concentration were tested and bioassays were replicated twice. Mortality was 
determined after 7 days of incubation and used to determine the Cry1F protoxin 
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concentration killing 50% of the larvae (LC50) for each strain by Probit analysis 
using the PoloPlus software117. Differences between LC50s were considered 
significant if there was no overlap between the corresponding 95% confidence 
intervals.  
3.3.4 Larval treatments 
Neonates from the Ben, 456LS3, 456M, and 456F populations described 
above were placed either on meridic diet or V3-V4 stage leaves from corn event 
TC1507 producing Cry1F toxin or the non-transgenic isoline (2T777). Leaf sections 
(2.5 x 1.5 cm) were placed in individual plastic cups containing 1% agar to prevent 
desiccation. A single S. frugiperda neonate was placed in each cup, with 60 larvae 
used per strain. Leaf sections were replaced after the first 6 days of larval growth, 
and then every day as needed. Larvae were kept on corn leaves or meridic diet 
until they reached 4th instar (11-14 days), and then weighed. Weight 
measurements were rank transferred before statistical analysis using two-way 
analysis of variance (ANOVA) testing for the effect of the different insect strains/ 
treatments on the average weight measurements with p < 0.01.  
3.3.5 Tissue sample preparation and metabolite extraction 
Polar metabolites were extracted from pools of five dissected 4th instar guts 
to create a single biological replicate of approximately 100 mg, and a total of four 
biological replicates were prepared for each strain/treatment. Pooled guts were 
homogenized to fine pieces on ice using disposable micro tissue homogenizers 
(Kimble™), snap frozen in liquid nitrogen and stored at -80⁰ C until further use. 
Sample preparation and extraction was done at 4°C unless otherwise specified. 
Extraction and detection methods were modified from procedures published 
elsewhere 118, 119. Briefly, each biological replicate was extracted with 1.3 mL of 
extraction solvent (40:40:20 HPLC grade methanol: acetonitrile: water with formic 
acid at a final concentration of 0.1 M) pre-chilled to 4˚C, and allowed to proceed 
for 20 minutes at -20°C. The supernatant was collected after 5 minutes of 
centrifugation at 13,300 x g and the pellets were re-extracted with 200 µL of fresh 
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extraction solvent and allowed to sit for 20 minutes at -20°C before being 
centrifuged at the same conditions as mentioned earlier. Both supernatant 
fractions were combined, and a stream of dry nitrogen was used to evaporate the 
solvent. Sterile water (300 µL) was used to for suspend the metabolites prior to 
being placed in the instrument’s autosampler.   
3.3.6 Ultra performance liquid chromatography- high resolution mass 
spectrometry metabolomic analysis 
Samples extracted above were separated on a Dionex Ultimate 3000 UPLC 
(Thermo scientific, Waltham, MA) by injecting a 10 µL sample on to a Synergi 2.5 
µm reverse phase Hydro-RP 100 Å, 100 mm x 2.00 mm LC column (Phenomenex, 
Torrance, CA) kept at 25˚C. All solvents used for mobile phases were HPLC grade 
and purchased from Fisher Scientific. Solvent A consisted of 97:3 water: methanol, 
10 mM tributylamine, and 15 mM acetic acid and solvent B was 100% methanol. 
The gradient steps included from 0 to 5 minutes 0% B, from 5 to 13 minutes 20% 
B, from 13 to 15.5 minutes 55% B, from 15.5 to 19 minutes 95% B, and from 19 to 
25 minutes 0% B, with a flow rate of 200 µl/min. The eluent was introduced into 
the mass spectrometer via an electrospray ionization source conjoined to an 
Exactive™ Plus Orbitrap Mass Spectrometer (Thermo Scientific, Waltham, MA) 
120. Data was collected in negative mode from 85-1000 m/z with a resolution of 
140,000 and an automatic gain control of 3x106 ions. 
Raw data was analyzed using MAVEN121, 122 to align and annotate peaks 
within a 5-ppm window. Area under the chromatographic curve was integrated 
based upon an in-house verified list of metabolites using exact m/z and known 
retention times. All metabolite values were normalized based on the exact mass 
of the sample extracted prior to all statistical calculations. Heat maps were made 
by Cluster 3.0 123 and Javatreeview 1.1124, using log2 transformed data. P-values 
were calculated using Student’s T-test. Partial Least Squares Discriminant 
Analysis (PLSDA) and Variable Importance in Projection (VIP) scores were 
constructed using the statistical package DiscriMiner in R version 3.1.1125. These 
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VIP scores provide a metric for determining how much influence a metabolite has 
on the group separation seen in the PLSDA plots. A value >1 indicates that the 
metabolite contributes to the group differentiation, and this was considered as a 
significant VIP score 126-128. Global pathway maps were created by imputing KEGG 
IDs for each metabolite detected into iPath 2.0129. 
 
3.4 Results 
3.4.1 Cry1F protoxin bioassay 
As expected from resistance in 456LS3 being recessive and autosomal114, 
bioassays with purified Cry1F protoxin showed no significant difference (based on 
overlapping 95% confidence intervals) in toxicity against Ben, 456F, and 456M 
larvae (Table 3.1). In contrast, only low mortality (12.5%) was observed when 
larvae from the 456LS3 strain were exposed to the highest Cry1F protoxin 
concentration tested (36.1 µg/cm2). Based on this observation, we estimated that 
larvae from 456LS3 were >75 fold resistant to Cry1F compared to larvae from the 
Ben, 456F or 456M strains. In agreement with these observations, exposure of 
neonates from the Ben, 456M or 456F strains to Cry1F corn leaf tissue resulted in 
100% mortality after seven days, while no mortality was observed for larvae of the 
456LS3 strain (data not shown). 
No significant difference was detected when comparing weights of 4th instar 
larvae from all strains fed on control diet (p = 1). When comparing artificial diet to 
corn leaf tissue, the mean larval weights from all the strains was significantly higher 
(Tukey- Kramer, p < 0.05) on meridic diet compared to non-Bt corn leaves (Figure 
3.1). No significant differences were detected when comparing all four strains fed 
on meridic diet (p = 1), yet a significant difference in mean larval weight was 
detected between parental (456LS3 and Ben) strains compared to heterozygous 
(456F and 456M) strains when feeding on non-Bt corn leaf tissue (p < 0.05). 
Weights of larvae from the 456LS3 strain were not significantly different when fed 
on non-Bt or Cry1F corn leaves (p = 0.9994). 
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Table 3.1 Susceptibility of S. frugiperda lines to Cry1F protoxin in diet incorporation 
bioassays 
Strain LC50 (µg/cm2) 
95% CI* 
(lower- upper) 
Slope ± Standard 
Error 
Ben 0.52 0.39- 0.71 1.90 ± 0.20 
456LS3** NA NA 0.02 ± 0.00 
456M 0.46 0.38- 0.56 2.20 ± 0.30 




Figure 3.1 Average weight of Spodoptera frugiperda neonates fed on diet (Diet), corn event 
TC1507 producing Cry1F (BtC) or the non-transgenic isoline 2T777 (NBtC) until reaching 4th 
instar.  
Shown are the average larval weight and the corresponding standard error from 4 biological 
replicates with 5 larvae each per treatment (n=20). Data was analyzed using ANOVA, 
significant differences in comparisons connected with lines (p < 0.05) are denoted with an 
asterisk 
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3.4.2 Metabolomics and multivariate data analysis 
Untargeted metabolomic profiling analyses identified a large number of 
endogenous metabolites in larval guts, but only 126 were selected for further 
analysis based on annotation via known exact m/z and retention time. These 
identified metabolites were classified into different categories including amino 
acids, carbohydrates, organic acids, nucleotides, nucleosides, fatty acids, vitamins 
and other metabolites. The cellular pathways related to these metabolites are 
represented in Appendix Figure 3.5. As expected from an analysis that was 
focused on polar metabolites and that preferentially annotates small hydrophilic 
compounds, pathways with metabolites detected included metabolism of 
nucleotides, energy, carbohydrates, cofactors and vitamins as well as biosynthesis 
of secondary metabolites and degradation of xenobiotics. No metabolites related 
to lipid, glycan or terpenoid metabolism were identified, due to their hydrophobic 
nature. 
In general, the majority of detected metabolite levels were higher in 456LS3 
compared to the other strains (data not shown). The metabolite profiles of all S. 
frugiperda strains fed on either meridic diet (shorten as diet) or non-Bt corn 
(shorten as NBtC) were evaluated using multivariate analysis (Figure 3.2). For 
each strain, the metabolite profiles were represented using a Partial Least Squares 
Discriminate Analysis (PLSDA) scores plot (Figures 3.2A and 3.2B). In these 
PLSDA plots, the 456LS3 and Ben strains clearly displayed unique metabolite 
profiles from one another, while the heterozygous strains (456F and 456M) did not 
separate in the PLSDA and formed a third group distinct from Ben and 456LS3. 
These differences appeared clearer in metabolites from insects fed on meridic diet 
(Figure. 3.2A) than when fed on non-transgenic corn (Figure 3.2B).  
In order to determine which metabolites drove the separation among the 
groups, the metabolites with Variable Importance in Projection (VIP) scores >1 




Figure 3.2 Partial Least Squares Discriminate Analysis (PLSDA) scores plots displaying 
different clusters when comparing metabolite profiles of midguts from S. frugiperda larvae 
from different strains fed on meridic diet (Top) or non-Bt corn leaf tissue (Bottom). 
180 
to the group differentiation. When fed the meridic diet, 51 metabolites had 
significant VIP scores and resulted in a clear separation of the three unique group 
456LS3, 456F/456M, and Ben (Appendix Table 3.6). The same grouping of 
strains was observed using metabolites detected when larvae were fed on the non-
Bt corn leaf tissue, with 63 metabolites with significant VIP scores (Appendix 
Table 3.7). Twenty of the metabolites with significant VIP scores were common to 
the meridic diet and non-Bt corn (Table 3.2), although the VIP scores varied for 
the same metabolite depending on treatment. Considering the total number of 
metabolites with significant VIP scores for each treatment, 43% of the important 
metabolites for the strain separation on artificial diet were shared with the non-Bt 
leaf treatment, while 35% of the significant metabolites for the non-Bt leaf 
treatment were shared with the artificial diet. 
3.4.3 Comparative metabolite profiling 
Comparison of the relative levels for all detected metabolites in the Ben, 
456M, and 456F compared to the 456LS3 gut metabolome for larvae fed on 
meridic diet (Figure 3.3 Appendix Table 3.8) or non-Bt corn leaf tissue (Figure 
3.4, Appendix Table 3.9) identified metabolites with increased and reduced levels 
associated to the 456LS3 sample. Given that metabolome differences may result 
from differential metabolic states in larvae, and that we detected small but 
significant weight differences between parental and F1 lines when feeding on corn 
leaf tissue (Figure 3.1), we focused metabolite profiling on all four strains fed on 
meridic diet, on Ben and 456LS3 fed on non-Bt corn, and on 456LS3 when fed on 
Cry1F corn compared to non-Bt corn. 
Out of the total 126 metabolites identified, only 7 metabolites were found to 
display statistically significant (p < 0.05) altered levels (Table 3.3) when comparing 
metabolite patterns between susceptible (Ben, 456M and 456F) and Cry1F-
resistant (456LS3) larvae fed on meridic diet. Altered metabolites included organic 
acids (hydroxyphenylacetate), amino acids (asparagine), nucleosides (dCMP, 
dTMP, and dAMP), and carbohydrates (trehalose 6-phosphate and sedoheptulose 
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Table 3.2 Metabolites with VIP* score >1 that support differentiation of Ben, 456M/456F and 
456LS3 samples in the PLSDA multivariate space regardless of the food source. 
Shown are VIP scores for samples from larvae fed on diet (Diet) and non-Bt corn leaf (NBtC). 
Metabolite Diet NBtC 
Aconitate 1.13 1.27 
Allantoate 1.16 1.11 
Cysteine 1.43 1.01 
D.Gluconate 1.69 1.06 
dAMP 1.21 1.09 
dCMP 1.24 1.18 
dTMP 1.15 1.10 
Gluconolactone 1.20 1.00 
Hydroxyisocaproic.acid 1.01 1.34 
Hydroxyphenylacetate 1.43 1.30 
Inosine 1.21 1.28 
N-Acetylglutamine 1.39 1.23 
Pantothenate 1.31 1.13 
S-Ribosyl L-homocysteine 1.19 1.28 
Sedoheptulose1/7-phosphate 1.38 1.07 
Trehalose.6.phosphate 1.34 1.26 
UDP N-acetylglucosamine 1.02 1.02 
Uracil 1.30 1.03 
Uric acid 1.18 1.23 





Figure 3.3 Heat maps of relative levels of metabolites detected in guts of S. frugiperda larvae 
fed on meridic diet.  
The specific larvae compared in each column are shown at the top. Data are log2 ratios of 
metabolites identified when comparing metabolomes from Ben, 456F, or 456M to 
metabolomes in guts of larvae from the 456LS3 strain. The relative fold levels for each 
metabolite in each comparison are shown by the key, orange indicates induction > 0, blue 
indicates repression < 0, with maximums at >2 and <−2. Asterisks represent level of 




Figure 3.4 Heat maps of relative levels of metabolites detected in guts of S. frugiperda larvae 
fed on non-Bt corn leaf tissue.  
The specific larvae compared in each column are shown at the top. Data are log2 ratios of 
metabolites identified when comparing metabolomes from Ben, 456F, or 456M to 
metabolomes in guts of larvae from the 456LS3 strain. The relative fold levels for each 
metabolite in each comparison are shown by the key, orange indicates induction > 0, blue 
indicates repression < 0, with maximums at >2 and <−2. Asterisks represent level of 
significance (*p < 0.05, **p < 0.01), as noted in the key 
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Table 3.3 Metabolites with significantly altered levels (p < 0.05) in Ben, 456M and 456F lines compared to larvae from the 456LS3 
strain fed on meridic diet. 
Shown are the fold change (FC) and corresponding p-value and VIP scores. Row shaded in black with white font represents lower 
metabolite levels in guts of larvae from the 456LS3 compared to other strains. All the other metabolites accumulated in guts from 
larvae of the 456LS3 compared to other strains tested. 
Metabolite 
Ben/456LS3 456F/456LS3 456M/456LS3 
FC* (p-value) VIP FC (p-value) VIP FC (p-value) VIP 
Organic acids 
Hydroxyphenylacetate 2.51 (0.007) 1.40 3.23 (0.002) 1.82 2.62 (0.044) 1.45 
Amino acids 
Asparagine 0.73 (0.002) 1.31 0.79 (0.029) 1.43 0.82 (0.015) 1.35 
Nucleosides 
dCMP 0.34 (0.001) 1.43 0.65 (0.016) 1.48 0.53 (0.002) 1.60 
dTMP 0.31 (0.004) 1.36 0.63 (0.047) 1.31 0.46 (0.009) 1.50 
dAMP 0.28 (0.001) 1.40 0.67 (0.027) 1.42 0.51 (0.006) 1.55 
Carbohydrates / conjugates 
Trehalose 6-phosphate 0.76 (0.005) 1.26 0.74 (0.007) 1.42 0.62 (0.0003) 1.61 
Sedoheptulose 1/7 phosphate 0.55 (0.0002) 1.45 0.72 (0.023) 1.50 0.56 (0.0001) 1.66 
 
185 
1/7-phosphate). When comparing abundance, only hydroxyphenylacetate 
appeared to be at lower levels in the guts of 456LS3 larvae, while the other 6 
metabolites significantly accumulated in 456LS3 compared to the other strains. 
In the case of the Ben and 456LS3 gut metabolome samples fed on non-Bt 
corn leaf tissue (Figure 3.4 and Table 3.4), we observed four metabolites with 
significantly different levels (p < 0.05). Two of these metabolites, a vitamin B 
(orotate) and a purine nucleoside (inosine) were found at significant lower levels 
in the 456LS3 larval guts, while amino acids and derivatives homocysteine and 
cystine accumulated in the guts of resistant compared to larvae of the Ben strain 
(Table 3.4).  
Metabolomic profiling of larval guts from the 456LS3 strain fed on Cry1F-
producing corn and non-Bt corn leaf tissue identified 7 metabolites with distinct 
abundance between the two treatments. All these metabolites significantly 
accumulated in the guts when the larvae fed on the non-Bt isoline and included 




Members of the ABC transporter gene family are involved in cellular 
defense against xenobiotics, including insecticides112. Despite their functional 
diversity 113, generally ABC proteins actively export xenobiotics from cells to 
reduce their intracellular concentration. Selected ABC transporter genes have 
been reported as functional receptors for Cry toxins in insects104, 130-132, and 
mutations in these genes or alterations in their expression are linked to resistance 
against diverse Cry toxins104, 106, 107, 133. Given their ATP-driven transport activity, 
our hypothesis was that mutations affecting functionality of ABC transporter genes 
would result in alterations in the intracellular metabolome. In support of this 
hypothesis, previous reports demonstrated that a truncated ABCC2 protein in 
Cry1Ac-resistant Helicoverpa armigera larvae resulted in accumulation and altered 
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Table 3.4 Metabolites with significantly altered levels (p < 0.05) in Ben, 456F and 456M when compared to 456LS3 larvae fed non-
Bt corn leaf tissue.  
Shown are the fold change (FC) and corresponding p-value and VIP scores. Rows shaded in black with white font represents lower 
metabolite levels in guts of larvae from the 456LS3 compared to other strains. All the other metabolites accumulated in guts from 
larvae of the 456LS3 compared to other strains tested 
Metabolite 
Ben/456LS3 456F/456LS3 456M/456LS3 







Fats and fatty acids 
3-Hydroxyisovaleric acid 2.54 (0.020) 1.67 2.03 (0.009) 1.60 3.05 (0.014) 1.67 
Hydroxyisocaproic acid 6.75 (0.026) 1.76 6.06 (0.000) 1.76 6.20 (0.004) 1.79 
Organic acids and derivatives 
Phenyllactic acid 2.43 (0.003) 1.75 1.80 (0.014) 1.54 1.69 (0.044) 1.37 
2-Isopropylmalate 0.44 (0.008) 1.72 0.39 (0.007) 1.60 0.45 (0.039) 1.33 
Amino acids and derivatives 
3-Phosphoserine 0.24 (0.007) 1.79 0.11 (0.006) 1.80 0.29 (0.006) 1.59 
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Table 3.5 Metabolites with significantly altered levels (p < 0.05) in guts from 456LS3 larvae 
fed leaf tissue from Cry1F-producing or the non-Bt corn isoline. 
Shown are the fold change (FC) and corresponding p-value and VIP scores *Fold changes 
(FC) were calculated by dividing the value of metabolites of 456LS3 larvae receiving Bt-corn 
by 456LS3 line fed on non-Bt corn. 
Metabolite FC (p-value) VIP 
Amino acid metabolism 
3-Phosphoserine 0.30 (0.007) 1.69 
Cystine 0.41 (0.026) 1.68 
Purine metabolism 
AICA ribonucleotide 0.63 (0.041) 1.39 
TCA cycle 
2-Oxoglutaric acid 0.50 (0.009) 1.66 
Glutathione metabolism 
Pyroglutamic acid 0.61 (0.018) 1.61 
N-Acetyl-beta-alanine metabolism 
N-Acetyl-beta-alanine 0.61 (0.031) 1.51 
Valine biosynthesis 
2-Oxoisovalerate 0.68 (0.047) 1.39 
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susceptibility to selected synthetic pesticides107. In testing our hypothesis, 
we performed a comparative metabolite  analysis between the midgut epithelium 
from a Cry1F-resistant strain of S. frugiperda homozygous for a mutation in an 
ABC subfamily C2 gene (SfABCC2mut) predicted to result in a truncated non-
functional ABCC2 protein104, and larvae with the wild type (SfABCC2) genotype or 
heterozygous for the SfABCC2mut allele. 
Results from bioassays with Cry1F protoxin were in agreement with 
previous reports114 and supported high levels of resistance in the 456LS3 strain, 
and that resistance is transmitted as a recessive trait. Reduced larval weights in 
larvae fed corn versus meridic diet, independently of the S. frugiperda strain, are 
in agreement with optimized nutritional value and adaptation of the strains to 
meridic diet. Lack of significant effects of Cry1F-corn compared to non-transgenic 
corn on 456LS3 larvae support no fitness costs associated with the SfABCC2mut 
allele, as previously reported 134. Given the significant differences between meridic 
diet and non-transgenic corn treatments, we considered metabolome comparisons 
between the strains for both diets independently. Moreover, since parental and F1 
strains displayed significantly different weight when grown on non-Bt corn tissue, 
we focus metabolic profiling to Ben-456LS3 comparisons for that treatment. It’s 
interesting to note that we found a clear separation of the Ben, 456F/M and 456LS3 
groups in the multivariate analysis (PLSDA), but there were only seven metabolites 
categorized as significant in the comparative analysis. This could point to multiple 
small changes in a suite of metabolites being related to the resistant phenotype; 
indicating that  a measurement of a set of metabolites would be necessary to 
differentiate between the phenotypes. 
While there is a lack of information on substrate specificity for ABCC2 
proteins in insects, much is known in similar proteins in mammals. In BLASTp 
searches of the mammalian subset of proteins in NCBI, the most similar proteins 
to SfABCC2 are members of the multidrug resistance-associated protein 4 (MRP4) 
group (maximum 41% identity, 0.0 Evalue), which are unidirectional transporters 
localized in diverse tissues and involved in resistance to xenobiotics135. Substrates 
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of MRP4 include nucleotide analogues, glucuronide and sulphate conjugates, 
prostaglandins, methotrexate, and bile acids136. There is also evidence for 
specificity towards anionic conjugates, including N-acetyl-(2,4-dinitrophenyl)-
cysteine137. In agreement with these observations, half of the metabolites 
accumulating in 456LS3 compared to Ben or F1 larvae when fed meridic diet were 
nucleosides (dCMP, dTMP, dAMP). Also, in comparisons of Ben and 456LS3 
larvae fed on non-Bt corn leaf tissue, homocysteine and cysteine accumulated in 
456LS3 guts. Although preliminary, these observations support that lack of a 
functional SfABCC2 may result in accumulation of metabolites (nucleosides and 
cysteine derivatives) that may be otherwise transported out of the cell by this 
protein. In mammals transport of nucleosides is a major feature of MRP4 proteins 
136, and this may also be the case for the orthologous SfABCC2. Other metabolites 
accumulated in 456LS3 larvae lacking a functional SfABCC2 were carbohydrates 
(trehalose 6-phosphate and sedoheptulose 1/7-phosphate) and an amino acid 
(asparagine), which have not been described as substrates for MRP4. 
Interestingly, different metabolites were found to accumulate in 456LS3 compared 
to wild type larvae fed meridic diet and non-Bt corn leaf tissue. This observation 
suggests important nutritional and metabolite differences based on diet, which is 
reflected in the significant differences detected in larval weight between the diet 
treatments. Differences in metabolite composition between meridic diet and corn 
leaf tissue may have prevented detection of common significant differences 
between susceptible and resistant larvae when fed on these two diverse diets. 
Interestingly, we detected 7 metabolites that were at lower levels in guts of 
larvae from the 456LS3 strain when they fed on Cry1F-producing corn compared 
to the non-Bt isoline. In this case, metabolic alterations detected would reflect 
interactions between Cry1F and the midgut epithelium that in 456LS3 are not 
conducive to toxicity. In fact, while Cry1F binding to the SfABCC2mut protein from 
456LS3 larvae is not detected104, the toxin still displays (albeit reduced) binding to 
midgut brush border membrane vesicles (BBMV) from 456LS3 compared to 
Ben114, suggesting the potential for Cry1F interacting with midgut proteins. While 
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it is complex to discern the physiological relevance of the detected metabolome 
changes in that case, it is interesting to note the reduced levels of components of 
the TCA cycle (2-oxoglutaric acid) and glutathione metabolism (cystine and 
pyroglutamic acid), which may suggest alterations on pathways related to energy 
conservation and reduced oxidative stress when feeding on Cry1F corn. Although 
speculative, reduced levels of AICA ribonucleotide, which in hepatocytes has been 
shown to participate in activation of AMP-activated protein kinase and inhibition of 
autophagy 138, may suggest increased autophagy in 456LS3 when feeding on 
Cry1F-corn compared to the non-transgenic isoline. Further work to identify the 
pathways involved in these metabolome differences would be needed to identify 
physiological effects of feeding on Bt versus non-transgenic corn by Bt-resistant 
larvae. 
In summary, we used comparative metabolomics on the midgut epithelium 
of susceptible and Cry1F-resistant S. frugiperda larvae in an attempt to identify 
candidate metabolites transported by SfABCC2, a transporter putatively involved 
in xenobiotic transport outside of the cell. Importantly, as far as we know this work 
represents the first metabolomics analysis of an insect midgut epithelium and 
provides a list of candidate metabolites that accumulate in Cry1F-resistant S. 
frugiperda lacking a functional SfABCC2 protein. Further work is needed to 
determine if any of these metabolites is a substrate for SfABCC2 transport. 
Specifically, nucleosides are good candidates as they accumulate in Cry1F-
resistant larvae and are metabolites selectively and uniquely transported by 
homologous proteins to SfABCC2 in mammals. It is important to note that we found 
diverse metabolomic results depending on the diet used (meridic versus corn leaf) 
to rear the larvae, which suggests that diet has an important impact on the gut 
metabolome. Further functional assays are needed to confirm substrate specificity 
for SfABCC2 and to identify metabolites that may serve as markers for resistance 




Figure 3.5 Pathway map of all the detected metabolites (red circles). 
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Table 3.6 Metabolites with Variable Importance in Projections (VIP) scores. 
Values >1 support differentiation of Ben, 456M/456F and 456LS3 samples in the PLSDA 






















Glutathione disulfide 1.420421 




















Pyroglutamic acid 1.042945 
Ribose phosphate 1.06305 
S-Adenosyl L-homocysteine 1.500882 
S-Ribosyl L-homocysteine 1.192648 
Sedoheptulose 1/7 phosphate 1.382373 
Serine 1.078238 
Sulfolactate 1.347575 
Trehalose 6-phosphate 1.344063 
Tryptophan 1.021307 
Tyrosine 1.010975 
UDP N-acetylglucosamine 1.015052 
Uracil 1.304287 
Uric acid 1.184786 
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Table 3.7 Metabolites with Variable Importance in Projections (VIP) scores. 
Values  >1 support differentiation of Ben, 456M/456F and 456LS3 samples in the PLSDA 















































Phenyllactic acid 1.287237 
Phenylpyruvate 1.04756 
Pyridoxine 1.236147 
Pyroglutamic acid 1.250988 
Pyruvate 1.03419 
S-Ribosyl L-homocysteine 1.277389 
Salicylate 1.347085 




Table 3.7 continued 
Non-Bt corn 
Metabolite VIP 
Trehalose 6-phosphate 1.261634 
UDP glucose 1.098695 
UDP N-acetylglucosamine 1.021573 
Uracil 1.0281 










Xanthurenic acid 1.048492 
Xylitol 5-phosphate 1.114975 
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Table 3.8 Ratios and p-values used to make heat map for samples fed meridic diet  
Metabolite 
Ratio p-p-value 
Ben 456F 456M Ben 456F 456M 
Pyruvate 1.57 1.35 1.43 0.0775 0.0948 0.1280 
Alanine/Sarcosine 0.85 0.97 0.92 0.1046 0.7850 0.4182 
Lactate 2.94 3.13 2.10 0.0222 0.2915 0.1921 
4-Aminobutyrate (GABA) 0.63 0.86 0.77 0.0083 0.2272 0.0576 
Alanine/Sarcosine 0.85 0.97 0.92 0.1046 0.7850 0.4182 
Lactate 2.94 3.13 2.10 0.0222 0.2915 0.1921 
4-Aminobutyrate (GABA) 0.63 0.86 0.77 0.0083 0.2272 0.0576 
Serine 1.56 0.85 1.13 0.2225 0.2431 0.5062 
Histamine 0.67 0.85 0.81 0.0446 0.2873 0.0965 
Uracil 1.37 0.71 0.70 0.1169 0.1812 0.1952 
Proline 0.67 0.75 0.80 0.0178 0.1250 0.0718 
Fumarate 0.78 1.13 1.12 0.0397 0.1917 0.2547 
2-Oxoisovalerate 0.90 0.91 0.85 0.1211 0.4985 0.1406 
Indole 0.91 1.30 1.51 0.6931 0.2791 0.2242 




Table 3.8 continued  
Metabolite 
Ratio p-p-value 
Ben 456F Ben 456F Ben 456F 
Succinate/Methylmalonate 0.97 0.87 0.90 0.8014 0.3359 0.3232 
3-Hydroxyisovaleric acid 7.63 6.19 4.71 0.0188 0.2140 0.1249 
Homoserine/Threonine 0.61 0.75 0.77 0.0191 0.0988 0.0738 
Cysteine 0.81 0.49 0.43 0.1619 0.0045 0.0026 
Nicotinate 1.18 1.07 1.01 0.0238 0.5412 0.8845 
Taurine 0.58 0.97 1.05 0.0111 0.9001 0.8150 
Thymine 0.98 0.85 1.03 0.8845 0.3650 0.9077 
Pyroglutamic acid 0.79 0.71 0.69 0.0290 0.0636 0.0197 
N-Acetyl-beta-alanine 0.64 0.81 0.74 0.0426 0.1998 0.1270 
Hydroxyproline 0.89 0.86 0.74 0.4975 0.3463 0.1903 
Leucine/Isoleucine 0.83 0.88 0.90 0.0874 0.3097 0.2915 
Asparagine 0.73 0.79 0.82 0.0020 0.0300 0.0153 
Hydroxyisocaproic acid 10.12 8.95 5.01 0.0175 0.2395 0.1111 
Ornithine 1.01 0.98    0.9107 0.8757 0.9152 
Aspartate 0.57 0.93 0.82 0.0375 0.5978 0.1601 
Malate 0.81 1.02 1.03 0.0428 0.8475 0.7458 
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Table 3.8 continued 
Metabolite 
Ratio p-p-value 
Ben 456F Ben 456F Ben 456F 
Homocysteine 0.85 0.90 0.78 0.0248 0.5150 0.1914 
Anthranilate 2.75 0.60 0.70 0.0029 0.0597 0.1904 
Salicylate 1.02 0.98 0.90 0.9346 0.9225 0.2594 
Hydroxybenzoate 0.91 1.27 0.79 0.6875 0.3417 0.3766 
2-Oxoglutaric acid 0.88 0.79 0.75 0.5437 0.3483 0.0778 
Glutamine 0.77 0.80 0.90 0.0420 0.1038 0.3263 
Lysine 0.81 0.89 0.76 0.1523 0.3940 0.1007 
Glutamate 0.88 0.98 0.92 0.2601 0.8676 0.4567 
2-Hydroxy-2-
methylsuccinate 
2.18 1.54 1.23 0.0036 0.4428 0.5739 
L-Methionine 0.87 0.86 0.85 0.2437 0.1391 0.0418 
Guanine 1.56 2.12 1.79 0.3943 0.0048 0.1527 
Xanthine 3.05 2.02 2.15 0.1190 0.1547 0.1604 
Hydroxyphenylacetate 2.51 3.23 2.62 0.0070 0.0024 0.0445 
Xylitol 1.13 1.18 1.18 0.3618 0.3202 0.3351 
2_3-Dihydroxybenzoate 0.98 0.97 1.01 0.8806 0.8439 0.9491 
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Table 3.8 continued 
Metabolite 
Ratio p-p-value 
Ben 456F Ben 456F Ben 456F 
Histidine 0.74 0.86 0.87 0.0215 0.1981 0.1757 
Orotate 1.03 1.03 0.90 0.9221 0.9165 0.7181 
Dihydroorotate 3.95 1.62 1.60 0.2400 0.1691 0.4404 
Allantoin 1.03 1.33 1.23 0.8556 0.1725 0.1659 
2-Aminoadipate 0.68 1.01 0.85 0.1364 0.9475 0.4154 
Phenylpyruvate 11.59 6.40 5.07 0.0412 0.2545 0.1017 
Phenylalanine 0.94 0.86 1.00 0.5047 0.2911 0.9885 
Phenyllactic acid 2.81 3.50 2.43 0.0343 0.2679 0.0843 
Phosphoenolpyruvate 0.99 0.74 1.16 0.9837 0.6711 0.8350 
Uric acid 0.62 0.51 0.70 0.0735 0.1611 0.1778 
Cysteate 1.09 0.99 0.69 0.3941 0.9484 0.0347 
Pyridoxine 1.44 1.24 1.18 0.0686 0.0495 0.1149 
Sulfolactate 0.83 0.61 0.60 0.0744 0.0071 0.0027 
Glycerone phosphate 0.66 0.72 0.76 0.0251 0.0475 0.0711 
sn-Glycerol 3-phosphate 0.82 0.87 0.87 0.2319 0.4211 0.4942 
Aconitate 0.93 0.87 0.68 0.6470 0.4229 0.0023 
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Table 3.8 continued 
Metabolite 
Ratio p-p-value 
Ben 456F Ben 456F Ben 456F 
N-Acetylornithine 1.20 0.93 0.94 0.0038 0.3985 0.7472 
Arginine 0.81 0.80 0.89 0.1312 0.0584 0.2586 
Citrulline 2.73 2.42 2.01 0.0733 0.2422 0.1075 
N-Carbamoyl-L-aspartate 1.81 1.68 1.15 0.0657 0.0908 0.5871 
Allantoate 0.70 1.15 1.14 0.0198 0.2700 0.2691 
2-Isopropylmalate 0.62 1.28 1.31 0.0737 0.3340 0.3914 
Gluconolactone 1.10 0.63 0.61 0.4120 0.0518 0.0323 
Glucosamine 0.89 0.59 0.58 0.4752 0.0476 0.1054 
Hydroxyphenylpyruvate 2.26 1.58 1.55 0.0090 0.1755 0.0592 
myo-Inositol 1.12 0.99 1.26 0.3648 0.9372 0.4772 
Tyrosine 0.82 0.94 1.13 0.1191 0.6700 0.5717 
4-Pyridoxate 1.26 1.27 1.43 0.1927 0.3647 0.2110 
3-Phosphoserine 0.56 0.55 0.38 0.0920 0.1181 0.0285 
N-Acetylglutamine 1.04 0.53 0.59 0.7851 0.0028 0.0088 
Acetyllysine 1.46 0.77 0.83 0.2072 0.1631 0.5093 
N-Acetylglutamate 2.38 2.97 2.29 0.1365 0.2406 0.2470 
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Table 3.8 continued 
Metabolite 
Ratio p-p-value 
Ben 456F Ben 456F Ben 456F 
2-Dehydro-D-gluconate 0.67 1.01 0.85 0.0097 0.9105 0.1717 
D-Gluconate 0.81 0.97 0.67 0.0616 0.8352 0.0034 
D-Erythrose 4-phosphate 0.44 0.78 0.78 0.0049 0.1009 0.3436 
N-N Dimethylarginine 0.78 0.92 0.90 0.2855 0.7165 0.6215 
Tryptophan 0.91 1.19 1.30 0.3256 0.2917 0.2196 
Xanthurenic acid 0.73 1.13 1.16 0.1185 0.6654 0.3240 
D-Glucarate 0.95 1.38 1.25 0.6531 0.2557 0.4385 
Pantothenate 0.78 1.05 0.94 0.0130 0.4581 0.3634 
N-Acetylglucosamine 0.94 0.84 0.82 0.7359 0.4260 0.3699 
Cystathionine 0.81 1.04 1.01 0.3195 0.8123 0.9433 
Carnosine 1.49 1.40 1.77 0.0833 0.3519 0.2041 
Ribose phosphate 0.75 0.92 0.78 0.0076 0.5605 0.0098 
Xylitol 5-phosphate 0.46 0.66 0.63 0.0107 0.0642 0.0569 
Cystine 0.76 0.53 0.62 0.4356 0.1022 0.1906 
Cytidine 0.53 0.79 1.09 0.0022 0.3419 0.6528 
Uridine 0.66 0.63 0.70 0.1079 0.0907 0.1443 
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Table 3.8 continued 
Metabolite 
Ratio p-p-value 
Ben 456F Ben 456F Ben 456F 
Deoxyinosine 0.92 0.89 0.77 0.6567 0.3643 0.0141 
6-Phospho-D-
gluconolactone 
1.53 1.48 1.22 0.4029 0.2858 0.4819 
Glucosamine phosphate 0.94 0.90 0.79 0.7055 0.4559 0.2023 
Glucose 6-phosphate 1.40 1.07 1.24 0.3684 0.6342 0.2473 
S-Ribosyl-L-homocysteine 1.11 0.76 0.76 0.3107 0.0778 0.1239 
Adenosine 0.64 0.83 0.80 0.0547 0.3198 0.2341 
Inosine 2.28 1.01 0.98 0.0249 0.9730 0.9225 
6-Phospho-D-gluconate 1.40 0.51 0.41 0.6506 0.0209 0.0119 
1-Methyladenosine 1.03 1.23 1.15 0.7965 0.3930 0.3437 
Guanosine 1.61 0.97 0.93 0.0845 0.9057 0.7083 
Glycinamide ribotide (GAR) 0.54 0.55 1.84 0.2717 0.1957 0.5969 
Ophthalmate 0.41 0.60 0.55 0.0947 0.2174 0.1764 
Sedoheptulose 1/7-
phosphate 




Table 3.8 continued 
Metabolite 
Ratio p-p-value 
Ben 456F Ben 456F Ben 456F 
N-Acetylglucosamine1/6-
phosphate 
0.88 0.88 0.92 0.2164 0.3120 0.4544 
dCMP 0.34 0.65 0.53 0.0007 0.0165 0.0022 
Glutathione 0.89 1.06 0.92 0.1784 0.3646 0.2829 
dTMP 0.31 0.63 0.46 0.0037 0.0466 0.0093 
CMP 0.75 1.02 1.03 0.0210 0.8175 0.7826 
UMP 0.76 0.92 0.95 0.0221 0.3654 0.5922 
dAMP 0.28 0.67 0.51 0.0011 0.0270 0.0058 
AICAR 0.49 0.94 1.24 0.0237 0.7219 0.2680 
Trehalose/Sucrose/ 
Cellobiose 
0.68 1.21 1.15 0.1624 0.4500 0.4930 
AMP/dGMP 0.75 0.82 0.85 0.0035 0.0710 0.0440 
IMP 0.89 0.70 0.95 0.4300 0.1000 0.7965 
GMP 0.73 0.93 0.89 0.0098 0.4703 0.1478 




Table 3.8 continued 
Metabolite 
Ratio p-p-value 
Ben 456F Ben 456F Ben 456F 
S-Adenosyl-L-
homocysteine 
0.93 0.45 0.49 0.5893 0.0068 0.0083 
Trehalose 6-phosphate 0.76 0.74 0.62 0.0048 0.0449 0.0003 
CDP-ethanolamine 0.80 0.86 0.81 0.2387 0.4075 0.3003 
UDP-glucose 0.85 0.98 0.91 0.0631 0.8048 0.2041 
UDP-N-acetylglucosamine 0.95 0.91 0.98 0.4746 0.4185 0.7811 
Glutathione disulfide 0.97 1.81 1.36 0.8872 0.0375 0.0207 
NAD+ 0.79 0.89 1.00 0.0175 0.4182 0.9832 
NADP+ 0.95 0.56 0.72 0.8960 0.3236 0.5341 
FAD 1.25 0.86 0.89 0.6160 0.8003 0.8073 
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Table 3.9 Ratios and p-values used to make heat map for samples fed non-Bt corn 
Metabolite 
Ratio p-p-value 
Ben 456F Ben 456F Ben 456F 
Pyruvate 1.00 0.88 1.48 0.9940 0.5910 0.2677 
Alanine/Sarcosine 1.16 1.10 1.18 0.5336 0.6927 0.4629 
Lactate 1.57 1.11 1.51 0.1067 0.5861 0.0290 
4-Aminobutyrate (GABA) 0.94 1.32 1.09 0.8029 0.2818 0.7453 
Serine 0.97 0.97 0.93 0.9154 0.9031 0.7662 
Histamine 0.74 0.51 0.77 0.2605 0.0455 0.2977 
Uracil 1.82 1.00 1.28 0.0608 0.9961 0.3571 
Proline 1.10 1.07 1.25 0.6906 0.6835 0.2153 
Fumarate 1.40 1.45 1.31 0.3033 0.1039 0.2237 
2-Oxoisovalerate 0.67 0.69 0.69 0.0826 0.0455 0.0369 
Indole 1.21 1.28 0.85 0.6587 0.5741 0.6910 
Valine 1.01 0.87 0.89 0.9743 0.5563 0.6240 
Succinate/Methylmalonate 1.49 1.27 1.19 0.1797 0.3914 0.5299 
3-Hydroxyisovaleric acid 2.54 2.03 3.05 0.0205 0.0089 0.0141 




Table 3.9 continued  
Metabolite 
Ratio p-p-value 
Ben 456F Ben 456F Ben 456F 
Cysteine 0.75 0.56 0.81 0.0806 0.1063 0.3156 
Nicotinate 1.00 1.12 1.26 0.9943 0.5585 0.2053 
Taurine 0.64 1.00 0.69 0.3849 0.9920 0.4408 
Thymine 1.06 1.23 1.72 0.8342 0.5033 0.1316 
Pyroglutamic acid 0.78 0.57 0.86 0.1779 0.0121 0.3873 
N-Acetyl-beta-alanine 1.04 1.34 1.32 0.8736 0.0591 0.1383 
Hydroxyproline 0.99 1.17 1.16 0.9777 0.5437 0.5450 
Leucine/Isoleucine 1.08 0.91 0.88 0.7168 0.6838 0.5811 
Asparagine 2.30 0.87 1.34 0.0942 0.4707 0.3344 
Hydroxyisocaproic acid 6.75 3.06 6.20 0.0265 0.0005 0.0039 
Ornithine 0.95 0.93 1.26 0.8099 0.7309 0.3054 
Aspartate 0.89 0.66 0.66 0.6553 0.2030 0.2129 
Malate 1.33 1.27 1.20 0.3380 0.2118 0.3306 
Homocysteine 0.54 0.87 0.82 0.0449 0.4549 0.3467 
Anthranilate 1.26 1.02 0.97 0.4852 0.9648 0.9476 
Salicylate 1.26 2.53 5.37 0.4204 0.0040 0.0794 
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Table 3.9 continued  
Metabolite 
Ratio p-p-value 
Ben 456F Ben 456F Ben 456F 
Hydroxybenzoate 0.71 0.69 0.54 0.4029 0.3930 0.2144 
2-Oxoglutaric acid 0.57 0.51 0.58 0.0893 0.0104 0.0187 
Glutamine 1.17 0.88 0.86 0.5814 0.3957 0.5042 
Lysine 0.85 0.87 1.11 0.5117 0.4541 0.5887 
Glutamate 1.05 1.04 0.98 0.8318 0.7597 0.8850 
2-Hydroxy-2-
methylsuccinate 2.15 1.20 1.96 0.0395 0.3954 0.0007 
L-Methionine 1.20 0.71 0.95 0.4285 0.1869 0.8055 
Guanine 0.72 0.19 0.38 0.4301 0.0548 0.0998 
Xanthine 1.89 1.31 1.81 0.1003 0.2743 0.0388 
Hydroxyphenylacetate 1.31 13.26 6.81 0.2486 0.0497 0.1554 
Xylitol 1.48 1.45 1.60 0.1916 0.1883 0.1533 
2_3-Dihydroxybenzoate 1.40 0.66 0.98 0.0790 0.1192 0.9529 
Histidine 0.91 0.71 0.92 0.7047 0.1452 0.6588 
Orotate 4.24 1.11 0.65 0.0481 0.8335 0.2073 
Dihydroorotate 1.02 0.39 0.46 0.9678 0.0433 0.0653 
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Table 3.9 continued  
Metabolite 
Ratio p-p-value 
Ben 456F Ben 456F Ben 456F 
Allantoin 1.08 1.42 1.90 0.6644 0.2853 0.0023 
2-Aminoadipate 0.91 1.33 1.10 0.7361 0.4305 0.7514 
Phenylpyruvate 1.59 0.85 1.16 0.0927 0.4200 0.6071 
Phenylalanine 1.11 0.88 1.00 0.6520 0.5610 0.9865 
Phenyllactic acid 2.43 1.80 1.69 0.0034 0.0145 0.0443 
Phosphoenolpyruvate 1.59 1.23 0.69 0.4702 0.7799 0.6359 
Uric acid 2.86 3.12 1.76 0.1893 0.0214 0.0056 
Cysteate 0.84 1.10 1.09 0.4289 0.6560 0.7245 
Pyridoxine 1.08 1.61 1.14 0.7476 0.0456 0.6334 
Sulfolactate 1.07 0.73 0.85 0.6722 0.0939 0.4888 
Glycerone phosphate 0.86 0.66 0.62 0.5225 0.1057 0.0649 
sn-Glycerol 3-phosphate 1.21 0.99 0.78 0.5281 0.9807 0.3504 
Aconitate 1.23 0.53 0.45 0.3290 0.0674 0.0426 
N-Acetylornithine 1.59 1.15 1.54 0.1309 0.5123 0.0721 
Arginine 0.68 0.67 0.74 0.1092 0.1081 0.1802 
Citrulline 2.15 1.51 3.88 0.0169 0.1928 0.0212 
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Table 3.9 continued  
Metabolite 
Ratio p-p-value 
Ben 456F Ben 456F Ben 456F 
N-Carbamoyl-L-aspartate 1.38 0.93 1.07 0.0872 0.7818 0.8379 
Allantoate 0.97 1.00 1.26 0.8300 0.9850 0.1354 
2-Isopropylmalate 0.44 0.39 0.45 0.0085 0.0069 0.0387 
Gluconolactone 1.49 0.98 0.88 0.1977 0.9330 0.6078 
Glucosamine 0.45 0.91 0.52 0.1936 0.8069 0.2529 
Hydroxyphenylpyruvate 1.66 0.46 0.52 0.1655 0.0444 0.0750 
myo-Inositol 1.24 1.09 0.93 0.4709 0.6504 0.5893 
Tyrosine 1.08 1.10 0.84 0.8034 0.6812 0.4640 
4-Pyridoxate 1.58 1.01 0.98 0.1528 0.9681 0.9541 
3-Phosphoserine 0.24 0.11 0.29 0.0067 0.0064 0.0064 
N-Acetylglutamine 1.24 0.30 0.64 0.4442 0.0002 0.1117 
Acetyllysine 1.60 0.74 0.94 0.4071 0.2177 0.7337 
N-Acetylglutamate 1.56 1.55 1.25 0.0784 0.1584 0.2524 
2-Dehydro-D-gluconate 1.16 0.89 0.84 0.4794 0.4719 0.2915 
D-Gluconate 1.48 1.02 0.88 0.1518 0.9283 0.4951 
D-Erythrose 4-phosphate 1.17 1.53 1.22 0.6347 0.2965 0.4706 
 
212 
Table 3.9 continued 
Metabolite 
Ratio p-p-value 
Ben 456F Ben 456F Ben 456F 
N-N Dimethylarginine 0.67 0.65 0.62 0.1355 0.1291 0.1031 
Tryptophan 1.10 1.20 0.88 0.7581 0.5066 0.6398 
Xanthurenic acid 0.89 0.33 0.42 0.7211 0.0417 0.0641 
D-Glucarate 1.13 0.63 0.55 0.3620 0.0359 0.0143 
Pantothenate 0.98 1.44 1.06 0.9582 0.0722 0.7715 
N-Acetylglucosamine 1.94 3.26 1.85 0.3710 0.3247 0.3718 
Cystathionine 0.64 1.03 0.95 0.1622 0.9075 0.8684 
Carnosine 0.58 0.92 0.51 0.0902 0.7689 0.0396 
Ribose phosphate 0.92 0.78 0.81 0.5439 0.0904 0.1388 
Xylitol 5-phosphate 0.95 0.91 0.67 0.8135 0.6455 0.1278 
Cystine 0.33 0.60 0.59 0.0147 0.0790 0.0787 
Cytidine 0.91 1.04 1.04 0.6160 0.8253 0.7168 
Uridine 1.45 0.74 1.06 0.2570 0.2494 0.7548 
Deoxyinosine 1.46 0.66 0.66 0.1009 0.1527 0.1578 
6-Phospho-D-
gluconolactone 0.75 0.60 0.57 0.2695 0.1029 0.0893 
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Table 3.9 continued 
Metabolite 
Ratio p-p-value 
Ben 456F Ben 456F Ben 456F 
Glucosamine phosphate 1.69 1.33 1.90 0.0872 0.2633 0.0072 
Glucose 6-phosphate 1.62 1.31 1.26 0.1913 0.1041 0.1770 
S-Ribosyl-L-homocysteine 2.51 1.84 2.56 0.0059 0.0831 0.0449 
Adenosine 1.50 1.25 0.95 0.2341 0.4838 0.9083 
Tyrosine 1.08 1.10 0.84 0.8034 0.6812 0.4640 
4-Pyridoxate 1.58 1.01 0.98 0.1528 0.9681 0.9541 
3-Phosphoserine 0.24 0.11 0.29 0.0067 0.0064 0.0064 
N-Acetylglutamine 1.24 0.30 0.64 0.4442 0.0002 0.1117 
Acetyllysine 1.60 0.74 0.94 0.4071 0.2177 0.7337 
N-Acetylglutamate 1.56 1.55 1.25 0.0784 0.1584 0.2524 
2-Dehydro-D-gluconate 1.16 0.89 0.84 0.4794 0.4719 0.2915 
D-Gluconate 1.48 1.02 0.88 0.1518 0.9283 0.4951 
D-Erythrose 4-phosphate 1.17 1.53 1.22 0.6347 0.2965 0.4706 
N-N Dimethylarginine 0.67 0.65 0.62 0.1355 0.1291 0.1031 
Tryptophan 1.10 1.20 0.88 0.7581 0.5066 0.6398 
Xanthurenic acid 0.89 0.33 0.42 0.7211 0.0417 0.0641 
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Table 3.9 continued 
Metabolite 
Ratio p-p-value 
Ben 456F Ben 456F Ben 456F 
D-Glucarate 1.13 0.63 0.55 0.3620 0.0359 0.0143 
Pantothenate 0.98 1.44 1.06 0.9582 0.0722 0.7715 
N-Acetylglucosamine 1.94 3.26 1.85 0.3710 0.3247 0.3718 
Cystathionine 0.64 1.03 0.95 0.1622 0.9075 0.8684 
Carnosine 0.58 0.92 0.51 0.0902 0.7689 0.0396 
Ribose phosphate 0.92 0.78 0.81 0.5439 0.0904 0.1388 
Xylitol 5-phosphate 0.95 0.91 0.67 0.8135 0.6455 0.1278 
Cystine 0.33 0.60 0.59 0.0147 0.0790 0.0787 
Cytidine 0.91 1.04 1.04 0.6160 0.8253 0.7168 
Uridine 1.45 0.74 1.06 0.2570 0.2494 0.7548 
Deoxyinosine 1.46 0.66 0.66 0.1009 0.1527 0.1578 
6-Phospho-D-
gluconolactone 0.75 0.60 0.57 0.2695 0.1029 0.0893 
Glucosamine phosphate 1.69 1.33 1.90 0.0872 0.2633 0.0072 
Glucose 6-phosphate 1.62 1.31 1.26 0.1913 0.1041 0.1770 
S-Ribosyl-L-homocysteine 2.51 1.84 2.56 0.0059 0.0831 0.0449 
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Table 3.9 continued  
 
Ratio p-p-value 
Ben 456F Ben 456F Ben 456F 
Adenosine 1.50 1.25 0.95 0.2341 0.4838 0.9083 
Inosine 2.52 0.71 1.19 0.0147 0.1845 0.4339 
6-Phospho-D-gluconate 0.64 0.46 0.44 0.3314 0.1617 0.1542 
1-Methyladenosine 2.13 3.63 1.95 0.3329 0.3005 0.3602 
Guanosine 1.42 0.90 1.07 0.2081 0.6313 0.7290 
Glycinamide ribotide (GAR) 0.25 0.25 0.21 0.1342 0.1321 0.1209 
Ophthalmate 0.65 0.26 0.76 0.3455 0.0495 0.4542 
Sedoheptulose 
1/7phosphate 0.78 0.57 0.58 0.2351 0.0475 0.0496 
N-Acetylglucosamine 
1/6-phosphate 1.08 0.98 0.87 0.7469 0.9045 0.3904 
dCMP 0.28 0.23 0.25 0.0563 0.0448 0.0528 
Glutathione 1.19 1.03 1.55 0.4646 0.9310 0.2428 
dTMP 0.38 0.36 0.39 0.0657 0.0615 0.0685 
CMP 0.92 1.03 0.90 0.7492 0.8693 0.5591 
UMP 0.91 0.84 0.78 0.7115 0.3894 0.2398 
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Table 3.9 continued 
Metabolite 
Ratio p-p-value 
Ben 456F Ben 456F Ben 456F 
dAMP 0.47 0.57 0.47 0.0476 0.0860 0.0495 
AICAR 0.92 0.47 0.65 0.8410 0.0504 0.2252 
Trehalose/Sucrose 
/Cellobiose 0.78 0.97 0.69 0.4786 0.9335 0.3365 
AMP/dGMP 0.87 0.84 0.81 0.5128 0.3719 0.2974 
IMP 1.48 0.93 1.07 0.2506 0.8385 0.8420 
GMP 0.81 0.91 0.77 0.3051 0.5696 0.1853 
Riboflavin 1.09 1.33 1.01 0.8576 0.4401 0.9778 
S-Adenosyl-L-
homocysteine 1.34 0.97 1.13 0.1014 0.8139 0.5253 
Trehalose 6-phosphate 3.72 1.46 0.98 0.0810 0.2847 0.9454 
CDP-ethanolamine 0.70 0.89 0.89 0.0510 0.3471 0.4215 
UDP-glucose 0.97 0.59 0.74 0.8389 0.0303 0.1089 
UDP-N-acetylglucosamine 1.14 0.70 0.85 0.4585 0.0443 0.2062 
Glutathione disulfide 1.14 1.43 1.68 0.6086 0.1809 0.1554 
NAD+ 0.92 0.76 0.77 0.7297 0.2782 0.2935 
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Table 3.9 continued 
Metabolite 
Ratio p-p-value 
Ben 456F Ben 456F Ben 456F 
NADP+ 1.24 1.37 0.56 0.6605 0.4779 0.2754 




This dissertation has showcased three different systems each with a 
different goal, but all benefiting greatly from the use of metabolomics. Even though 
there will never be a single universal method for the detection of all metabolites, 
metabolomics is now being used as a screening tool that helps guide researchers 
into asking the right questions, and less of an approach to verify hypotheses.  
Metabolomics is a very powerful tool and the technique is becoming requested 
more by researchers outside of chemistry.  As protocols and techniques become 
more standardized, publicly accessible libraries and databases will begin to 
flourish, fostering interdisciplinary work, and reducing the knowledge gap between 
the metabolite level and the phenotype observed. Those without specialized 
training can now start comprehending the data and what it means in the context of 
their system. No longer will there be chemists producing gigabytes of data, passing 
that off to the biologist, and neither knowing what the data really means. 
As shown by the first chapter of this dissertation, metabolomics provides a 
great framework for hypothesis generating experiments. It was shown that if a 
bacterial cell loses the ability to produce a single enzyme, it is possible to keep 
growing without drastic morphological effects, but the small molecules that are 
present provide a unique pattern. Over 2,000 metabolite-like features indicated 
there is a global shift in metabolite intensities due to a single genetic mutation. Not 
all mutations are created equal either. Even if there are two effected enzymes in 
the same cycle, they will both produce a unique metabolic signature. In addition to 
monitoring metabolites from a global perspective, individual metabolites and the 
associated turnover rates were monitored. This analysis pushed the barriers of 
science by collecting information about metabolites that have not yet been 
identified. By beginning to identify these metabolites and their roles, scientists can 
continue to complete the understanding of metabolism.  
In a completely different avenue of metabolomics I was able to develop a 
targeted method using a hybrid Orbitrap. Instead of using the data to make theories 
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about a physical phenomenon, the goal was to connect specific lipids and their 
changes to the bacteria’s tolerance to antibiotics. Tolerance was only observed 
when the organism comes into contact with unsaturated fats produced by 
mammals.  By using parallel reaction monitoring, it was possible to not only 
quantify specific lipids, but also learn about how these exogenous fats were 
restructuring the bacterial membrane. Since this method had detection limits on 
the order of 50 nM, it was possible to quantify even the smallest lipid change from 
relatively few cells. Currently, this method is being used to asses genetically 
modified bacteria and correlate the relationship between lipid levels and antibiotic 
tolerance.  
The third chapter of this dissertation exemplifies the diversity of 
metabolomic analyses on complex systems, and its ability to answer very specific 
questions. The goal of this experiment was to determine what metabolites were 
directly connected to the resistance of a toxin in the fall armyworm. The insect 
investigated developed a genetic mutation that allowed it to feed on a once toxic 
food source. This toxin resistance was previously examined from a genomic and 
proteomic standpoint, but this was first time a small molecule analysis was 
performed. By combining several omics approaches together, it becomes possible 
to start understanding how metabolism works as a whole to produce an organism 
that is resistant. By identifying specific metabolites that significantly accumulate in 
the resistant strains, researches can learn what substrates are being used by the 
protein of interest and create new, targeted technologies to block this mode of 
action. This research had culminated in providing a finite list of metabolites that 
show promise as candidates for further investigations. 
Taken together, metabolomic analyses are capable to providing insight into 
many of the most complex and challenging biological processes. What is 
presented here are only the highlights of the many types of samples and 
techniques I have been a part of for the last four and a half years. I feel my 
contributions to the field of metabolomics will strengthen and further the knowledge 
220 
for not only those chemists who work in the laboratory but also for those scientists 
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